Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy; not engaging in sexual activity is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; male patients should refrain from sperm donation throughout this periodXx_NEWLINE_xXFemale partners (of childbearing potential) of male patients must also use a highly effective method of contraception throughout this periodXx_NEWLINE_xXFemale patients of childbearing potential must agree to use 2 adequate methods of contraception with their partner starting with the screening visit through 150 days after the last dose of study therapy.Xx_NEWLINE_xXWomen of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of radiation therapy (RT) and for at least 28 days following the last dose of sorafenib (whichever is later)Xx_NEWLINE_xXFor male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 180 days for female and male patients, of the final FOLFIRI dose. Patients who receive single agent napabucasin without FOLFIRI must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days for female patients and 90 days for male patients, of the final napabucasin dose.Xx_NEWLINE_xXMale and female participants of reproductive potential must agree to effective contraception during and after study treatmentXx_NEWLINE_xXSexually active males and pre/perimenopausal women must agree to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 3 months after discontinuation of therapyXx_NEWLINE_xXWomen of child-bearing potential and sexually active males must agree to use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for the duration of their participation in the study, and for at least 4 weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination with trametinib; women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 5 months after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or abstain from sexual intercourse for at least 7 months after the last dose of nivolumab and/or ipilimumab; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXSexually active males must use an accepted and effective method of double barrier contraception or abstain from sexual intercourse for the duration of their participation in the study and for 26 weeks after the last dose of study drugXx_NEWLINE_xXWomen of child-bearing potential and men must agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 90 days (for female patients) and 120 day (for male patients) after the last dose of study drug, or agree to completely abstain from heterosexual intercourse; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men must agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drugXx_NEWLINE_xXMen who have a female partner of childbearing potential must be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; men who have a pregnant partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocol-specified therapyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and sexually active males must use an accepted and effective method of contraception while receiving protocol treatment or abstain from sexual intercourse for the duration of their participation in the study; WOCBP must use birth control for two weeks prior to the start of the treatment and continue for 6 weeks after the last dose of the study drug; sexually active male patients must use effective contraception from day 1 of treatment and continue for 4 months after the last dose of the study drugXx_NEWLINE_xXWomen of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; Men with female partners of child-bearing potential must agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after the last dose of bevacizumab and 6 months after the last dose of mFOLFOX6Xx_NEWLINE_xXThe patient must agree not to donate sperm during the study treatment and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; women of child-bearing potential and their partners should agree to use two (2) highly effective forms of contraception throughout study participation and for at least one (1) month after the last dose of olaparib; male study participants should avoid fathering a child or donating sperm during the study and for three (3) months after the last dose of olaparibXx_NEWLINE_xXMen must agree to use adequate contraception prior to enrollment, for the duration of study participation and for at least 3 months thereafterXx_NEWLINE_xXMale participants who are partners of women of childbearing potential must use a condom + spermicide and their female partners if of childbearing potential must use a highly effective method of contraception (see methods described in Inclusion Criterion #12) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 120 days after the last dose of study drug, unless the male participants are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile.Xx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 180 days after the DSP-7888 Dosing Emulsion doseXx_NEWLINE_xXMale participants with partners of childbearing potential must agree to adhere to contraception guidelines. Men with pregnant or lactating partners or partners who plan to become pregnant during the study or within 6 months of the last dose of study drug are excluded.Xx_NEWLINE_xXFemales of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 180 days after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; they must also refrain from egg cell donation for 180 days after the final dose of investigational product\r\n* Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause)\r\n* A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctlyXx_NEWLINE_xXNon-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from days 1 through 90 post last dose; in addition, they must refrain from sperm donation for 90 days after the final dose of investigational productXx_NEWLINE_xXPatients of childbearing potential must agree to use an effective form of contraception during this study and for 90 days following the last dose of chemotherapy; an effective form of contraception is an oral contraceptive or a double barrier methodXx_NEWLINE_xXA male is eligible to enter and participate in this study if he and his female sexual partner in the reproductive age group agree to use effective methods of contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants agree to practice adequate contraceptionXx_NEWLINE_xX8. For females of childbearing potential, use effective contraception from time of screening though 90 days post last dose of TAB001.Xx_NEWLINE_xXPatients must agree to use effective means of contraception (for treatment phase)Xx_NEWLINE_xXWomen of childbearing potential must agree to follow instruction for method(s) of contraception for the duration of treatment with study drug PRS-343 plus 90 days post-treatment completion.Xx_NEWLINE_xXMale and female patients able to have children must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after last dose of chemotherapy or at least 30 days after last dose of avelumab, whichever is longerXx_NEWLINE_xXMale patients should be willing to use barrier contraception (i.e. condoms)Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception during the study treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.Xx_NEWLINE_xXFemale participants of childbearing age must agree to remain abstinent or use reliable contraceptive methods during the treatment period, and at least 3 months after last dose of study drugXx_NEWLINE_xXMale participants must agree to refrain from donating sperm, to abstain or use a condom during the treatment period, and at least 60 days after last dose of study drugXx_NEWLINE_xXBoth male and female subjects must be willing to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) throughout the study and for at least 30 days after last avelumab treatment administration if the risk of conception exists\r\n* (NOTE: Women of childbearing potential and men must agree to use highly effective contraception, as stipulated in national or local guidelines; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the treating physician should be informed immediately)Xx_NEWLINE_xXHighly effective contraception (i.e., methods with a failure rate of less than 1 % per year) for both male and female subjects if the risk of conception exists (Note: The effects of the trial treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in Protocol Appendix 9.3, or as stipulated in national or local guidelines. Highly effective contraception must be used for the duration of trial treatment, and at least for 60 days after stopping trial treatment or 6 months after stopping chemotherapy [or per label]. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately).Xx_NEWLINE_xXSubjects must use effective contraception.Xx_NEWLINE_xXEffective contraception:\r\n* Women of childbearing potential must agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 120 days after the last dose of study therapy, or agree to completely abstain from heterosexual intercourse\r\n* Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study therapy, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXPatient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of TVB-2640, as follows:\r\n* For women: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile or postmenopausal\r\n* For men: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile; men whose sexual partners are of child-bearing potential must agree to use 2 methods of contraception prior to study entry, during the study, and for 3 months after the treatment periodXx_NEWLINE_xXFemale subjects of reproductive potential (FSRP) must have a negative urine or serum pregnancy test. NOTE: FSRP is defined as premenopausal and not surgically sterilized. FSRP must agree to use maximally effective birth control or to abstain from heterosexual activity throughout the study, starting at the first dose of chemotherapy for at least 12 months after receiving the T-cell infusion, or 4 months after there is no evidence of persistence/ gene modified cells in the subject's blood, whichever is longer. FSRP randomized to Arm 2 must use effective contraception for at least 4 months after the last dose of pembrolizumab if this time frame is longer than the duration of contraception required in the context of chemotherapy and gene modified cells.Xx_NEWLINE_xXAgreement to use effective methods of contraception per the protocol requirementsXx_NEWLINE_xXPregnancy, breast feeding, or unwillingness to use effective contraception during the study.Xx_NEWLINE_xXMale subjects with female partners of childbearing potential must agree to use an adequate method of contraception for 2 weeks prior to screening, during, and at least 4 weeks after last dose of trial medication.Xx_NEWLINE_xXPatients with reproductive potential (male/female) must agree to use accepted and highly effective methods of contraception while receiving study therapy and for at least 6 months after the completion of study therapy. The definition of effective method of contraception will be based on the investigator's discretion.Xx_NEWLINE_xXSexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.Xx_NEWLINE_xXAll participants (male and female) with reproductive potential must practice an effective method of contraception while on this study in order to minimize risks to fetuses.Xx_NEWLINE_xXEffective contraception during the study period and for 5 months after the last study treatment administration (male and female patient)Xx_NEWLINE_xXWoman of childbearing potential unwilling to use effective contraception during protocol treatment and for 3 months after last dose of talimogene laherparepvecXx_NEWLINE_xXParticipants should agree to practice effective contraceptive precautions and to use at least one method of contraception for the duration of the study and for 3 months post-transplantXx_NEWLINE_xXIf a sexually-active male, must agree to use a latex condom during any sexual contact with females of child bearing potential while participating in the study and for 3 months following last dose of TB-403.Xx_NEWLINE_xXFemale patients of child-bearing potential and male patients must agree to use adequate contraceptionXx_NEWLINE_xXMale patients are eligible to enter and participate in the study if they are vasectomized or agree to use of contraception during the study treatment period and for at least 90 days after the last dose investigational product.Xx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 2 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXWOCPB must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study therapy plus 5 months after the last dose of nivolumabXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 7 months after the last dose of nivolumabXx_NEWLINE_xXInvestigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception; highly effective methods of contraception have a failure rate of < 1% per year when used consistently and correctlyXx_NEWLINE_xXFor females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative serum pregnancy test must be documented in the 14 days before the first dose of study treatment For females who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, during the study treatment period and for at least 6 months after the last dose of study treatment For males: agreement to use a barrier method of contraception during the study treatment period and for at least 6 months after the last dose of study treatmentXx_NEWLINE_xXFor women who are not postmenopausal and have not undergone surgical sterilization: agreement to remain abstinent or use two adequate non-hormonal methods of contraception, including at least one method with a failure rate of <1 percent (%) per year, during the treatment period and for a period of time after the last dose of study drug(s) as defined in the protocolXx_NEWLINE_xXIf female of child-bearing potential (i.e. not postmenopausal or surgically sterile), must be willing to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods. If male, must be sterile or willing to abstain from sexual intercourse or employ a barrier method of contraception during the study treatment and follow-up periods.Xx_NEWLINE_xXFemales of childbearing potential must agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects, even if surgically sterilized (i.e., status post-vasectomy), must agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects who are unwilling to use acceptable method of effective contraception.Xx_NEWLINE_xXIf participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drugXx_NEWLINE_xXMale participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception and use a condom throughout the study period and for 90 days after study drug discontinuation)Xx_NEWLINE_xXFemale patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participationXx_NEWLINE_xXWomen of childbearing potential must agree to use a highly effective method of contraception. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception.Xx_NEWLINE_xXAgree to use an effective means of contraception (per site-specific guidelines) that is planned to continue until 6 months after the last dose of OPN-305.Xx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraceptionXx_NEWLINE_xXMale subjects must agree to practice contraception for at least 90 days after the last dose of carfilzomib, and must agree not to donate sperm for at least 90 days after the last dose of carfilzomibXx_NEWLINE_xXAgreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.Xx_NEWLINE_xXSexually active fertile subjects (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 30 days after the last dose of study treatmentXx_NEWLINE_xXMale or female not willing to use adequate contraceptive precautions during the study period. Females must either be surgically sterile, post-menopausal for 12 months, or use a contraceptive approved by sponsor.Xx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of study drugXx_NEWLINE_xXWOCBP must be using an acceptable method of contraception to avoid pregnancy throughout the study and for up to 10 weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXPatients must not be pregnant or breastfeeding; sexually active patients are strongly advised to use accepted, effective forms of contraceptionXx_NEWLINE_xXSubject (male and female) of childbearing/reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug.Xx_NEWLINE_xXFor male patients, agreement not to donate sperm during the study and for 3 months after the final dose of vismodegib; male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with pregnant partners or female partners of reproductive potential during treatment with vismodegib; vismodegib is present in semenXx_NEWLINE_xXFemale and male patients who are of childbearing potential must agree to use an effective form of contraception with their sexual partners from enrollment through 30 days after the end of treatmentXx_NEWLINE_xXFemale participants of childbearing potential and male participants with partners of childbearing potential must agree to use 2 adequate methods of contraception as defined by protocol during the course of this study and for at least 6 months after completion of study treatmentXx_NEWLINE_xXMale and female patient of child bearing potential, (for female entering the study after a menstrual period and who have a negative pregnancy test at baseline) must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.Xx_NEWLINE_xXSexually active patients of childbearing potential must agree to use effective contraceptionXx_NEWLINE_xXAgree to practice effective contraceptionXx_NEWLINE_xXPatients capable of fathering children must agree to use an effective method of contraception for the duration of the trial.Xx_NEWLINE_xXSubjects of fertile potential who engage in heterosexual intercourse with partners of childbearing potential must agree to use highly effective contraception while enrolled in the study and for at least 6 months following the last dose of study drugXx_NEWLINE_xXPatients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment.Xx_NEWLINE_xXWilling to use contraception throughout the study period.Xx_NEWLINE_xXMale subjects must be willing to use a recommended method of contraception throughout the study period, and to refrain from sperm donation throughout the study period.Xx_NEWLINE_xXIf male, must agree to use contraception or practice abstinence as well as refrain from donating sperm for at least 180 days after the last dose of study treatment.Xx_NEWLINE_xXFemale participants of child-bearing potential must be willing to use effective contraception starting with the screening visit through 120 days after the last dose of study therapyXx_NEWLINE_xXFemales of child bearing potential and male partners of female patients must agree to use adequate contraception during the study and for 6 months after their last dose of study drug.Xx_NEWLINE_xXIf male, must agree to use contraception and refrain from donating sperm during the treatment period and for ?120 days after last dose of study treatment.Xx_NEWLINE_xXIf female, is not pregnant or breastfeeding, and agrees to use contraception during the treatment period and for ?120 days after last dose of study treatment.Xx_NEWLINE_xXIf female of child-bearing potential (i.e. not postmenopausal or surgically sterile), must be willing to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and for at least 6 months following last treatment. If male, must be sterile or willing to abstain from sexual intercourse or employ a barrier method of contraception during the study treatment and for at least 6 months following last treatment.Xx_NEWLINE_xXBe nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for 6 months after completion of study therapy (see Section 4.5.3).Xx_NEWLINE_xXFertile men must also agree to use adequate contraception (2 barrier methods or abstinence) during the study and for up to 4 months after the last dose of study drugXx_NEWLINE_xXNon-sterile male patients who are sexually active with female partners of childbearing potential must agree to follow instructions for acceptable or highly effective method(s) of contraception for the duration of study treatment and for 7 months after the last dose of study treatment with nivolumabXx_NEWLINE_xXWillingness to use protocol-recommended methods of contraception or to abstain from heterosexual intercourse from start of therapy until at lest 30 days after the last dose of study therapyXx_NEWLINE_xXAcceptable method of contraceptionXx_NEWLINE_xXAre currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period or for 28 days after study drug discontinuation.Xx_NEWLINE_xXMust not be pregnant or breastfeeding; male or female of reproductive potential must agree to use effective contraception for the duration of study participationXx_NEWLINE_xXdo not agree to use a highly effective method of contraception for the entire study period and for 28 days after study drug discontinuation, ie:Xx_NEWLINE_xXMale and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment; a patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually activeXx_NEWLINE_xXPregnant or breastfeeding; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after last dose of investigational productXx_NEWLINE_xXMale patients: Willing to use adequate contraception (barrier or abstinence) while on treatment with study drug and for 3 months after finishing treatmentXx_NEWLINE_xXFemale patients: Willing to use adequate contraception (barrier or abstinence) while on treatment with study drug and for 3 months after finishing treatmentXx_NEWLINE_xXMale patients must agree to use a condom during treatment and for 90 days after dosing and must agree not to donate sperm for 90 days after dosingXx_NEWLINE_xXMen must agree to use adequate contraception; specifically, they must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; they must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXMen must agree to use adequate contraception prior to study entry, for the duration of study participation and for at least 6 months after last radium 223 doseXx_NEWLINE_xXSubjects must agree while on study drug and for 6 months following the last dose of study drug to:\r\n* Use a condom during sexual activity\r\n* Not donate spermXx_NEWLINE_xXFemale subjects of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of investigational product; male partners of a female subject must also agree to use male condom plus spermicide throughout this period; cessation of birth control after this point should be discussed with a responsible physician; not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; female patients should refrain from breastfeeding throughout this period; females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as >= 12 months with no menses without an alternative medical cause)Xx_NEWLINE_xXNon-sterilized male subjects who are sexually active with a female partner of childbearing potential must use male condom plus spermicide from screening through 180 days after the last dose of investigational product; not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not\r\nacceptable methods of contraception; male patients should refrain from sperm donation throughout this period; female partners of a male subject must use a highly effective method of contraception throughout this periodXx_NEWLINE_xXSubjects who may become pregnant or who are sexually active with a partner who could become pregnant are to use an effective form of barrier contraception during the study and for at least 60 days for female patients and 180 days for male patients after administration of study drug; andXx_NEWLINE_xXFemale subject of childbearing potential (ie, premenopausal or not surgically sterile) must agree to use effective contraception from Day 1 until 28 days after the last dose of study drug, and have a negative serum or urine pregnancy test within 2 weeks prior to Day 1. Sexually active male subjects must also use effective contraception from Day 1 until 90 days after the last dose of any study drug.Xx_NEWLINE_xXWOCBP must agree to follow instructions for method(s) of contraception from the time of signing consent and until 6 months after last dose of study therapyXx_NEWLINE_xXMen able to father children who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception from the time of signing consent and until 6 months after last dose of study therapy; men able to father children are defined as those who are not surgically sterile (i.e. patient has not had a vasectomy)Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use a highly effective method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study drug through 130 days after last dose of study drug. Male participants of reproductive potential must agree to use a highly effective method of contraception during sexual contact with females of childbearing potential starting with the first dose of study drug through 130 days after the last dose of study drug.Xx_NEWLINE_xXMen who are not surgically sterile (vasectomy) must agree to use an acceptable method of contraception. Male subjects with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms from the first dose of study drug through at least 120 days after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative.Xx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methods as follows: fertile females of childbearing potential who agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation; male patients willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for 3 months after treatment stopsXx_NEWLINE_xXRequired that female patients of childbearing potential use two methods of contraception with their partnerXx_NEWLINE_xXFemales must not be pregnant or lactating. Women of child-bearing potential must use a highly effective method of contraception throughout their study participation and for at least 6 months following the last dose of study drug.Xx_NEWLINE_xXMales must be surgically sterile, abstinent, or if engaged in sexual relations with a female of child-bearing potential, must be willing to use a highly effective method of contraception throughout their study participation and for at least 6 months after the last dose of study drug.Xx_NEWLINE_xXFor male or female patients of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 180 days after the final dose of nab-paclitaxel and gemcitabine or for 30 days for female patients and for 90 days for male patients, after the final napabucasin dose if nab-paclitaxel and gemcitabine were not administered.Xx_NEWLINE_xXMale patients willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for 3 months after treatment stopsXx_NEWLINE_xXAgree not to try to become pregnant during the study for 6 months after the final study drug administrationXx_NEWLINE_xXAnd, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and throughout the study period and for 6 months after the final study drug administration.Xx_NEWLINE_xXMale participants (even if surgically sterilized), and partners who are women of childbearing potential must be using highly effective contraception in addition to a barrier method throughout the study drug treatment period and for 127 days after the final study drug administration.Xx_NEWLINE_xXVasectomy (A vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.)Xx_NEWLINE_xXIf they are of childbearing potential, agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through 90 days (or longer, as mandated by local labeling [e.g., United Surgical Partners International, summary of product characteristics, etc.] after the last dose of the study drugs, ORXx_NEWLINE_xXAgree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of the study drugs, ORXx_NEWLINE_xXMale patients should be willing to use barrier contraception (i.e., condoms).Xx_NEWLINE_xXPregnancy or breast-feeding (patients with reproductive potential must use effective contraception methods throughout the entire study period, as determined by their investigator/gynecologist)Xx_NEWLINE_xXWillingness to use effective contraception.Xx_NEWLINE_xXFemales and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time or agree to abstinence.Xx_NEWLINE_xXAgree to use effective contraception until 30 days following the last dose of investigational product and have a male partner who uses a condom orXx_NEWLINE_xXFemale subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception.Xx_NEWLINE_xXFemale patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.Xx_NEWLINE_xXFor male patients who are sexually active and who are partners of premenopausal women: agreement to use two forms of contraception as in criterion 10 above during the treatment period and for at least 3 months after the last dose of study drug.Xx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXFemale subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.Xx_NEWLINE_xXMale patients should be willing to use barrier contraception for the duration of the study and for 3 months after treatment discontinuation. Inclusion Criteria for Phase 1b Expansion CohortsXx_NEWLINE_xXMale patients should be willing to use barrier contraceptive (ie, condoms) until 3 months after last study drug is taken.Xx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after the last dose of MPDL3280AXx_NEWLINE_xXMale w/partner(s) (childbearing) unwilling to use contraceptionXx_NEWLINE_xXSubjects must agree to use adequate contraception (i.e. barrier method) for the duration of study participation, and for three months after discontinuing therapyXx_NEWLINE_xXWilling to use adequate contraception for the duration of time on the study and for 6 months after the last therapyXx_NEWLINE_xXSubjects of childbearing potential must agree to use adequate contraception beginning at the signing informed consent form until at least 3 months after the last dose of study drug.Xx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXPregnant or nursing (fertile patients must use effective contraception during and for up to 3 months after completion of study treatment)Xx_NEWLINE_xXFemale subjects of childbearing potential who agree to practice 2 effective methods of contraception.Xx_NEWLINE_xXMale subjects, even if surgically sterilized (i.e. Status post-vasectomy) must agree to agree to practice contraception.Xx_NEWLINE_xXFemales and males must agree to contraceptive methods and avoid conceiving throughout the study, and for up to 8 weeks following the last dose of CC-90002. If participating in Part B, females of child bearing potential should continue to use effective contraceptive methods for 12 months following treatment with rituximabXx_NEWLINE_xXPregnancy or breastfeeding; patients of childbearing capability should agree to use contraceptionXx_NEWLINE_xXPatients who are not pregnant; committed to using adequate contraception through week 15 if of childbearing age; condom use will be encouragedXx_NEWLINE_xXFor women who are not postmenopausal and have not undergone surgical sterilization: agreement to remain abstinent or use two adequate non-hormonal methods of contraception including at least one method with a failure rate of <1% per year during the treatment period and for at least five months after the last dose of atezolizumab and at least four months after the last dose of cergutuzumab amunaleukin, whichever is the longestXx_NEWLINE_xXAgreement to use contraception during the study and for 90 days after the last dose of study drugs if sexually active and able to bear or beget children.Xx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, ORXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study Treatment period and through 90 days after the last dose of study drug, ORXx_NEWLINE_xXPregnancy and breast feeding are exclusion factors; enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and 180 days (female patients) or 90 days (male patients) after the end of the treatment; in addition male patients must refrain from sperm donation for 90 days after the final dose of investigational product; female patients must refrain from egg cell donation for 180 days after the final dose of investigational product; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXSexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of IP.Xx_NEWLINE_xXFemale patients who:\r\n* Are postmenopausal for at least 1 year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale patients, even if surgically sterilized (i.e., status post-vasectomy), who:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or\r\n* Agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale patients must agree to use a condom during treatment and for 90 days after dosing and must agree not to donate sperm for 90 days after dosingXx_NEWLINE_xXFertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplantXx_NEWLINE_xXMale patient whose sexual partner(s) are women of child bearing potential, who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMale patients (even those post vasectomy) who are willing to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drugXx_NEWLINE_xXMale subjects must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until 16 weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant must continue to use condoms for 7 days after stopping study medications.Xx_NEWLINE_xXFemale patients of childbearing potential and sexually active males and female partners of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 90 days after the last dose of assigned treatmentXx_NEWLINE_xXSexually active males unwilling to practice contraception during the study and 6 months beyondXx_NEWLINE_xXPatients must agree to use adequate contraception (barrier method for males) for the duration of study participation, and for three months after discontinuing therapyXx_NEWLINE_xXWomen of child-bearing potential (WoCBP) may be included only if acceptable contraception is in place for two weeks before study entry, for the duration of the treatment with the study drug, and for 2 months after the last dose of AZD1775; male patients who are involved in the study must agree to avoid procreative and unprotected sex (i.e., by using acceptable forms of contraception) and must not donate sperm during the study and for 3 months after the last dose of AZD1775; where the female partner is pregnant or not using effective birth control, men should be advised to abstain while in the study and for 3 months after the last dose of AZD1775; female partners, who are of child-bearing potential, of men participating in clinical studies of AZD1775 will also be required to use effective contraceptive measures while their partner is on study drug and for 3 months thereafter; male patients will be advised to arrange for the freezing of sperm samples prior to the start of the study should they wish to father children while on AZD1775 or during the 3 months after stopping AZD1775Xx_NEWLINE_xXFertile males not willing to use contraceptionXx_NEWLINE_xXPatients capable of childbearing are using adequate contraceptionXx_NEWLINE_xXMen not azoospermic who are sexually active with WOCBP must agree to follow instructions for acceptable contraception, from the time of signing consent, and for 31 weeks after their last dose of protocol-indicated treatment.Xx_NEWLINE_xXSubjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug. Sperm donation is prohibited during the study and for 30 days after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinentXx_NEWLINE_xXWomen of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug plus 30 days (duration of ovulatory cycle); the half-life of nivolumab and ipilimumab is up to 25 days and 18 days, respectively; WOCBP should therefore use an adequate method to avoid pregnancy for a total of 23 weeks posttreatment completionXx_NEWLINE_xXWomen of childbearing potential and their partners, who are sexually active, must agree to the use of 2 highly effective forms of contraception in combination or must totally/truly abstain from any form of sexual intercourse. This should be started from the signing of the informed consent, throughout their participation in the study and for at least 1 month after the last dose of olaparibXx_NEWLINE_xXMale patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking olaparib and for 3 months following the last dose of olaparibXx_NEWLINE_xXWOCBP must be willing to abstain from heterosexual activity or to use at least 1 highly effective method of contraception from the time of informed consent until 180 days after durvalumab and tremelimumab combination therapy is stopped; or 90 days after durvalumab monotherapy treatment is discontinued (whichever is longer).Xx_NEWLINE_xXMale patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 6 months (180 days) after the last dose of durvalumab and tremelimumab combination therapy; or 90 days after durvalumab monotherapy is discontinued (whichever is longer).Xx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception exists. Highly effective contraception must be used 30 days prior to first trial administration, for the duration of trial treatment, and at least for 4 months after stopping trial treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately.Xx_NEWLINE_xXMale or female participant of reproductive potential must agree to use appropriate methods of contraception for the duration of study treatment and for at least 30 days after last dose of protocol treatmentXx_NEWLINE_xXNonsterilized males who are sexually active with a female of childbearing potential must agree to use an acceptable method of effective contraception from Day 1 and for 90 days after the final dose of study drug.Xx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for 6 months afterwards; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 14 days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigatorsXx_NEWLINE_xXFor male subjects: agreement not to father a child. Participants must be surgically sterile (e.g, vasectomy) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of study treatment.Xx_NEWLINE_xXMales or females of childbearing potential who do not agree to practice 2 effective methods of contraception, at the same time through 90 days after the last dose of study drugXx_NEWLINE_xXNot of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.Xx_NEWLINE_xXA male participant must agree to use a contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participantXx_NEWLINE_xXSubjects must agree to use a condom and acceptable contraceptive method with their partner during the study and for one month after the last dose of vaccinesXx_NEWLINE_xXWomen of child-bearing potential must use at least two accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 4 months (120 days) after the last dose of nivolumab and/or ipilimumab; sexually active males must also use at least two accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 4 months (120 days) after the last dose of nivolumab and/or ipilimumabXx_NEWLINE_xXNon-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug; male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drugXx_NEWLINE_xXWomen who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of randomization and for at least 30 days after the last dose of study drug. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of randomization and for at least 90 days after the last dose of study drug.Xx_NEWLINE_xXWillingness to use contraception by a method that is deemed effective by the investigator throughout the treatment period and for at least 30 days following the last dose of therapyXx_NEWLINE_xXAll patients of reproductive potential (heterosexually active men and women) must agree to a use of a barrier method of contraception and a second method of contraception and men must agree not to donate sperm during the study and for 4 weeks after receiving the last dose of study treatmentXx_NEWLINE_xXMale subjects must agree to use an acceptable method of contraception beginning prior to study entry, for the duration of the study, and for six months following last dose of avelumab/utomilumabXx_NEWLINE_xXWOCBP and male partners of WOCBP must agree to use two methods of contraception until at least 5 months after last dose of each study drug for WOCBP subjects, and 7 months for male partners of WOCBPXx_NEWLINE_xXPregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal,or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.Xx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception exists. Highly effective contraception must be used 30 days prior to first trial administration, for the duration of trial treatment, and at least for 4 months after stopping trial treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately.Xx_NEWLINE_xXMale subjects must be willing to use barrier contraceptionXx_NEWLINE_xXSTRATUM A: Female participants of childbearing potential must have a negative pregnancy test at the time of SJDAWN study enrollment and be willing to use a highly effective method of contraception throughout the study and for 16 weeks after discontinuation of the study drugXx_NEWLINE_xXSTRATUM A: Male participants of child fathering potential must be willing to use medically acceptable form of contraception during treatment and for 16 weeks after stopping treatmentXx_NEWLINE_xXSTRATUM B: Female participants of childbearing potential must have a negative pregnancy test at the time of SJDAWN study enrollment and be willing to use a highly effective method of contraception throughout the study and for 16 weeks after discontinuation of the study drugXx_NEWLINE_xXSTRATUM B: Male participants of child fathering potential must be willing to use medically acceptable form of contraception during treatment and for 16 weeks after stopping treatmentXx_NEWLINE_xXSTRATUM C: Female participants of childbearing potential must have a negative pregnancy test at the time of SJDAWN study enrollment and be willing to use a highly effective method of contraception throughout the study and for 8 months after discontinuation of the study drugXx_NEWLINE_xXSTRATUM C: Male participants of child fathering potential must be willing to use medically acceptable form of contraception during treatment and for 8 months after stopping treatmentXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy agree to use effective contraception as described in the full protocol for at least 14 days prior to administration of the first dose of study treatment, during the study, and for 90 days following the last dose of osimertinibXx_NEWLINE_xXParticipants who are WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) and up to 5 months post last dose of study drug(s)Xx_NEWLINE_xXParticipants who are males and who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) and up to 7 months post last dose of study drug(s); in addition, male participants must be willing to refrain from sperm donation during this timeXx_NEWLINE_xXWomen of child-bearing potential must have a negative serum pregnancy test within 24 hour of initiation of dosing and must agree to use an effective form of contraception during the study from the time of the negative pregnancy test up to 6 months after the last dose of study drug; effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 year; fertile men must also agree to use an effective method of birth control while on study drug and up to 6 months after the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study. Sexually active men and women of child-bearing potential must use highly effective contraceptives (e.g., condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 30 days after the last dose of study drug for females and 90 days for males. If a female subject or the partner of a male subject becomes pregnant, the sponsor must be notified. Male subjects should refrain from sperm donation for 90 days after the last dose of study drugXx_NEWLINE_xXMale patients must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 20 weeks after the last dose of study treatmentsXx_NEWLINE_xXFor male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use an effective method of contraception from the start of study therapy until ?3 months after the last dose of cirmtuzumab and ?1 month after the last dose of ibrutinib, whichever is later and to refrain from sperm donation from the start of study therapy until ?3 months after administration of the final dose of either of the study drugs. Note: A male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.Xx_NEWLINE_xXIf the patient is of childbearing potential or their partner(s) is of childbearing potential, they must agree to use highly effective method of contraception while on study and for 6 months after receiving all protocol-related therapy.Xx_NEWLINE_xXFor patients post pubertal: Female patients must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator.Xx_NEWLINE_xXFor men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenibXx_NEWLINE_xXMale participants must agree to use approved contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this periodXx_NEWLINE_xXFemale participants who are not pregnant or breastfeeding, and who are either not a woman of childbearing potential (WOCBP), or are a WOCBP who agrees to use approved contraception during the treatment period and for at least 120 days after the last dose of study treatmentXx_NEWLINE_xXMales must be willing to use an effective method of contraception/method to avoid seminal transfer (barrier method or abstinence) from the time consent is signed until 4 weeks after treatment discontinuation. Subject's partner must also use barrier protection while subject is on study until 4 weeks after treatment discontinuation.Xx_NEWLINE_xXWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatmentXx_NEWLINE_xXIf of reproductive potential, agrees to use a highly effective from of contraception or avoid intercourse during and upon completion of the study and for at least 4 months after the last dose of study drug, and agrees not to retrieve, freeze or donate sperm or ova starting at Screening and throughout the study period, and at least 4 months after the final study drug administrationXx_NEWLINE_xXSTUDY TREATMENT: For female patients of childbearing potential, agreement (by patient) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use at least until ICS or if ICS is not performed then 90 days post last dose of atezolizumab.Xx_NEWLINE_xXMales and females not willing to use effective contraception.Xx_NEWLINE_xXMale and female patients able to have children must agree to use 2 highly effective methods of contraception throughout the study and for at least 60 days after last doseXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment; female study participants of child-bearing potential and their partners, should agree to use highly effective forms of contraception for at least 3 weeks after the last dose of palbociclib; male study participants should avoid fathering a child, donating sperm, and should agree to use highly effective forms of contraception for at least 3 months after the last dose of palbociclibXx_NEWLINE_xXMale Participants who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.Xx_NEWLINE_xXMales with female partners of child-bearing potential must agree to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/suppository) throughout the duration of the study until 6 months following the last dose of study drug; in addition to their female partner using either an intrauterine device or hormonal contraception and continuing until 6 months following the last dose of study drug. Male patients should not donate sperm until 6 months following the last dose of study drug.Xx_NEWLINE_xXBoth female and male participants of child-bearing potential must agree to use highly effective contraceptive precautions during the trial and up to 3 months following the last dose of olaratumab, or longer for other study drugs according to their label.Xx_NEWLINE_xXWomen of childbearing potential must have negative pregnancy test performed within 14 days of randomization and on the first day of treatment. All subjects must agree to use an effective form of contraception for the duration of study treatment and for 7 months after the last dose of study drug. Infusion sub-study prior therapy requirements: Same as above, except:Xx_NEWLINE_xXNegative serum pregnancy test result; Note: women of child-bearing potential and men must agree to use 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [e.g. United States product insert (USPI), Summary of Product Characteristics (SmPC), etc]) after the last does of study drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use highly effective barrier contraception prior to the study, for the duration of study participation, and 4 months after completion of MLN0128 (TAK-228) administrationXx_NEWLINE_xXMale patients willing to use adequate contraceptive measures.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 5 months after the last dose of study treatment i.e., 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo approximately five half-livesXx_NEWLINE_xXMales who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment i.e., 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-livesXx_NEWLINE_xXAgreement to use acceptable methods of contraception during the study and for at least 120 days after the last dose of APX3330 if sexually active and able to bear or beget children.Xx_NEWLINE_xXMale subjects must agree to use adequate contraception (e.g., condoms; abstinence) for the duration of study treatment and 3 months after completionXx_NEWLINE_xXMust agree not to donate sperm from first dose of study drug through 3 months after the last dose of study drugXx_NEWLINE_xXMales must agree to use an acceptable form of contraception per institutional practicesXx_NEWLINE_xXFertility requirements\r\n* Female patients with child bearing potential must have a negative pregnancy test at least 7 days before starting treatment drugs\r\n* Male patients must agree to use an adequate method of contraception for the duration of the study and for 7 months afterwards\r\n* Female patients must be either posy-menopausal, free from menses >= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening and for 5 months afterwards\r\n* Female patients of child bearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist programXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 4 months for both females and males after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMale participants must agree to use a contraception as detailed in protocol during the treatment period and for at least 120 days after the last dose of trial treatment and refrain from donating sperm during this period.Xx_NEWLINE_xXMale and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the studyXx_NEWLINE_xXFertile patients unwilling to use contraception during and for 12 months after treatmentXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after trial completionXx_NEWLINE_xXFemales of reproductive potential that are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from Screening through the end of the study.Xx_NEWLINE_xXAll men and women must agree to practice effective contraception during the entire study period and after discontinuing study drug, unless documentation of infertility exists.Xx_NEWLINE_xXNot of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.Xx_NEWLINE_xXChildbearing potential and agrees to use method(s) of contraception. For a teratogenic study drug and/or when there is insufficient information to assess teratogenicity (preclinical studies have not been done), a highly effective method(s) of contraception (failure rate of less than 1% per year) is required. The individual methods of contraception and duration should be determined in consultation with the investigator. Women of childbearing potential (WOCBP) must follow instructions for birth control when the half-life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 30 days plus the time required for the investigational drug to undergo five half-lives. WOCBP should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.Xx_NEWLINE_xXSubjects of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug; contraception can be either abstinence of penetrative intercourse, condom use, or prior vasectomyXx_NEWLINE_xXUnwilling to use approved contraception for at least 6 months following transplantXx_NEWLINE_xXFemales of childbearing potential and males who are not surgically sterile and with partners of childbearing potential must agree to use effective contraception during study treatment for 5 months for females and 7 months for males after the last dose of nivolumabXx_NEWLINE_xXIf male, must be sterile or agree to use an effective method of contraception or a highly effective method of contraception during the study and for at least 12 weeks following the last dose of study treatment.Xx_NEWLINE_xXagree to use a highly effective method of contraception during the study and for 3 months following the last dose of study treatment.Xx_NEWLINE_xXFertile male and female patients must be willing to use an effective contraceptive method before, during, and for at least 4 months after the CAR T cell infusionXx_NEWLINE_xXWOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 30 days (duration of ovulatory cycle) for a total of 5 months post treatment completion.Xx_NEWLINE_xXMen who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days duration of sperm turnover for a total of 5 months post-treatment completion.Xx_NEWLINE_xXThe effects of INCB039110, dabrafenib, and trametinib on the developing human fetus are unknown. For this reason, women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraception (barrier method of birth control, or abstinence; hormonal contraception is not allowed due to drug-drug interactions which can render hormonal contraceptives ineffective) from 14 days prior to registration, throughout the treatment period, and for 4 months after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Based on studies in animals, it is also known that dabrafenib may cause damage to the tissue that makes sperm. This may cause sperm to be abnormal in shape and size and could lead to infertility, which may be irreversible. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception. Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 4 months following completion of therapy.Xx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 24 hours prior to the first dose of study treatment and agree to use appropriate highly effective methods of contraception, during the study and for 5 months following completion of study treatment;\r\n* A woman of childbearing potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\r\n* Female subjects: women of child bearing potential are expected to use one of the highly effective methods of contraception\r\n* Male subjects: male subjects must inform their female partners who are women of child bearing potential of the contraceptive requirements and are expected to adhere to using contraception with their partner; female partners of male subjects, who are women of child bearing potential, are expected to use one of the highly effective methods of contraception; in addition, male subjects are expected to use a condomXx_NEWLINE_xXMen with a female partner of childbearing potential must agree to use highly effective methods of contraception or any contraceptive method with a failure rate of less than 1% per year during the study and for 7 months following completion of study treatmentXx_NEWLINE_xXFemale patients who: are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.Xx_NEWLINE_xXMale patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, OR agree to completely abstain from heterosexual intercourse.Xx_NEWLINE_xXAll sexually active subjects agree to use barrier contraception (i.e., condoms) while receiving study treatment and for 120 days following their last dose of study treatment; female subjects of child-bearing potential and male subjects whose sexual partners are women of childbearing potential (WOCBP) agree to use barrier contraception and a second form of contraception while receiving study treatment and for 4 months following their last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXFemales of childbearing potential must agree and meet the following conditions below: toXx_NEWLINE_xXMale or female subjects of reproductive potential who do not agree to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 90 days after the last study treatmentXx_NEWLINE_xXDo not agree to use a highly effective method of contraception for the entire study period and for 6 months after study drug discontinuation, ie:Xx_NEWLINE_xXMales who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period or for 3 months after study drug discontinuation). No sperm donation is allowed during the study period or for 3 months after study drug discontinuation.Xx_NEWLINE_xXFemale subject who is of childbearing potential must agree not to breastfeed starting at screening and throughout the study and for 28 days after the final study drug administration.Xx_NEWLINE_xXMale subject who is of childbearing potential must not donate sperm starting at screening and throughout the study and, for 90 days after the final study drug administration.Xx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for 6 months afterwards; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 14 days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigatorsXx_NEWLINE_xXPregnancies\r\n* Females: females may not take part in this study if pregnant or breast-feeding for 6 months after last dose of study drug; women of child-bearing potential (WOBCP) will be asked to take a pregnancy test prior to starting study medication\r\n* Males: Male subjects should avoid fathering a child while receiving study medication and for 6 months after the last dose of study medication; males must agree to complete abstinence from heterosexual contact or use a condom during sexual contact with a female of child bearing potential while receiving study medication and within 6 months after last dose of study medication; if a female partner of a male subject taking investigational product becomes pregnant, the male subject taking the product should notify the principal investigator, and the pregnant female partner should be advised to call their healthcare provider immediately\r\n* Subjects (both males and female) should practice effective contraception during study and for 6 months after the last dose of study medicationXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after trial completionXx_NEWLINE_xXFemales of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception. Male subjects must agree to practice contraceptionXx_NEWLINE_xXPatient must be willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least 35 days after study treatment. Patients surgically sterilized or who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) do not require contraception.Xx_NEWLINE_xXWOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 30 days (duration of ovulatory cycle) for a total of 5 months post treatment completionXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completionXx_NEWLINE_xXMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drugXx_NEWLINE_xXFemale patient has a negative serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of non-childbearing potential; non-childbearing potential is defined as follows (by other than medical reasons):\r\n* >= 45 years of age and has not had menses for > 1 year\r\n* Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\r\n* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation; documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound; tubal ligation must be confirmed with medical records of the actual procedure; otherwise the patient must be willing to employ methods to avoid pregnancy; abstinence is an acceptable method to avoid pregnancy if this is the established and preferred method for the patient; alternatively, the patient and partner must use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment; information must be captured appropriately within the sites source documents\r\n** Male patients must also agree to use an adequate method to avoid pregnancy, which may include abstinence, if this is the established and preferred method for the patient starting with the first dose of study treatment through 180 days after the last dose of study treatment.\r\n** Additionally, the participants must agree to not breastfeed during the study or for 180 days after the last dose of study treatmentXx_NEWLINE_xXFemale patients of childbearing potential and male patients who are not surgically sterile or with female partners of childbearing potential must agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel) prior to study entry, for the duration of study participation and for 6 months (10 half-lives of Lu-177) after the last dose of Lu-177-DOTATATEXx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth\r\ncontrol during the course of the study and for 4 months after the last dose of study drug(s); male subjects must agree to not donate sperm for at least 90 days after the last dose of carfilzomibXx_NEWLINE_xXHighly effective contraception for both male and female subjects throughout the study and for at least 120 days after last avelumab treatment administration if the risk of conception existsXx_NEWLINE_xXFemales of child bearing potential must have a negative serum pregnancy test with 7 days prior to first dose of treatment; female patients of childbearing potential and all male partners must agree to use double barrier methods of contraception throughout the study period and for at least 30 days following investigational product discontinuationXx_NEWLINE_xXPregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ?6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for 3 months following last dose of carotuximab (TRC105). All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 3 months following last dose of carotuximab (TRC105). The definition of effective contraception is provided in Section 2.6.1 of this protocol.Xx_NEWLINE_xXHighly effective contraception for male subjects with childbearing potential throughout the study and for at least 60 days after last avelumab treatment administration if the risk of conception existsXx_NEWLINE_xXAll women of childbearing potential must agree to use an effective barrier method of contraception during the treatment period and for at least 1 month after discontinuation of the study drug; male subjects should use effective barrier method of contraception during the treatment period and for at least 1 month after discontinuation of the study drugXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for at least 12 months after the last dose of atezolizumabXx_NEWLINE_xXWomen of childbearing potential must agree and commit to the use of a highly effective method of contraception; men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after last dose of investigational productsXx_NEWLINE_xXWOCBP and male subjects who are sexually active with WOCBP must agree to use 2 highly effective methods of contraception (including a physical barrier) during the study and for 30 days following the last dose of investigational productXx_NEWLINE_xXFemale patients of childbearing potential must use two highly effective forms of contraceptionXx_NEWLINE_xXMale patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potentialXx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception exists; Note: women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1% per year; highly effective contraception is required at least 28 days prior, throughout and for at least 60 days after avelumab treatmentXx_NEWLINE_xXAre not currently abstinent or do not agree to refrain from sexual activity during the study period and for 6 months after study drug discontinuation;Xx_NEWLINE_xXMales who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period or for 6 months after study drug discontinuation)Xx_NEWLINE_xXMust use a condom when having sex with a pregnant woman from the time of the first dose of study drug through 105 days after last dose of study drug. An additional highly effective form of contraception must be used from the time of the first dose of study drug through 105 days after last dose of study drug when having sex with a non pregnant female partner of childbearing potential.Xx_NEWLINE_xXFertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 105 days after the last dose of investigational product.Xx_NEWLINE_xXFemale patients who: Are postmenopausal for at least 1 year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.Xx_NEWLINE_xXMale patients, even if surgically sterilized (i.e., status post-vasectomy), who: Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or Agree to completely abstain from heterosexual intercourse.Xx_NEWLINE_xXPatients are not of childbearing potential or they must agree to use a physical method of contraception.Xx_NEWLINE_xXPatients with reproductive potential (e.g., females menopausal for less than 1 year and not surgically sterilized) must practice two highly effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of durvalumab monotherapy or for at least 180 days after completion of durvalumab/tremelimumab combination therapy. Female patients of childbearing potential must provide a negative pregnancy test (urine) prior to treatment initiationXx_NEWLINE_xXBecause the effects of zydelig on the developing human fetus are unknown, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Female subjects of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of zydelig. Male subjects must agree to use an adequate method of contraception starting with the first dose of the study drug Zydelig. Female and male participants must agree to use contraception for at least 30 days after the last dose of Zydelig. Women of childbearing potential is defined as women who continues to have menstrual periods, have not had a tubal ligation, or the removal of fallopian tubes, ovaries or uterus.Xx_NEWLINE_xXSexually active patients (male and female) must use medically acceptable methods of contraception during the course of the study and for 3 months after completion of study treatment; if a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately; while on the study and for 3 months after final drug administration, women may not breast-feedXx_NEWLINE_xXFemale participants of childbearing age must be willing to use contraception methods, or abstain from sexual activity throughout the course of the study and for 7 months after the last dose of atezolizumabXx_NEWLINE_xXWoman of childbearing potential and is not willing to use 2 highly effective methods of contraception while receiving protocol-specified therapy and for an additional 24 hours after the last dose of protocol-specified therapy.Xx_NEWLINE_xXMale who has a female partner of childbearing potential, and is not willing to use 2 highly effective forms of contraception while receiving protocol-specified therapy and for at least an additional 24 hours after the last dose of protocol-specified therapy.Xx_NEWLINE_xXInvestigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy; investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception; highly effective methods of contraception have a failure rate of < 1% when used consistently and correctlyXx_NEWLINE_xXParticipants who are pregnant or lactating; males or females of reproductive potential must agree to use effective contraception for the duration of study participationXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a non-sterilized male partner and non-sterilized male subjects who are sexually active with a female partner of childbearing potential must be willing to use 2 methods of effective contraception from time of screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXMale patients must use a form of barrier contraception approved by the investigator during the study and for 4 months after the last dose of study drug;Xx_NEWLINE_xXAgreement on the part of any male participant to use effective contraception during sexual activity throughout the duration of treatment and for 2 months after discontinuation, for protection against the risk of embryofetal toxicityXx_NEWLINE_xXAge, sex, and reproductive status:\r\n* Women of childbearing potential (WOCBP=premenopausal woman capable of becoming pregnant) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug\r\n* Women must not be breastfeeding.\r\n* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 30 days (duration of ovulatory cycle) for up to 5 months post-treatment completion\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for up to 7 months post treatment completion\r\n* Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements; however, they must still undergo pregnancy testing as described in this section\r\n* Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy; investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception; highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly\r\n* At a minimum subjects must agree to the use of one method of highly effective contraception as listed below. In addition, male subjects are expected to use a condomXx_NEWLINE_xXMale patients whose sexual partner(s) are WCBP who are not willing to use adequate contraception, during the study and for 12 weeks after the end of treatmentXx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective barrier contraceptive method for at least 6 months after the last dose of huJCAR014Xx_NEWLINE_xXPatients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatmentXx_NEWLINE_xXPatients (male and female) having procreative potential who are not willing or not able to use adequate contraception or practicing abstinenceXx_NEWLINE_xXWomen of childbearing potential (per University of Wisconsin Carbone Cancer Center [UWCCC] policy definition) must agree to use effective contraception as discussed with treating oncologist for the duration of the studyXx_NEWLINE_xXFemale patients of childbearing potential must agree to use 2 methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum pregnancy test at screening. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test at screening and agree to use 2 reliable methods of contraception throughout the study and for 3 months after their last dose of medication. Female patients are considered NOT of childbearing potential if they have a history of surgical sterility (including hysterectomy and/or bilateral oophorectomy, but not tubal ligation alone) or evidence of post-menopausal status defined as any of the following:\r\n* Natural menopause with last menses > 1 year ago and confirmed by follicle stimulating hormone (FSH) blood level\r\n* Radiation-induced oophorectomy with last menses > 1 year ago\r\n* Chemotherapy-induced menopause with last menses > 1 year ago\r\nMale patients and their partners must use 2 reliable methods of contraception, at least one of them a barrier method (if sexually active with a female of child-bearing potential)Xx_NEWLINE_xXMale patients, even if surgically sterilized, should agree to practice effective barrier contraception for the entire study treatment period and through 120 days after the last dose of the study treatment or agree to completely abstain from heterosexual intercourse. Female patients who are postmenopausal for at least one year before the screening visit or are surgical sterile or if they are of child bearing potential must have a negative pregnancy test within 72 hours of treatment of the start date and agree to practice two effective methods of contraception forms at the same time from the time of signing the informed consent through 120 days of the last dose of the study treatment or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXContraception should be continued using two highly effective methods for a period of 90 daysXx_NEWLINE_xXFemales of childbearing potential and males must be willing to abstain from heterosexual activity or must agree to use adequate contraception (hormonal or barrier method) for the duration of study participation and for 3 weeks after discontinuation of study treatment.Xx_NEWLINE_xXFemales of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception from the time of screening, and must agree to continue using such precautions for 180 days after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; female subjects must also refrain from egg cell donation for 180 days after the final dose of investigational product\r\n* Females of childbearing potential are defined as those who are not surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or those who are not postmenopausal (defined as 12 months with no menses with postmenopausal gonadotropin levels [luteinizing hormone and follicle-stimulating hormone], or estradiol levels within the postmenopausal range according to local guidelines without an alternative medical cause)\r\n** A highly effective method of contraception is defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctlyXx_NEWLINE_xXMale subjects capable of fathering a child must agree to use an adequate method of contraception starting with the first dose of the study drug through 120 days after the last dose of the study drug; male subjects will be considered to be capable of fathering a child unless they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition)Xx_NEWLINE_xXEffective contraception if the risk of conception exists.Xx_NEWLINE_xXWilling to use appropriate contraception from time of NanoPac injection until prostatectomyXx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception exists; (Note: women of childbearing potential and men must agree to use highly effective contraception, defined as 2 barrier methods, or 1 barrier method with a spermicide, an intrauterine device or use of oral female contraceptive; effective contraception must be used 30 days prior to first study drug administration, for the duration of trial participation, and at least for 30 days after last avelumab treatment administration if the risk of conception exists; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately)\r\n* Pregnancy test: negative serum or urine pregnancy test at screening for women of childbearing potentialXx_NEWLINE_xXEffective contraception for both male and female subjects if the risk of conception exists; women of childbearing potential and men able to father a child must agree to use a method of effective contraception; effective contraception is required throughout the study and for at least 1 month after avelumab treatment, 2 months after last dose of trabectedin for women of reproductive potential, and 5 months following the last dose of trabectedin for males with female partners of reproductive potentialXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of the study drug(s) plus 90 days (duration of sperm turnover); the half-life of nivolumab and ipilimumab is up to 25 days and 18 days, respectively; men should therefore use an adequate method of contraception for a total of 31 weeks post-treatment completionXx_NEWLINE_xXMale participants who are sexually active, must agree, from Study Day 1 through at least 180 days after the last dose of study drug, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 180 days after the last dose of study drug.Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 28 days prior to study registration; female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study including throughout the initial evaluation period (100 days after CIML NK cell infusion)Xx_NEWLINE_xXFemale and male subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in the Duke Contraception PolicyXx_NEWLINE_xXMale patients with partners of childbearing potential must agree to use adequate contraception while on studyXx_NEWLINE_xXWomen of child-bearing potential (those who have had a menstrual cycle within the last year and have not had a tubal ligation or surgical removal of both ovaries and/or hysterectomy) must agree to abstain from vaginal intercourse and continue contraception for 3 weeks after discontinuation of study treatmentXx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception exists; (Note: the effects of the trial drug on the developing human fetus are unknown; thus, women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1 % per year; highly effective contraception is required at least 28 days prior, throughout and for at least 60 days after avelumab treatmentXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (>= 45 years old and without menses for >= 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potentialXx_NEWLINE_xXMale participants and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3 months after last dose of study drug to prevent pregnancy in a partnerXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 2 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXSubjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug; sperm donation is prohibited during the study and for 30 days after the last dose of study drug; female partners must use hormonal or barrier contraception unless postmenopausal or abstinentXx_NEWLINE_xXAll patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the studyXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use two forms of highly effective contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 150 days after the last dose of all study drugs (atezolizumab, entinostat, and bevacizumab)Xx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after the last dose of MPDL3280AXx_NEWLINE_xXMust agree to the use of effective contraception while on study treatment, unless they are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] postmenopausal [i.e., a woman who is > 50 years old or who has not had menses for >= 1 year], or [3] not heterosexually active for the duration of the study)Xx_NEWLINE_xXFor the duration of the study and for 1 week after the last study drug administration, sexually active male patients must be willing to use barrier contraception i.e., condoms with all sexual partnersXx_NEWLINE_xXParticipants must agree to use appropriate contraception.Xx_NEWLINE_xXUse of the following:Xx_NEWLINE_xXFemales of childbearing potential and males must agree to use an acceptable form of contraception per institutional practicesXx_NEWLINE_xXPatients of reproductive potential must agree to follow the contraception requirements.Xx_NEWLINE_xXAgreement to use highly effective forms of contraception during the study and 90 days after the last dose of acalabrutinib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longest .Xx_NEWLINE_xXIf they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc.]) after the last dose of study drug, ORXx_NEWLINE_xXAgree not to try to become pregnant during the study and for 6 months after the final study drug administrationXx_NEWLINE_xXFemale subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study drug administration.Xx_NEWLINE_xXMale subjects with a female partner of childbearing potential must commit to true abstinence from heterosexual contact or commit to the use of male condom plus spermicide throughout the course of the study, and avoid fathering a child during the course of the study (including dose interruptions) and for 6 months following the last dose of azacitidineXx_NEWLINE_xXiC9-CAR19 CELL INFUSION: Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the last dose of study therapyXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 5 months after the last dose of atezolizumabXx_NEWLINE_xXMale subjects must agree to use an acceptable method of contraception beginning prior to study entry, for the duration of the study, and for six months following duration of study participationXx_NEWLINE_xXWilling to use adequate contraception throughout the study and for 3 weeks after study drug discontinuationXx_NEWLINE_xXMale subject, even if surgically sterilized (i.e., status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent), or completely abstain from heterosexual intercourse during the entire study treatment period through 6 months after the last dose of brentuximab vedotinXx_NEWLINE_xXAll patients must agree to use barrier contraception (i.e. condom) during study treatment and for 2 months after the last virus treatment and 4 months after the last dose of chemotherapy and pembrolizumab.Xx_NEWLINE_xXMen who are unwilling to employ adequate contraception measures during the study and for 30 days after the final dose of study therapyXx_NEWLINE_xXSubjects of reproductive potential must agree to avoid becoming pregnant or impregnating a partner, respectively, while receiving study drug and for 120 days after the last dose of study drug by complying with one of the following: (1) practice abstinence from heterosexual activity; OR (2) use (or have their partner use) acceptable contraception during heterosexual activity.Xx_NEWLINE_xXSexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.Xx_NEWLINE_xXA female of childbearing potential unwilling to use highly effective method of contraception during treatment and for an additional 48 hours (Period 1) or 72 hours (Period 2), respectively, after the last dose of blinatumomab.Xx_NEWLINE_xXMale patients with a female partner of childbearing potential should agree to use a barrier method of contraception, or agree to abstain from heterosexual activity for the course of the study through 120 days after the last dose of trial treatmentXx_NEWLINE_xXMale patients must be willing to use barrier contraception (i.e., condoms) for the duration of the trial and for 6 months after trial treatment discontinuation.Xx_NEWLINE_xXMale patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: a) agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR b) latex or non-latex condom with or without a spermicidal agent, diaphragm with spermicide; cervical cap with a spermicide; sponge with a spermicideXx_NEWLINE_xXWillingness to use effective contraceptive methods during the study; if female (or female partner of male subject), either is not of childbearing potential (defined as postmenopausal for >= 1 year or surgically sterile) or is practicing two forms of contraception; sexually active male participants must agree to use a physical barrier method (male latex rubber condom with or without spermicide)Xx_NEWLINE_xXMen treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of enzalutamide administrationXx_NEWLINE_xXMen treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of chemotherapy, radiation, and pembrolizumab administrationXx_NEWLINE_xXFemale patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product; male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational productXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the administration of the first dose of study treatment until 3 months after the last dose of study treatment to allow for clearance of any altered sperm.Xx_NEWLINE_xXRefusal to use adequate contraception for fertile patients (females and males)Xx_NEWLINE_xXFemales must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study and for 30 days after the last dose of study drug or DasXx_NEWLINE_xXWillingness to use barrier contraception from the time of first dose of MGA271 until the time of prostatectomyXx_NEWLINE_xXPatients may be pre- or post-menopausal; pre-menopausal patients must be on ovarian suppression and must be adequately suppressed on luteinizing hormone-releasing hormone (LHRH) agonists with estradiol levels in the post-menopausal range\r\n* Premenopausal patients cannot be pregnant and must agree to adequate birth control in addition to ovarian suppression; agreement by the patient and/or partner to use highly effective, non-hormonal form of contraception or two effective forms of non-hormonal contraception; contraception use should continue during the duration of study treatment and for at least 6 months after the last dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy after the receipt of brachytherapy; male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapyXx_NEWLINE_xXFemale subjects must not be pregnant, or breast feeding and must have a negative urine or serum pregnancy test within 28 days prior to treatment on day 1; females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from the time of screening, and must agree to continue using such precautions for 90 days after the final dose of durvalumab; they must also refrain from egg cell donation for 90 days after the final dose of durvalumabXx_NEWLINE_xXNonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception and refrain from sperm donation from day 1 through 90 days after receipt of the final dose of durvalumabXx_NEWLINE_xXMale patients who are not surgically sterile unless they are using a double barrier contraception method from enrollment through treatment and for 6 months following administration of the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug (25 days) plus 30 days (duration of ovulatory cycle) for a total of 155 days post-treatment completionXx_NEWLINE_xXMales who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of the study drug plus 90 days (duration of sperm turnover) for a total of 215 days post-treatment completion; in addition, male subjects must be willing to refrain from sperm donation during this timeXx_NEWLINE_xXFemale subjects may be enrolled in the trial if they are: \r\n* of non-childbearing potential which is defined as: \r\n* of childbearing potential who are willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy, or to abstain from heterosexual activity throughout the trial, starting with the screening visit (visit 1) through 120 days after the last dose of MK-3475 (pembrolizumab)Xx_NEWLINE_xXFemale participants of childbearing potential must have a negative pregnancy test, and female participants of childbearing potential and male participants must agree to use adequate contraception\r\n* Decitabine has been assigned to pregnancy category D by the Food and Drug Administration (FDA); pregnant women must not take decitabine and female participants must immediately stop taking decitabine and inform their doctor if they become pregnant during treatment; decitabine is expected to result in adverse reproductive effects and can cause fetal harm when administered to a pregnant woman; in preclinical studies in mice and rats, decitabine was teratogenic, fetotoxic, and embryotoxic\r\n* Studies in pregnant animals to evaluate the effect of talazoparib on pregnancy have not been performed\r\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of decitabine and talazoparib administration\r\n* It is not known whether decitabine is excreted in human milk; similarly, studies in lactating animals to evaluate the effect of talazoparib have not been performed, and thus, it is not known whether talazoparib is excreted in human milk; therefore, breast-feeding should be stopped during decitabine and talazoparib treatmentXx_NEWLINE_xXMale subjects must agree to use effective contraception or abstinence while on study and for 90 days after infusion of the ACTolog T-cell product.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug; post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements; male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potentialXx_NEWLINE_xXPHASE II: Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug; post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements; male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potentialXx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine beta human chorionic gonadotrophin (beta-hCG) pregnancy test result within 7 days prior to the first dose of treatment and must agree to use an effective contraception method during the study and for 6 months following the last dose of the study drugs; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of study drugsXx_NEWLINE_xXFertile males not willing to use contraception, as stated aboveXx_NEWLINE_xXPatients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose; the definition of effective method of contraception will be based on the investigators judgmentXx_NEWLINE_xXFemales of childbearing potential (FOCBP), and non-sterilized males who are sexually active must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective; they must also refrain from egg and/or sperm cell donation and breastfeeding for 90 days after the final dose of investigational product(s)\r\n* Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause)\r\n* Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives of nivolumab (19 weeks) plus 30 days (duration of ovulatory cycle) for a total of 23 weeks post-treatment completion.\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives of the study drug (19 weeks) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment\r\ncompletionXx_NEWLINE_xXFemale patients of childbearing potential must agree to use 2 methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum pregnancy test at screening; male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential; for both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatmentXx_NEWLINE_xXFemales and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time, or agree to abstinenceXx_NEWLINE_xXA WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for at least 6 months following completion of study treatmentXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from the time of screening, and must agree to continue using such precautions for 180 days after the final dose of investigational productXx_NEWLINE_xXAre willing to abstain from heterosexual activity or practice physical barrier contraception prior to time of study entry to 6 months after the last day of treatmentXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from the time of screening, and must agree to continue using such precautions for 180 days after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; they must also refrain from egg cell donation for 180 days after the final dose of investigational productXx_NEWLINE_xXNonsterilized males who are sexually active with a female partner of childbearing potential must agree to use a highly effective method of contraception from day 1 through 90 days after receipt of the final dose of investigational product; in addition, they must refrain from sperm donation for 90 days after the final dose of investigational productXx_NEWLINE_xXMen treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of abiraterone and PDMX1001/niclosamide administrationXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 28 days prior to study registration; female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study including throughout the initial evaluation period (100 days after CIML NK cell infusion)Xx_NEWLINE_xXFemales must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study and for 30 days after the last dose of study drug or LDACXx_NEWLINE_xXMales must agree to use an adequate method of contraception during the study and for at least 30 days after the last dose of study drug or LDACXx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: Males and females who are sexually active must agree to use effective contraception during and for three months after treatmentXx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: Males and females who are sexually active must agree to use effective contraception during and for three months after treatmentXx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: Males and females who are sexually active must agree to use effective contraception during and for three months after treatmentXx_NEWLINE_xXDASATINIB\r\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study drug\r\n* Women must not be breastfeeding\r\n* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug, plus 30 days (duration of ovulatory cycle) for a total of 30 days post-treatment completion\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 90 days (duration of sperm turnover) for a total of 90 days post-treatment completion\r\n* Azoospermic males and WOCBP, who are not heterosexually active, are exempt from contraceptive requirements; however, WOCBP must still undergo pregnancy testing\r\n* Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of unexpected pregnancy; investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective contraception; highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly\r\n* At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effectiveXx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 24 hours from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators; patients who are breastfeeding are not allowed on studyXx_NEWLINE_xXWomen of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective, non-hormonal form of contraception (including abstinence) or two effective forms of non-hormonal contraception by the patient and/or partner; contraception must continue for the duration of study treatment and for at least seven (7) months after the last dose of study treatmentXx_NEWLINE_xXPatients (male and female) having procreative potential who are not willing or not able to use adequate contraception or practicing abstinenceXx_NEWLINE_xXMale or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of ARQ 751.Xx_NEWLINE_xXMale patients should be willing to use barrier contraception; male patients should be asked to use barrier contraceptives (i.e., by use of condoms) during sex with all of their female partners during the trial and for a washout period of 3 months; patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing osimertinib treatment; if male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of osimertinib treatmentXx_NEWLINE_xXMale subject agrees to use an acceptable method of contraception for the duration of the studyXx_NEWLINE_xXHave a negative serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1, and agree to use contraception if they or their partner are of reproductive potentialXx_NEWLINE_xXMales must agree to abstain from sexual activity or agree to utilize a medically-approved contraception method during and for 3 months after the treatment periodXx_NEWLINE_xXThe subject must agree to use two effective forms of contraception beginning at least four (4) weeks prior to study entry, and continuing to do so for the duration of their participation in the studyXx_NEWLINE_xXMen must agree to the use of male contraception during the study treatment period and for at least 12 weeks after the last dose of study drugXx_NEWLINE_xXMales who have partners of reproductive potential must agree to use an effective barrier contraceptive method for 90 days after the last dose of study therapy (durvalumab or JCAR014)Xx_NEWLINE_xXMale subject with a female partner of childbearing potential or pregnant must agree to use two acceptable methods of contraception and not to donate sperm from time of screening until 3 months after the last dose of study treatmentsXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a non-sterilized male partner and non-sterilized males must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 180 days after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physicianXx_NEWLINE_xXPregnant or lactating patients; patients of childbearing potential must agree to avoid pregnancy during study treatment and for at least two weeks after the last dose of the study drugXx_NEWLINE_xXAll patients must use adequate contraception during participation in this trial and for 3 months following completing therapyXx_NEWLINE_xXWomen of childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) and fertile men must agree to use two highly effective forms of contraception while they are receiving study treatment and for 30 days after last dose of study drug; male subjects must agree to refrain from sperm donation during the study and for 30 days after the last dose of study drugsXx_NEWLINE_xXWomen of child bearing potential must agree to use of a highly effective method of contraception from the time of informed consent until 6 months after the last dose of ado-trastuzumab emtansine; men must agree to use a barrier method of contraception while on treatment and for 6 months after the last dose of ado-trastuzumab emtansineXx_NEWLINE_xXMale patients who are sexually active with a female partner of childbearing potential must be either surgically sterilized or agree to use barrier contraception (ie, condoms) for the duration of study participation, and for 90 days after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physicianXx_NEWLINE_xXMen must agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 3 months after the end of treatment if their partner is of childbearing potentialXx_NEWLINE_xXMale patients must agree to use condoms during intercourse throughout study drug therapy and the following 12 months.Xx_NEWLINE_xXIf sexually active, patients must agree to use appropriate contraceptive measures for the duration of the study and for 12 months afterwards as stated in the informed consentXx_NEWLINE_xXFemale patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment.Xx_NEWLINE_xXMale patients sexually active with a woman of childbearing potential must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator.Xx_NEWLINE_xXMale patients with female partners of childbearing potential who do not agree to use two Food and Drug Administration (FDA)-accepted forms of contraception during sexual intercourse with women of child-bearing potential from the start of PD-1 antibody therapy and up to at least 31 weeks from the last dose of nivolumab are excludedXx_NEWLINE_xXFemale patients of childbearing potential who do not agree to use two FDA forms of contraception during sexual intercourse from the start of PD-1 antibody and up to at least 23 weeks from the last dose of nivolumab are excludedXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration described below\r\n* WOCBP must use agree to use contraception until 5 half-lives plus 30 days following last study intervention (23 weeks after last dose of nivolumab)\r\n* Male subjects who are sexually active with WOCBP must agree to use adequate contraception until 5 half-lives plus 90 days following last study intervention (31 weeks after last dose of nivolumab)Xx_NEWLINE_xXNon-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception (as outlined above) from day 1 through 90 days after receipt of the final dose of MEDI4736 and tremelimumab; in addition, they must refrain from sperm donation for 90 days after the final dose of investigational productXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXA woman of child-bearing potential (WCBP) and a male patient with partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatmentXx_NEWLINE_xXMen participate in the study must be surgically sterile or must agree to use adequate contraception prior to study entry and for the duration of study participation and after for a certain amount of time (as defined below); the investigator shall review contraception methods and the time period that contraception must be followed; the duration of mandatory contraception is based on clearance of the investigational drug (5 half-lives after treatment completion); for males, an additional 90 days is required to complete turnover of drug-exposed sperm; calculation of duration of mandatory contraception: the half-life of cisplatin is 20-30 minutes, half-life of methotrexate is 8-15 hours and half-life of gemcitabine is 42-94 minutes; thus, contraception for men is required for up to 14 weeks after the last treatmentXx_NEWLINE_xXFemale patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment; male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment; the decision of effective contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXFemale participants of childbearing potential and male participants with partners of childbearing potential must agree to always use two effective methods of contraception including at least one method with a failure rate of <1% per year during the course of the study and for at least 6 months after completion of study treatmentXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXSubjects (male and female) of childbearing/reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]):\r\n* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug plus 5 half-lives of study drug plus 4 weeks (duration of ovulatory cycle) for a total of 23 weeks post treatment completion\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 5 half-lives of study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion\r\n* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluidsXx_NEWLINE_xXAgree to practice effective contraceptionXx_NEWLINE_xXWilling to use contraception when appropriateXx_NEWLINE_xXMale patients must be willing to use an appropriate method of contraception (e.g., condoms) or abstain from sexual intercourse and inform any sexual partners that they must also use a reliable method of contraception during the study and for 90 days after dosing.Xx_NEWLINE_xXWilling to use effective contraception for at least 28-days post study drug administration.Xx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 31 weeks following the last dose of study drugXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to C1D1 and agree to use dual methods of contraception during the study and for a minimum of 30 days following the last treatment. Post menopausal females (>45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 30 days following the last treatment if sexually active with a female of childbearing potential.Xx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and a period of 31 weeks after the last dose of investigational drugXx_NEWLINE_xXBe a pregnant or breast-feeding woman; female patients of childbearing potential must agree to use effective contraception, must be surgically sterile, or must be postmenopausal; male patients must agree to use effective contraception or be surgically sterile; barrier methods are a recommended form of contraceptionXx_NEWLINE_xXMale patients should be asked to avoid unprotected sex with all sexual partners but use condoms plus spermicide during the study, and for a washout period of 90 days after the last dose of study drug; where a sexual partner of a male participant is a woman of child-bearing potential, patients should avoid procreation for 90 days after completion of study drug treatment; patients should refrain from donating sperm from the start of dosing until 90 days after discontinuing study treatment; if male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of study treatmentXx_NEWLINE_xXMale and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 3 months after study treatmentXx_NEWLINE_xXWillingness to use effective contraceptive methods during the study; female patients may participate if patient is either not of childbearing potential (defined as postmenopausal for > 1 year or surgically sterile) or is practicing two forms of contraception; sexually active male participants must agree to use a physical barrier method (male latex rubber condom with or without spermicide)Xx_NEWLINE_xXIf the patient is a woman of child-bearing potential, the patient and their sexual partner must agree to practice effective contraceptionXx_NEWLINE_xXMale participants must be willing to use an adequate method of contraceptionXx_NEWLINE_xXFemale patients of childbearing potential must be willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study, starting with visit 1Xx_NEWLINE_xXMale patients must agree to use an adequate method of contraception for the duration of the studyXx_NEWLINE_xXMale subjects of reproductive potential in the combination treatment must be willing to use acceptable methods of effective contraception during treatment and through 4 months after the last dose of pembrolizumab.Xx_NEWLINE_xXMales of child bearing potential must agree to practice effective barrier contraception during the entire study treatment period and through 6 months) after the last dose of study drug, (includes males surgically sterilized  i.e. status post vasectomy).Xx_NEWLINE_xXMale patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the studyXx_NEWLINE_xXPatient must be willing to use effective contraception if female with reproductive capabilityXx_NEWLINE_xXPatients of child bearing potential who are sexually active must agree to the use of two highly effective forms of contraception from the time of informed consent through 6 months after last dose of study drug(s)Xx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nMen treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation and for 3 months after last dose of study drug; sexually active subjects and their female partners must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 3 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course of the study and for 3 months after the last dose of study drug(s); should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXPatients of childbearing potential must agree to abstinence or the use of effective contraceptionXx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be post-menopausal, or must agree to use effective contraception during the period of therapy; all female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment; male patients must be surgically sterile or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMale or female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during and after the study (six months after the last dose of paclitaxel or 3 months after the last dose of ARQ 092 whichever is longer)Xx_NEWLINE_xXA WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatmentXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXFemale subjects of childbearing potential or male subjects who are unwilling to use 2 highly effective methods of contraception during study treatment and through 3 months after the last dose of study treatmentXx_NEWLINE_xXMen of reproductive potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < 1% during and for 6 months after discontinuation of study treatment\r\n* If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occurXx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG])\r\n* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 23 weeks post treatment completion\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion\r\n* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluidsXx_NEWLINE_xXPatients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception.Xx_NEWLINE_xXMale patients must agree to use condoms for sexual intercourse with female partners of reproductive potential at all times, even after a vasectomy, during treatment with vismodegib and for 2 months after the last dose to avoid exposing a pregnant partner and unborn fetus to vismodegibXx_NEWLINE_xXMale patients must agree not to donate sperm during the study and for 2 months after discontinuation of vismodegibXx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine beta human chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective contraception method during the study and for 23 weeks following the last dose of the study drugs; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 31 weeks following the last dose of study drugsXx_NEWLINE_xXFemale patients who: are postmenopausal for at least 24 months before the screening visit, OR; are surgically sterile, OR; if they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, 28 days prior to starting study drug, during study treatment and for 28 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse; male patients, even if surgically sterilized (i.e., status post vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 28 days after the last dose of study treatment, OR; agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXFemales > 13 years of age or who have achieved menarche must have a negative pregnancy test within 2 weeks of starting treatment (urine or serum) to be eligible and if sexually active must also agree to use contraception; male sexually active patients must agree to use an effective method of contraceptionXx_NEWLINE_xXFemale patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraceptionXx_NEWLINE_xXPregnant or breastfeeding; if sexually active and with childbearing potential, must agree to use effective method of contraception, such as intrauterine device, bilateral tubal ligation for >= 6 months before randomization, partner vasectomized for >= 6 months before randomization, and sexual abstinence when in relation to the preferred and usual lifestyle of the subject; male subjects must use a condom when having sex with a pregnant woman and when having sex with a woman of childbearing potential from the time of the first dose of study drug through 105 days after the last dose of study drug; contraception should be considered for a nonpregnant female partner of childbearing potential; male subjects with partners of childbearing potential must use a condom and contraception should be considered for the female partner from the time of the first dose of study drug through 105 days after the last dose of study drug; male subjects whose partners are pregnant should use condoms for the duration of the pregnancy\r\nMale and female subjects must agree not to donate sperm or eggs, respectively, from the first dose of study drug through 105 days and 45 days after the last dose of study drug, respectively (hormonal contraception is not allowed) prior to study entry, during treatment, and for 45 days after last dose of study drug; females considered not of childbearing potential include those who are surgically sterile (bilateral salpingectomy, bilateral oophorectomy, or hysterectomy) or who are post menopausal, defined as: < 55 years of age with no spontaneous menses for >= 12 months before randomization and with a postmenopausal follicle stimulating hormone (FSH) concentration > 30 IU/L (or meeting criteria for post-menopausal status by the local laboratory)\r\nIf females with childbearing potential, a negative serum pregnancy test at screening and willing to have additional serum and urine pregnancy tests during the study [Note: Females without childbearing potential include those in menopause >= 2 years, with tubal ligation >=1 year before screening, or with total hysterectomy]Xx_NEWLINE_xXMale patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, prior to study entry and for at least 3 months after the last dose of study drugXx_NEWLINE_xXPatients of childbearing potential must agree to use effective contraception until at least 6 months after treatment with dabrafenib and trametinibXx_NEWLINE_xXFailure to use contraception in patients with preserved reproductive capacityXx_NEWLINE_xXMen who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternativeXx_NEWLINE_xXWomen of childbearing potential must agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 23 weeks (5 half-lives plus 30 days, the duration of an ovulatory cycle) after the last dose of nivolumab, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through 31 weeks (5 half-lives plus 90 days, the duration of sperm turnover) after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXSubjects must agree to use adequate contraception beginning at the signing of the ICF until at least 6 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigatorXx_NEWLINE_xXSubjects must agree to use effective means to prevent conception from enrollment through completion of the studyXx_NEWLINE_xXPatient agrees to practice effective contraception during the entire study period unless documentation of infertility existsXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, orXx_NEWLINE_xXSubject (male and female) of childbearing/ reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug.Xx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXMen with female partners (WOCBP) that are not willing to use contraceptionXx_NEWLINE_xXSexually active patients of childbearing potential must agree to use effective contraceptionXx_NEWLINE_xXPatients with reproductive potential must agree to use an effective non-hormonal method of contraception during therapy, and for at least 7 months after the last dose of study therapy.Xx_NEWLINE_xXWomen of child-bearing potential, who are biologically able to conceive, not employing 2 forms of highly effective contraception; male not using at least at least one form of highly effective contraception will be excluded; highly effective contraception (e.g. male condom with spermicide, diaphragm with spermicide, intra-uterine device) must be used by both sexes during the study and must be continued for 3 months after the end of study treatment; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this studyXx_NEWLINE_xXNonsterilized males who are sexually active with a female partner of childbearing potential must use 2 acceptable methods of effective contraception from day 1 and for 90 days after receipt of the final dose of investigational productXx_NEWLINE_xXWillingness to use effective and reliable methods of contraceptionXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days duration of sperm turnover for a total of 31 weeks post-treatment completionXx_NEWLINE_xXMales and their female partner(s) of child-bearing potential must use 2 forms of effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the last menstrual period of the female partner during the study treatment and for 6 months after the final dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential and male participants must agree to practice adequate contraceptionXx_NEWLINE_xXMen with reproductive potential who do not agree to use an accepted and effective method of contraception during the study treatment period and for at least 3 months after completion of the study treatmentXx_NEWLINE_xXWomen of child-bearing potential MUST have a negative serum or urine pregnancy test within 7 days unless prior hysterectomy or menopause (defined as 12 consecutive months without menstrual activity); patients should not become pregnant or breastfeed while on this study; women of child-bearing potential must agree to use 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [e.g.; United Surgical Partners International (USPI), Summary of Product Characteristics (SmPC), etc;]) after the last dose of study drug; or agree to practice true abstinence; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; male patients, even if surgically sterilized (i.e., status post-vasectomy), who:\r\n* Agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, or\r\n* Agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXAll patients who are having sex that can lead to pregnancy must agree to contraception for the duration of studyXx_NEWLINE_xXParticipants of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after T cell infusionXx_NEWLINE_xXParticipants of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after T cell infusionXx_NEWLINE_xXFor male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 28 days after discontinuing treatmentXx_NEWLINE_xXMale patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the studyXx_NEWLINE_xXMale patients must use an effective contraceptive method during the study and for a minimum of 8 weeks after study treatmentXx_NEWLINE_xXFor men with female partners of childbearing potential, agreement to use a latex condom, and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of MK-3475Xx_NEWLINE_xXMale and female subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental drug, and for one month after the last immunization.Xx_NEWLINE_xXPatients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial; patients must not be breastfeedingXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXPatients of reproductive potential and their partners must agree to use an effective (> 90% reliability) form of contraception during the study and for 4 weeks following the last study drug administrationXx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXAll women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose of chemotherapyXx_NEWLINE_xXWomen and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication.Xx_NEWLINE_xXMale subjects must agree to practice contraception.Xx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to practice effective contraceptive methods to avoid conception while on study and for 6 months after study completionXx_NEWLINE_xXFemale patients must be at least 1 year postmenopausal or surgically sterile; or must agree to use a medically acceptable form of contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test within 28 days prior to study registration; female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the dose-limiting toxicity (DLT) evaluation periodXx_NEWLINE_xXSexually active participants must agree to the use of a medically accepted barrier method of contraception (i.e. male condom or female condom) during the course of the study and for 3 months following discontinuation of study treatments; for participants of childbearing potential, a barrier method and a second method of contraception must be usedXx_NEWLINE_xXFemale patients should not be pregnant or breast-feeding; female patients, if not postmenopausal (< 12 months of amenorrhea) or surgically sterile, should agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of at least 6 months following the last administration of study drugs; female patients with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the studyXx_NEWLINE_xXFertile male patients must agree to use a highly effective contraceptive method (i.e., with a failure rate of < 1 % per year, such as vasectomy, sexual abstinence, or female partner's use of hormonal implants or combined oral contraceptives) during the trial and for a period of at least 6 months after the last dose of study drugXx_NEWLINE_xXWomen of child bearing potential must have a negative pregnancy test (blood or urine) within 14 days before treatment and agree to use appropriate contraception from study screen through the duration of the trial; men must agree to use appropriate contraception from study screen through the duration of the trialXx_NEWLINE_xXBoth genders must use contraception if of reproductive capacityXx_NEWLINE_xXSexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the investigatorXx_NEWLINE_xXMen must be willing not to father a new child while receiving therapy; they must use an effective barrier method of contraception during the study and for 3 months following the last doseXx_NEWLINE_xXPatients capable of reproduction and male patients who have partners capable of reproduction must agree to use an effective contraceptive method during the course of the study and for 2 months following the completion of their last treatment.Xx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 14 days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigatorsXx_NEWLINE_xXWomen of child bearing potential must have a negative pregnancy test (blood or urine) within 14 days before treatment and agree to use appropriate contraception from study screen through the duration of the trial; men must agree to use appropriate contraception from study screen through the duration of the trialXx_NEWLINE_xXDasatinib\r\n* Normal QTc interval on screening ECG evaluation, defined as < 450 msec for men and < 470 msec for women; discontinuation of any medications known to contribute significantly to the risk of QT prolongation at least 48 hours prior to start of study drug; Levaquin and Zofran are an exception; of note, certain agents that prolong the corrected QT interval may be allowed but only after discussion with the chemotherapy pharmacist; should the investigator believe that therapy with a potentially QT prolonging medication is vital to an individual subjects care, then additional ECGs should be done at the investigators discretion to ensure the subjects safety\r\n* Serum Na, K, Mg, and total serum Ca or ionized Ca levels must be greater than or equal to the institutional lower limit of normal; subjects with low K or Mg levels, total serum Ca and/or ionized Ca must be replete for protocol entry\r\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 90 days (duration of sperm turnover) for a total of 90 days post-treatment completion\r\n* Azoospermic males and WOCBP, who are not heterosexually active, are exempt from contraceptive requirements; however, WOCBP must still under pregnancy testing as described in this section\r\n* Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of unexpected pregnancy; investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective contraception; highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly\r\n* At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective as listedXx_NEWLINE_xXMale subject agrees to use an acceptable method of contraception for the duration of the studyXx_NEWLINE_xXMale patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the studyXx_NEWLINE_xXFemale and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatmentXx_NEWLINE_xXEligibility criteria specific to the CC-115 arm:\r\n* Participants must be willing and able to provide written informed consent for the CC-115 arm of the INSIGhT trial\r\n* Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from date of initial dose and for 28 days following the last dose of CC-115; men (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with a woman of child bearing potential from date of initial dose and for 28 days following the last dose of CC-115Xx_NEWLINE_xXMale patients must be surgically sterile or use double barrier contraception method from enrollment through treatment and for 6 months following administration of the last dose of study drug.Xx_NEWLINE_xXBe nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for 6 months after completion of study therapy.Xx_NEWLINE_xXWomen of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of careXx_NEWLINE_xXPatients or their partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter; the definition of effective contraception should be in agreement with local regulation and based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXAll sexually active subjects (males and females of child-bearing potential) agree to use 2 effective methods of contraception for the duration of the studyXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXPatients of childbearing or child-fathering potential must be willing use an effective method of contraception while being treated on this study and for 4 months after the last cell infusionXx_NEWLINE_xXPremenopausal women must have a negative pregnancy test and must agree to use barrier contraception throughout the study periodXx_NEWLINE_xXBoth male and female patients must be willing to consent to using highly effective contraception prior to study entry, while on treatment and at least 3 months thereafter.Xx_NEWLINE_xXFemale subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study treatment administration.Xx_NEWLINE_xXAgree to use a male condom starting at screening and continue throughout study treatment and for 6 months after the final study drug administration.Xx_NEWLINE_xXMale subject must not donate sperm starting at Screening and throughout the study period and for 6 months after the final study drug administration.Xx_NEWLINE_xXMale subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.Xx_NEWLINE_xXFor male patients with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 6 months from receiving the last dose of IPXx_NEWLINE_xXNot of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.Xx_NEWLINE_xXDo not agree to use a highly effective method of contraception for the entire study period and for 6 months after study drug discontinuation, ie:Xx_NEWLINE_xXMales who have not had a successful vasectomy (confirmed azoospermia) or if they and their female partners do not meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period or for 28 days after study drug discontinuation). No sperm donation is allowed during the study period or for 28 days after study drug discontinuation.Xx_NEWLINE_xXHighly effective contraceptionXx_NEWLINE_xXAble and willing to use double barrier method of contraception for at least 3 months prior to ST-400 infusion and through 6 months post-transplantXx_NEWLINE_xXAll female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 4 months after the last dose of study treatment. Additional Inclusion Criteria for Cohort 1:Xx_NEWLINE_xXIf of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 6 months following last treatment.Xx_NEWLINE_xXMale and female subjects must agree to medically accepted methods of contraceptionXx_NEWLINE_xXMust be using at least 1 effective contraceptive method at screening and agree to practice 2 effective contraceptive methods1 for study duration, starting Screening through 30 days after stopping study drugXx_NEWLINE_xXMale participant who is not surgically sterile and is sexually active with female partner of childbearing potential must agree to practice 2 effective contraceptive methods1 for study duration, starting at Screening through 30 days after stopping study drugXx_NEWLINE_xXPatients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of tisotumab vedotin.Xx_NEWLINE_xXMale patients should be willing to use barrier contraceptionXx_NEWLINE_xXFemale patients who are of childbearing potential and all males must agree to practice true abstinence or use effective methods of contraceptionXx_NEWLINE_xXSubjects of childbearing potential must consent to utilize a medically accepted means of contraception throughout the active dosing period with study medication and for a minimum of 30 days following the administration of the last dose of study medication.Xx_NEWLINE_xXPatients with reproductive potential (male/female) must agree to use accepted and highly effective methods of contraception while receiving durvalumab, and for at least 3 months after the last dose of durvalumab.Xx_NEWLINE_xXConsent to use one highly effective method of contraceptionXx_NEWLINE_xXEstimated life expectancy of at least 8 weeks; 7. Eastern Cooperative Oncology Group (ECOG) performance status ? 2; 8. Significant toxicities incurred as a result of previous anti-cancer therapy resolved to ? Grade 1 (NCI-CTCAE version 4.03); 9. Acceptable laboratory values at screening; 10. Male patients must agree to use an adequate and medically accepted method of contraception throughout the study and for at least 3 months after if their sexual partners are women of child bearing potential (WOCBP).Xx_NEWLINE_xXWOCBP or males with a WOCB partners not willing to use highly effective and medically accepted methods of contraception for 90 days after last study drug administration.Xx_NEWLINE_xXMale subjects agree to ensure that they or their female partner(s) use adequate contraception during the study and for at least 12 weeks (or longer as per local requirement) after the subject receives their last dose of study treatment.Xx_NEWLINE_xXSubjects with reproductive capability must agree to practice adequate contraception methods.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception.Xx_NEWLINE_xXSubjects with reproductive capability must agree to practice adequate contraception methods.Xx_NEWLINE_xXDuring the study and for at least 120 days after receiving the last dose of study drug, in addition to the highly effective method of contraception, a man who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (example [eg.], condom with spermicidal foam/gel/film/cream/suppository), or who is sexually active with a woman who is pregnant must use a condomXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception.Xx_NEWLINE_xXMale patients who agree to practice effective barrier contraception.Xx_NEWLINE_xXFor female individuals of childbearing potential and male individuals of reproductive potential, willingness to use a protocol- recommended method of contraceptionXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug.Xx_NEWLINE_xXMale patients at screening must agree to practice adequate contraception from study entry through at least 6 months after discontinuation of study drug.Xx_NEWLINE_xXWomen of childbearing potential must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatmentXx_NEWLINE_xXMales not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatmentXx_NEWLINE_xXParts A and B: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drugXx_NEWLINE_xXParts C, D and E: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drugXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of imatinib. Male patients must use highly effective contraception during the study and for 30 days after the final dose of imatinib. Highly effective contraception is defined as either:Xx_NEWLINE_xXInclusion Criteria:\n\n        Patients must meet all of the following inclusion criteria to be eligible for enrollment:\n\n          -  Ability to understand the risks, benefits, and alternative to participation and give\n             informed consent\n\n          -  Have biopsy proven skin cancer on the medial forehead that is amenable to Mohs\n             surgery. Medial forehead is defined as the area superiorly from the hairline,\n             inferiorly at the eyebrow, and laterally to the tip of the lateral brow (see diagram).\n\n          -  Undergoing elective reconstruction of biopsy proven skin cancer that is amenable to\n             Mohs surgery with defect size measuring 1.0 cm or greater\n\n          -  If female, not currently pregnant, no potential for pregnancy, or if of child-bearing\n             age, must agree to use adequate contraception (e.g., hormonal or barrier method of\n             birth control; abstinence) for 30 days after the last dose of study drug. A negative\n             urine pregnancy test is required at study entry for female subjects of childbearing\n             potential: a woman is considered to be of child bearing potential unless she has had a\n             tubal ligation, total hysterectomy, bilateral oopherectomy, or is postmenopausal\n             (without a menstrual period for at least one year)\n\n          -  Agrees to not use disallowed concomitant medications (retinoids)\n\n        Exclusion Criteria:\n\n        The presence of any of the following will exclude a patient from study enrollment.\n\n          -  Pregnant women, women who are breastfeeding, or women of child bearing age who are\n             unwilling to use adequate contraception (described above) during the study period\n\n          -  Current or past history of a neuromuscular disease (such as myasthenia gravis,\n             amyotrophic lateral sclerosis, Eaton-Lambert syndrome)\n\n          -  Currently taking aminoglycosides or other agents interfering with neuromuscular\n             transmission (e.g., curare-like agents)\n\n          -  History of radiation therapy or chemotherapy\n\n          -  History of keloid or other hypertrophic scar formation\n\n          -  Current or past history of scleroderma\n\n          -  Has used botulinum toxin in the forehead area within one year.\n\n          -  Has significant resting eyebrow ptosis\n\n          -  Has used any topical retinoids to the forehead area within the past 4 weeks\n\n          -  Undergo any scar revision procedure for the duration of the study including\n             intralesional kenalog, laser treatment, and/or scar revision surgeries\n\n          -  Any hypersensitivity to any component of abobotulinumtoxinA (i.e. cow milk protein) or\n             any previous hypersensitivity to any botulinum toxin A or related product.\n\n          -  Non-English speaking: These patients are excluded since translation of the informed\n             consent into other languages is time-consuming and expensive as it requires a bona\n             fide translator for the particular language of interest and this type of person may be\n             difficult to locate.\n\n          -  House staff and students, medical students on a clerkship, and employees related to\n             study personnel or who work for any study personnel, and members of the study team are\n             not eligible to participate in this study as a subject.\n\n          -  The investigator feels that for any reason the subject is not eligible to participate\n             in the studyXx_NEWLINE_xXMan and woman of childbearing potential, (entering the study after a menstrual period and who have a negative pregnancy test) must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intakeXx_NEWLINE_xXSexually active male patients unwilling to practice contraception while participating on the study and up to 30 days after completion of treatmentXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing. The investigator should advise the patient how to achieve an adequate contraception.Xx_NEWLINE_xXWillingness to use effective contraception (both males and females of child-bearing potential) throughout the study and for at least 2 months after study treatment.Xx_NEWLINE_xXAgrees to protocol-defined use of effective contraceptionXx_NEWLINE_xXMale subjects must agree to contraceptive use during the study period (7 months) and non-menopausal female subjects must agree to contraception for the remainder of their childbearing yearsXx_NEWLINE_xXNon-childbearing potential (defined as surgically sterile or at least 2 years postmenopausal) or practicing effective contraception (defined as 2 concurrent methods of contraception, 1 of which is a barrier method) and agrees to continue using effective contraception throughout the duration of the study;Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of contraception during the study and for 1 month following the last dose with study drug. Post menopausal females (>45 years old and without menses for >1 year) and surgically sterilized females are exempt from this criterion.Xx_NEWLINE_xXMale subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.Xx_NEWLINE_xXMale subjects are eligible to participate if they agree to the following during the intervention period and for at least 140 days: Refrain from donating sperm; Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1 percent per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.Xx_NEWLINE_xXMales must be willing to use an effective method of contraception to avoid seminal transfer (double barrier method) or abstinence for the duration of treatment with TAR 200 in combination with nivolumab plus 5 half-lives of the study treatment, plus 90 days (duration of sperm turnover), for a total of 7 months post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time.Xx_NEWLINE_xXFemale patients who are not of child-bearing potential and fertile females of childbearing potential who agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 3 days prior to the start of study treatment; male patients willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for 3 months after treatment stopsXx_NEWLINE_xXMale subjects must agree to refrain from sperm donation throughout the duration of the study and for 90 days following the last dose of study drug;Xx_NEWLINE_xXMale or female, age 18 or above, who agree to use barrier contraception throughout the study. Females of child-bearing potential must be non-pregnant and non-lactating throughout the study.Xx_NEWLINE_xXFertile patients must use effective contraceptionXx_NEWLINE_xXMale patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner.Xx_NEWLINE_xX7. Participants must agree to use an adequate method contraception.Xx_NEWLINE_xXIs not pregnant, and if not postmenopausal or a surgically sterile male or female, is willing to use a highly effective contraceptive method upon enrollment, during the course of the study, and for 3 months following the last dose of investigational drugXx_NEWLINE_xXNot of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 3 months after the last dose of study drug.Xx_NEWLINE_xXThe contraception's used by female subject's be consistent with local regulations, regarding methods of contraception for those participating in clinical studies. A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (WOCBP) or Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, during the intervention period and for at least 120 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. WOCBP must have 2 negative highly sensitive serum pregnancy tests, as required by local regulations (first within 14 days of Cycle 1 Day 1 and the second one within 72 hours of dosing on Cycle1 Day1) and agree to use effective contraception during the study and for 120 days after the last dose of study medication; The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.Xx_NEWLINE_xXMale subject's using contraception should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Males are eligible to participate if they as detailed below: Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a WOCBP who is not currently pregnant.Xx_NEWLINE_xXMale participants must agree to use contraception during the treatment period and for ?195 days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condomXx_NEWLINE_xXMale patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partnerXx_NEWLINE_xXFemale participants must not be pregnant, not breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.Xx_NEWLINE_xXFor female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab; a negative serum pregnancy test is required for female subjects at screening; lactating females must agree to discontinue nursing before administration of study drugsXx_NEWLINE_xXFor male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugsXx_NEWLINE_xXMale patients must agree to use effective contraception or be abstinent while on study and for 90 days after the infusion of IMA202 productXx_NEWLINE_xXPregnancy, breast feeding, or unwillingness to use effective contraception during the study.Xx_NEWLINE_xXWillingness of male and female patients, if sexually active, to use an effective barrier method of contraception during the study and for 3 months following the last dose of study drugXx_NEWLINE_xXMen must use adequate methods of contraception during and at least 3 months after treatment if engaging in sexual activity with a female of child bearing ageXx_NEWLINE_xXWomen of child bearing potential who are unwilling to use effective contraception for the duration of the study drug administration and 6 months after final dose of drug is administered;Xx_NEWLINE_xXPregnancy, breast feeding, or unwillingness to use effective contraception during the studyXx_NEWLINE_xXFCBP who are unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvecXx_NEWLINE_xXWomen who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing two highly effective and acceptable forms of contraception throughout their participation in the study and for 90 days after last dose of study drugXx_NEWLINE_xXFemale and male patients must use an effective contraceptive method during the study and for at least 6 months thereafterXx_NEWLINE_xXMale patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner.Xx_NEWLINE_xXFor fertile patient (female able to become pregnant or male able to father a child), refusal to use effective contraception during the period of the trial and for 6 months after the last dose of rucaparibXx_NEWLINE_xXMen treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of enzalutamide and PDMX1001/niclosamide administrationXx_NEWLINE_xXFemales and males of reproductive potential must use effective contraception during and after treatment for 6 monthsXx_NEWLINE_xXFemale patients with childbearing potential should agree to use effective, nonhormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of at least 3 months following the last administration of study drugXx_NEWLINE_xXMale patients must agree to use effective contraception during the study and for a period of at least 6 months following the last administration of study drugs, even if they have been surgically sterilizedXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXSubjects must use effective contraceptive methods during the study and for three months following the last dose of study product, if of reproductive age and still retain fertility potential.Xx_NEWLINE_xXMale and female participants of reproductive potential must use an effective contraceptive method during the study and for a minimum of 6 months after study treatmentXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 5 months after the last dose of atezolizumabXx_NEWLINE_xXFemale subjects with childbearing potential and male subjects should use effective contraception methods (or abstain from sexual activity) while being treated with APX005M and for 30 days following treatmentXx_NEWLINE_xXMale subject with a female partner of childbearing potential or pregnant must agree to use two acceptable methods of contraception from time of first dose of study treatment until 4 months after the last dose of study treatmentsXx_NEWLINE_xXPatients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last infusion of HuMax-AXL-ADCXx_NEWLINE_xXSubjects with reproductive potential must be willing to use, in combination with his/her partner, 2 highly effective methods of effective contraception or practice sexual abstinence throughout the study and continue for 5 months after the study duration; subjects who are surgically sterile (e.g. history of bilateral tubal ligation, hysterectomy) or whose sexual partner is sterile (e.g. history of vasectomy) are not required to use additional contraceptive measuresXx_NEWLINE_xXFemale subject of child-bearing potential is not willing to use, in combination with her partner, 2 methods of highly effective contraception during treatment and for 5 months after the end of treatmentXx_NEWLINE_xXMale patients with partners of childbearing potential must use barrier contraception.Xx_NEWLINE_xXSexually active males must be strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of BAL101553; women of childbearing potential must agree to use highly-effective contraceptive methods for the duration of study participation and for an additional 90 days after the last dose of study drug; highly-effective contraceptive methods include male or female sterilization (bilateral tubal occlusion or vasectomy); intrauterine device (IUD); combined (estrogen- and progesterone-containing) hormonal contraception (oral, vaginal ring or transdermal patch) with an ethinylestradiol dose of at least 30 ug, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm or a cervical cap; or total sexual abstinence; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; male patients must agree not to donate sperm from the first dose of study drug until 90 days after the last dose of study drug; male patients, without a vasectomy and with a partner of childbearing potential, must agree to use condoms during the study and for at least 90 days after the last dose of study drug; the patient should be instructed that their female partner should use another form of contraception for the duration of the study and continue this use for at least 90 days after the last dose of study drugXx_NEWLINE_xXThe subject must agree to use two effective forms of contraception beginning at least four (4) weeks prior to study entry, and continuing to do so for the duration of their participation in the studyXx_NEWLINE_xXMales who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) study therapy plus 5 half-lives of the study drug study therapy up to 25 days plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completionXx_NEWLINE_xXA WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatmentXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Women of childbearing potential and men must agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study; breastfeeding should be discontinued while the patient is on this trial and for 30 days following last dose of study drugXx_NEWLINE_xXARM A: The patient and their partner agree to use a barrier method of contraception during the study and 4 months following end of active treatmentXx_NEWLINE_xXARM B: The patient and their partner agree to use a barrier method of contraception during the study and 4 months following end of active treatmentXx_NEWLINE_xXMale patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partnerXx_NEWLINE_xXMales and females of reproductive potential must use two forms of effective contraception during the duration of the trial and for minimum of 7 months after last dose of tocilizumab, trastuzumab, or pertuzumab; a woman of reproductive potential is defined as a premenopausal female with intact uterus and ovariesXx_NEWLINE_xXBoth female and male patients of reproductive potential must agree to avoid pregnancy or impregnating a partner (respectively) while receiving drug and for 120 days after last dose of study drugXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) must agree to use adequate contraception when sexually active; patients should continue contraception for 6 months after finishing study drugXx_NEWLINE_xXWomen of childbearing potential and male patients should use effective contraception during treatment with MM-398 and for 90 days following the final dose of veliparib and MM-398 for both female and male patients; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXThe patient must be willing to comply with fertility requirements as below:\r\n* Male patients must agree to use an adequate method of contraception for the duration of the study and for 28 days afterwards\r\n* Female patients must be either postmenopausal, free from menses >= 2 yrs, surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from heterosexual activity starting with screening (4 weeks prior to initiating treatment) and for 28 days after treatment, per POMALYST REMS program\r\n* Patients must agree not to donate blood, sperm/ova during the course of taking protocol therapy and for at least 4 weeks after stopping treatmentXx_NEWLINE_xXSubjects must agree to use effective contraception from enrollment through completion of the studyXx_NEWLINE_xXAll patients of reproductive potential (heterosexually active men and women) must agree to a use of a barrier method of contraception and a second method of contraception and men must agree not to donate sperm during the study and for at least 4 weeks after receiving the last dose of study treatmentXx_NEWLINE_xXMales & women of childbearing potential must agree to abstain from sex or use an adequate method of contraception for the duration of study, & for 6 months after last dose of study drugXx_NEWLINE_xXWomen of childbearing potential and males with partners of childbearing potential must agree to the use of barrier methods of contraception, hormonal contraceptives, or to abstain from heterosexual activity for the duration of study treatment and for 3 months after the last dose of study drugXx_NEWLINE_xXMen must agree to use adequate contraception; specifically, they must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 120 days (4 months) following the last dose of study drug; they must also agree not to donate sperm during the study and for 4 months after receiving the last dose of study drugXx_NEWLINE_xXIf sexually active, willingness to use effective barrier or medical contraceptionXx_NEWLINE_xXRefusal to use adequate contraception for fertile patients (females and males) while\n             on treatment and for 12 weeks after the last dose of rociletinibXx_NEWLINE_xXPatients must agree to use 2 methods of adequate contraception for the duration of study participation, and for four months after discontinuing therapyXx_NEWLINE_xXPatients must agree to use dual forms of contraception from the time of consent until 6 months after completion of the studyXx_NEWLINE_xXFemale subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects, even if surgically sterilized (ie, status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXSubjects must use 2 forms of highly effective contraception concomitantly from the initiation of study therapy until 6 months after the last dose of study therapy; additionally, the use of condoms is required; it should also be noted that, where 2 forms of effective contraception are required, a subject may choose to use a double-barrier method consisting of condom and cervical occlusive cap / diaphragm with spermicideXx_NEWLINE_xXIt is important patients understand the need to use birth control while on this study; female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening (< 3 days prior to first dose), male patients with partners of childbearing potential must agree to use effective contraception during the study period and a period of 3 months after the last dose of study drug; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last doseXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after the last dose of MPDL3280AXx_NEWLINE_xXA male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study (and for up to 12 weeks after the last dose of study drug) to minimize the risk of pregnancy; if the partner is pregnant or breastfeeding, the subject must use a condomXx_NEWLINE_xXMale subjects must agree to practice contraception as directedXx_NEWLINE_xXWomen of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy (chemotherapy, trastuzumab, pertuzumab, and estrogen deprivation therapy) and for at least 7 months after the last dose of study therapyXx_NEWLINE_xXPatients who do not agree to practice effective forms of contraceptionXx_NEWLINE_xXA highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctlyXx_NEWLINE_xXNonsterilized males who are sexually active with a female partner of child-bearing potential must use a highly effective method of contraception from day 1 through 90 days after receipt of the final dose of investigational productXx_NEWLINE_xXMale patients with female partners of childbearing potential who do not agree to use two Food and Drug Administration (FDA)-accepted forms of contraception during sexual intercourse with women of child-bearing potential from the start of ipilimumab and up to at least 6 months after ACT are excludedXx_NEWLINE_xXFemale patients of childbearing potential who do not agree to use two FDA forms of contraception during sexual intercourse from the start of ipilimumab and up to at least 6 months after ACT are excludedXx_NEWLINE_xXMale patients with female partners of childbearing potential who do not agree to use two Food and Drug Administration (FDA)-accepted forms of contraception during sexual intercourse with women of child-bearing potential from the start of vemurafenib and up to at least 6 months after discontinuing vemurafenib are excludedXx_NEWLINE_xXFemale patients of childbearing potential who do not agree to use two FDA forms of contraception during sexual intercourse from the start of vemurafenib and up to at least 6 months after discontinuing vemurafenib are excludedXx_NEWLINE_xXPatients of childbearing age who are unwilling to practice contraceptionXx_NEWLINE_xXFemale patients of childbearing potential (a female not free from menses > 2 years or not surgically sterilized) must be willing to use an adequate barrier method of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study; male patients who are able to father children must use an adequate barrier method of contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to practice adequate contraception during therapyXx_NEWLINE_xXSexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least 6 months after the completion of bevacizumab therapyXx_NEWLINE_xXWomen of childbearing potential and sexually active male participants must agree to practice adequate contraception while on study and for at least 60 days following the last dose of chemotherapy or trastuzumabXx_NEWLINE_xXMale subjects must agree to the use of male contraception during the treatment period and for at least 180 days after the last dose of any study drugXx_NEWLINE_xXMale subjects must agree to the use of male contraception during the treatment period and for at least 180 days after the last dose of any study drugXx_NEWLINE_xXMale patient agrees to use an adequate method of contraception for the duration of the studyXx_NEWLINE_xXMale patients must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 1 month following the last study drug infusionXx_NEWLINE_xXAnd, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and throughout the study period and for 180 days after the final study drug administration.Xx_NEWLINE_xXMale subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and continue throughout the study period and for 120 days after the final study drug administration.Xx_NEWLINE_xXPatients of reproductive potential must agree to use effective contraception during the period of therapyXx_NEWLINE_xXPatients (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMen of reproductive potential and those who are surgically sterilized (i.e., post-vasectomy) must agree to practice effective barrier contraception or agree to abstain from intercourse while receiving treatment on this study and for at least 4 months after protocol treatment endsXx_NEWLINE_xXIn a man whose sexual partner is a woman of childbearing potential, unwillingness or inability of the man or woman to use a highly effective contraceptive method for the entire study treatment period for at least 3 months after study completion. Male subjects must not freeze or donate sperm starting at Screening and throughout the study period, and 105 days after the final study drug administration.Xx_NEWLINE_xXAll sexually active subjects agree to use barrier contraception (i.e., condoms) while receiving study treatment and for 120 days following their last dose of study treatment. WOCBP and males whose sexual partners are WOCBP agree to use barrier contraception and a second form of contraception while receiving study treatment and for 120 days following their last dose of study treatment.Xx_NEWLINE_xXIf of childbearing potential (male or female), agree to practice an effective form of contraception during study treatment and for at least 23 weeks after for female and 31 weeks after for male following last treatment dose.Xx_NEWLINE_xXcommit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved contraception throughout the study without interruption, and while receiving study medication or for a longer period if required by local regulations. Male subjects must:Xx_NEWLINE_xXECOG performance status of 0 to 1  In sexually-active patients, willingness to use 2 effective methods of contraceptionXx_NEWLINE_xXFemale patients must:\r\n* Be postmenopausal for at least 1 year before the screening visit, OR\r\n* Be surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale patients, even if surgically sterilized (i.e., status post-vasectomy), must:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, OR\r\n* Agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale patient agrees to use an adequate method of contraceptionXx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception existsXx_NEWLINE_xXMan, who is sexually active with a woman of child-bearing potential potential must agree to use a latex or synthetic condom, even if he had a successful vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and for 4 weeks after last dose of lenalidomide and 4 months after last dose of daratumumabXx_NEWLINE_xXPatient who does not apply highly effective contraception during the study and through the duration as defined below after the final dose of study treatmentXx_NEWLINE_xXUse of highly effective contraception (as defined by protocol) and until 5 months after the last dose of atezolizumab and for 3 months after the last dose of alectinib or for 2 weeks after the last dose of erlotinib, whichever is longer; Males must also refrain from sperm donatation during this same time period. Participants must not be pregnant or breastfeeding.Xx_NEWLINE_xXSexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential must agree to use a highly effective method of contraception. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception.Xx_NEWLINE_xX? 18 years of age 7. Life expectancy of ? 6 months per the investigator 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 9. ECG without evidence of clinically significant arrhythmia or ischemia 10. If female of childbearing potential (FCBP), willing to undergo pregnancy testing and agrees to use at least one highly effective or two effective contraceptive methods during the dosing period and for three months after last CMB305 injection 11. If male and sexually active with a FCBP, must agree to use highly effective contraception such as latex condom during the dosing period and for three months after last CMB305 injectionXx_NEWLINE_xXParticipants must agree to be willing to use effective methods of contraception as defined in the protocolXx_NEWLINE_xXMale patients (except those with prior surgical contraceptive procedures) with female partners who are of childbearing potential: Recommendation is for male and partner to use effective contraceptive methods, such as latex condoms, during the studyXx_NEWLINE_xXFor female participants of childbearing potential, agreement to use highly effective form(s) of contraception and to continue its use for 6 months after the last dose of MOXR0916Xx_NEWLINE_xXMen treated or enrolled on this protocol must agree to use 2 adequate methods of contraception starting with the screening visit, for the duration of study participation, and through 120 days after the last dose of MK-3475 administrationXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP must agree to use adequate contraception as defined above during the study and for 8 weeks after the end of treatment; condom use is required by all male patients in order to prevent delivery of the drug via seminal fluidXx_NEWLINE_xXWomen of childbearing potential must agree and commit to the use of a highly effective non-hormonal method of contraception, ie, intrauterine device, bilateral tubal ligation, vasectomized partner, or abstinence (only when it is the preferred lifestyle of the patient), from the time of informed consent until 28 days after the last dose of the investigational products. Men and their female partners of childbearing potential must agree and commit to use a highly effective method of contraception (ie, any of the above methods or hormonal contraception associated with inhibition of ovulation) while on treatment and for 3 months after last dose of investigational productsXx_NEWLINE_xXPatients who are sexually active and unwilling to use effective contraception (if they are not already surgically sterile)Xx_NEWLINE_xXPregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within 28 days of study entry; female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraceptive during the period of the trial and for at least 90 days after completion of treatment; the decision of effective contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXA man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the studyXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study treatment, ANDXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, ANDXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use an effective method of contraceptionXx_NEWLINE_xXPregnancy or breast-feeding; patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the MSKCC and participating site principal investigator (PI); male patients must be surgically sterile or agree to use effective contraceptionXx_NEWLINE_xXMales who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment (i.e., 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives)Xx_NEWLINE_xXAgrees to follow protocol-defined method(s) of contraceptionXx_NEWLINE_xXMen should be willing to use barrier contraception (ie, condoms) and refrain from sperm donation during and after the conduct of the trial.Xx_NEWLINE_xXMale patients must use a condom from the time of the first administration of ONO-7475 until 4 months following administration of the last dose.Xx_NEWLINE_xXFemales of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.Xx_NEWLINE_xXAgree to use contraception from screening, through the study, and for at least 5 months after the last dose of nivolumab as follows: for women of childbearing potential agree to use highly effective contraceptive methods; for males, agree to use a condom with sexual partner.Xx_NEWLINE_xXFor male patients who are sexually active and who are partners of premenopausal women: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug.Xx_NEWLINE_xXShe must either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and be source documented) or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study treatment, during the study therapy (including dose interruptions), and for 90 days after discontinuation of study treatment.Xx_NEWLINE_xXIf female of childbearing potential (FCBP), willing to undergo pregnancy testing and agrees to use at least one highly effective or two effective contraceptive methods during the dosing period and for three months after last LV305 injection. If enrolled on the arm that includes pembrolizumab, agrees to use highly effective contraceptive methods during the dosing period and for 120 days after last injection of study drug.Xx_NEWLINE_xXIf male and sexually active with a FCBP, must agree to use highly effective contraception such as latex condom during the dosing period and for three months after last LV305 injection. If enrolled on the arm that includes pembrolizumab, agrees to use highly effective contraceptive methods during the dosing period and for 120 days after last injection of study drug.Xx_NEWLINE_xXWillingness to avoid pregnancy and breast feeding beginning two weeks before the first MSC2363318A dose and ending three months after the last trial treatment. Male subjects with female partners of childbearing potential and female subjects of childbearing potential must use adequate contraception in the judgment of the Investigator, such as a two barrier method or a one barrier method with spermicide or intrauterine device during trial treatment dosing and for 3 months after the last dose of the study.Xx_NEWLINE_xXAgrees to protocol-defined use of effective contraceptionXx_NEWLINE_xXIf female, is post-menopausal, surgically sterilized or willing to use an effective method of contraception for the duration of the study and for 3 months after the end of treatment. If male, has agreed to use barrier method for contraception for the duration of the study and for 3 months after the end of treatment.Xx_NEWLINE_xXPatients of child-bearing potential must agree to use a medically approved contraception method until at least six weeks after the last study drug administration.Xx_NEWLINE_xXUse of highly effective method of contraception as defined by the protocolXx_NEWLINE_xXAgree to practice true abstinence2 (which must be reviewed on a monthly basis and source documented) or agree to the use of a highly effective method of contraceptionuse from 28 days prior to starting durvalumab or azacitidine, and must agree to continue using such precautions while taking durvalumab or azacitidine (including dose interruptions) and up to 90 days after the last dose of durvalumab or azacitidine. Cessation of contraception after this point should be discussed with a responsible physician.Xx_NEWLINE_xXEither practice true abstinence3 from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of childbearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of durvalumab or azacitidine.Xx_NEWLINE_xXAMKL PATIENTS: Male patients, even if surgically sterilized (i.e. status post-vasectomy) agrees to use an acceptable method for contraception during the entire study treatment period through 120 days after the last dose of alisertib; likewise, female patients should agree to use acceptable method for contraception during the entire study treatment period through 90 days after the last dose of alisertibXx_NEWLINE_xXMF PATIENTS: Male patients, even if surgically sterilized (i.e. status post-vasectomy) agrees to use an acceptable method for contraception during the entire study treatment period through 120 days after the last dose of alisertib; likewise, female patients should agree to use acceptable method for contraception during the entire study treatment period through 90 days after the last dose of alisertibXx_NEWLINE_xXMen, capable of fathering a child, who are unwilling to use adequate contraception prior to study entry, for the duration of study participation, and for at least 28 days after treatment has ended.Xx_NEWLINE_xXIf male and sexually active with a FCBP, must agree to use highly effective contraception such as latex condom or is sterile (e.g. following a surgical procedure) during the dosing period and for three months after last study treatment, or if receiving pembrolizumab, four months after last treatmentXx_NEWLINE_xXSexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.Xx_NEWLINE_xXHighly effective contraception for both male and female subjects, if the risk of conception existsXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMale subjects must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until least 16 weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant while on study medication must continue to use condoms for 7 days after stopping study medications.Xx_NEWLINE_xXMale subject unwilling to use an acceptable method for contraception for the duration of the study and one year beyond treatment completion, will not be eligible to participate in the studyXx_NEWLINE_xXEffective contraceptionXx_NEWLINE_xXContraception.Xx_NEWLINE_xXFemale patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210Xx_NEWLINE_xXIf of childbearing potential (male or female), agrees to use effective contraception during study treatment and for at least 6 months following last treatment dose.Xx_NEWLINE_xXSubjects must use effective contraception:Xx_NEWLINE_xXFor female and male patients who are fertile, agree to use a highly effective form of contraception, as defined by the study protocol.Xx_NEWLINE_xXPatients (male or female) of reproductive potential must agree to use an effective method of contraception (as discussed with treating physician) from the time consent is signed, during study therapy, and for at least 90 days after the last dose of study therapy.Xx_NEWLINE_xXMen treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of the study participation, and for 3 months after completion of treatmentXx_NEWLINE_xXSubjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the studyXx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last doseXx_NEWLINE_xXcommit to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraceptionXx_NEWLINE_xXuse an effective barrier method of contraceptionXx_NEWLINE_xXMale subjects with a female partner of childbearing potential must either commit to true abstinence* or agree to the use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the study and for 3 months following the last dose of the IP (Investigational Product).Xx_NEWLINE_xXMale or female patients of child-producing potential agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 dose.Xx_NEWLINE_xXAgree to use contraception per protocolXx_NEWLINE_xXWOCBP and men must agree to use adequate contraception prior to study entry and for duration of treatment under this protocol; adequate contraception is defined as any medically recommended method (or combination of methods) per standard of careXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXFemale patients of childbearing potential and male patients with partners of childbearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the 30-day nontreatment follow-up period.Xx_NEWLINE_xXPregnancy or breastfeeding. Female patients must be surgically sterile (i.e.: hysterectomy) or be postmenopausal, or must agree to use effective contraception during the study and for 3 months following last dose of TRC105. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to first dose. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 3 months following last dose of TRC105. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate.Xx_NEWLINE_xXPatients of reproductive potential must practice effective contraception while on study and for at least 60 calendar days following treatment.Xx_NEWLINE_xXPatients must be willing to practice effective contraception for the duration of the studyXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXFemales of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in the study protocolXx_NEWLINE_xXFemale patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210.Xx_NEWLINE_xXWomen of childbearing potential and fertile men must agree to use adequate contraception when sexually active. This applies from the time period between signing of the informed consent until at least 6 months after the last administration of the last study drug. Male patients with a female partner of childbearing potential must use a condom and ensure that an additional form of contraception is also used during treatment and until 6 months after last study drug administration.Xx_NEWLINE_xXIf they are of childbearing potential, agree to practice 1 highly effective method of contraception, and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc;]) after the last dose of study drug, ORXx_NEWLINE_xXAgree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug (or longer, as mandated by local labeling [example, USPI, SmPC, etc]), ORXx_NEWLINE_xXAgreement to use highly effective forms of contraception during the study and for 90 days after the last dose of ACP 196, 120 days after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longest.Xx_NEWLINE_xXare currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation,Xx_NEWLINE_xXNonsterilized males who are sexually active with a female partner of childbearing potential must, with their partner, use 2 acceptable methods of effective contraception from Day 1 through 60 days after receipt of the final dose of study medication.Xx_NEWLINE_xXIf they are of childbearing potential, agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, orXx_NEWLINE_xXFemales of childbearing potential (not surgically sterile or less than 12 months post-menopausal) must be able and willing to use a highly effective form of pregnancy prevention from the time of screening, during the study and 30 days after last dose of study regimen. Males with a partner of childbearing potential must use condoms with spermicide from the date of screening to 30 days after their last dose of study regimenXx_NEWLINE_xXPregnancy Prevention Patients of childbearing or child fathering potential must use a highly effective method of contraception throughout the study while taking the drug and for 21 days after stopping treatmentXx_NEWLINE_xXMan, who is sexually active with a woman of child-bearing potential and has not had a vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and 3 months after last dose of daratumumabXx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last doseXx_NEWLINE_xXA man who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (eg, condom with spermicidal foam/gel/film/cream/suppository), man who is sexually active with a woman who is pregnant must use a condom and men must agree not to donate sperm for 90 days after the last dose of study drugXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate.Xx_NEWLINE_xXBoth females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXPatients who are sexually active must use a reliable form of contraception while on study and for 4 weeks after the last immunizationXx_NEWLINE_xXMale subjects with female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the studyXx_NEWLINE_xXFertile males or females of childbearing potential agree to use adequate contraception prior to study entryXx_NEWLINE_xXMale participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period and for 6 months after discontinuation of chemotherapy and for 5 weeks after Test Article (amatuximab or placebo) discontinuation (whichever is later). No sperm donation is allowed during the study period and for 90 days after Test Article discontinuation.Xx_NEWLINE_xXMale subject, even if surgically sterilized (ie, status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent), or completely abstain from heterosexual intercourse during the entire study treatment period through 4 months after the last dose of alisertibXx_NEWLINE_xXMales with female partners of child bearing potential must agree to use protocol defined methods of contraception (see below) and agree to refrain from donating sperm for the duration of the studyXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing a highly effective form of contraception. During the study treatment and for 8 weeks after stopping the treatment. Highly effective contraception methods include combination of any two of the following:Xx_NEWLINE_xXMale patients should be willing to use barrier contraception, i.e., condoms, until 3 months after last study drug is taken.Xx_NEWLINE_xXWOCBP and men must agree to use adequate contraception prior, to study entry, for the duration of study participation, and 8 weeks after the end of treatmentXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the administration of the first dose of study treatment until 3 months after the last dose of study treatment to allow for clearance of any altered sperm.Xx_NEWLINE_xXFor female participants of childbearing potential, agreement (by both participant and partner) to use an effective form of contraception for the duration of the study and for 6 months after last dose of study treatmentXx_NEWLINE_xXFemale participants of childbearing potential and male partners with female partners of childbearing potential must agree to use 2 adequate barrier methods of contraception during the study and for 120 days after last dose of study drug and up to 180 days after last dose of chemotherapyXx_NEWLINE_xXEffective contraception as defined by protocolXx_NEWLINE_xXMale and female participants of reproductive potential must agree to use medically approved contraceptive precautions during the trial and 3 to 4 months (as appropriate) following last dose of study drug.Xx_NEWLINE_xXUse of highly effective contraception as defined by the study protocolXx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 14 days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigatorsXx_NEWLINE_xXFor female participants of childbearing potential, agreement to use highly effective forms of contraception Dose-Escalation Portion of the Study:Xx_NEWLINE_xXPatients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.Xx_NEWLINE_xXMales and females of childbearing potential must agree to use protocol-specified method(s) of contraceptionXx_NEWLINE_xXBoth females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXMale subjects must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.Xx_NEWLINE_xXFemale patients who:\r\n* Are postmenopausal for at least 1 year before the Screening visit, OR\r\n* Are surgically sterile OR\r\n* If they are of childbearing potential, agree to practice 2 effective methods of contraception at the same time from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale patients, even if surgically sterilized (ie, status postvasectomy), who: must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXWomen of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the participant and/or partner for the duration of the study treatment and for at least 7 months after the last dose of study drugXx_NEWLINE_xXSubject agrees to use adequate contraception during the study period and for 12 weeks after last dose of study therapyXx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 14 days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigatorsXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 90 days after the last dose of Atezolizumab.Xx_NEWLINE_xXPregnancy, lactation, or breast-feeding; patients must be surgically sterile, postmenopausal, or must agree to use effective contraception during the period of therapy and for 5 months after the last dose of atezolizumab; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate; male patients must be surgically sterile or agree to use effective contraception; male patients will be encouraged to notify the study team if their female partner becomes pregnant while on studyXx_NEWLINE_xXA male subject must agree to use and to have their female partners of childbearing potential to use a highly effective contraception (i.e., methods with a failure rate of less than 1 % per year) as detailed in Appendix VII of this protocol from the first dose of study treatment, during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period. Male subjects should always use a barrier method such as condom concomitantly.Xx_NEWLINE_xXAnd, if heterosexually active, agree to consistently use 2 forms of effective contraception per locally accepted standards, 1 of which must be a barrier method, starting at screening and throughout the study period and for 180 days after the final study drug administration.Xx_NEWLINE_xXMale subject and their female partners who are of childbearing potential must be using 2 forms of effective contraception per locally accepted standards, 1 of which must be a barrier method, starting at screening and continue throughout the study period, and for 120 days after the final study drug administration.Xx_NEWLINE_xXMust not be pregnant or breastfeeding; female patients who are sexually active and of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients who are sexually active must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; for both male and female patients who are sexually active, effective methods of contraception must be used throughout the study and for three months following the last dose; abstinence is an acceptable form of contraceptionXx_NEWLINE_xXSurgically sterile patients or patients of child-bearing potential who agree to use highly effective methods of contraception during study dosing and for 6 months after last dose of study drugXx_NEWLINE_xXPatients of childbearing potential are permitted in the study so long as they consent to avoid getting their partner pregnant or becoming pregnant, respectively, by using a reliable method(s) of contraception during and for 3 months following the last dose of the study drugsXx_NEWLINE_xXIf male, patient must be sterile or willing to use an approved method of contraception from the time of Informed Consent to 90 days after study drug treatment. Males must be willing to refrain from sperm donation within 90 days after study treatment.Xx_NEWLINE_xXPersons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 3 months after completion of study.Xx_NEWLINE_xXSubject is using effective contraception.Xx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal or, if of childbearing potential, must agree to use an adequate method of contraception during the study until 30 days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatmentXx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXAll subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on studyXx_NEWLINE_xXAll participants must agree to use double barrier contraception during study participation and for at least 2 months after the last dose of study drug.Xx_NEWLINE_xXFemale subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of investigational product; the male partner of a female subject must also use male condom plus spermicide throughout this period; cessation of birth control after this point should be discussed with a responsible physician; not engaging in sexual activity is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; female patients should refrain from breastfeeding and egg cell donation throughout this period\r\n* Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause)\r\n* A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctlyXx_NEWLINE_xXNon-sterilized male subjects who are sexually active with a female partner of childbearing potential must use male condom plus spermicide from screening through 180 days after the last dose of investigational product; not engaging in sexual activity is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; male patients should refrain from sperm donation throughout this period; female partners of a male subject must use an effective method of contraception throughout this periodXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the consent form until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXHave negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use highly effective precautions to prevent pregnancy during the study and for 12 weeks following last dose of study treatment.Xx_NEWLINE_xXFor male patients with female partners of childbearing potential, agreement to use adequate contraception while you are participating in the study and 1 month after applying your last doseXx_NEWLINE_xXFemales of child-bearing potential must have a negative serum pregnancy test within 14 days prior to start of study treatment and must use an adequate method of contraception during the study. All sexually active males must also use an adequate method of contraception during the study.Xx_NEWLINE_xXMale subjects with female partners of child bearing potential must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until 16 weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant on study medication must continue to use condoms for 7 days after stopping study medicationXx_NEWLINE_xXInclusion Criteria: Each patient MUST:\n\n          -  Have histologically confirmed advanced or metastatic pancreatic adenocarcinoma and\n             have failed or did not tolerate first-line therapy.\n\n          -  Have either archival tissue available for immune testing OR if not, a baseline biopsy\n             of a primary or metastatic lesion (including ascites) which is accessible for a biopsy\n             that can be accomplished with reasonable safety.\n\n          -  Be available and agree to; a post-treatment tumor biopsy of either a primary or\n             metastatic lesion (including ascites).\n\n          -  Have measurable disease.\n\n          -  Have no continuing acute toxic effects (except alopecia) of any prior anticancer\n             treatment, i.e., all such effects must have resolved to Common Terminology Criteria\n             for Adverse Events (CTCAE), version 4.02 [2], Grade ?1. Any major surgery (except\n             biopsies) must have occurred at least 28 days prior to study enrolment.\n\n          -  Have an ECOG Performance Score ? 2.\n\n          -  Have baseline laboratory results as follows:\n\n               -  Absolute neutrophil count (ANC) ? 1.5 x 10E9 [SI units 10E9/L].\n\n               -  Platelets ? 100 x10E9 [SI units 10E9/L] (without platelet transfusion)\n\n               -  Serum creatinine ? 1.5 x ULN.\n\n               -  Creatinine clearance (measured over 24 hours) OR calculated creatinine clearance\n                  (Cockcroft-Gault formula) of ? 60 mL/min.\n\n               -  Bilirubin ? 1.5 x ULN.\n\n               -  AST/ALT ? 3 x ULN (? 5 x ULN if patients have liver metastasis).\n\n               -  TSH, T4 and ACTH must be within normal range.\n\n               -  Proteinuria with normal or grade 1 OR Urinary protein < 1 g/24hr.\n\n               -  Negative pregnancy test for females of childbearing potential.\n\n          -  Have signed an informed consent indicating that the patient is aware of the neoplastic\n             nature of their disease and have been informed of the procedures of the protocol, the\n             experimental nature of the therapy, alternatives, potential benefits, side effects,\n             risks, and discomforts.\n\n          -  Be willing and able to comply with scheduled visits, the treatment plan, and\n             laboratory tests.\n\n        Exclusion Criteria: Each patient MUST NOT:\n\n          -  Receive concurrent therapy with any other investigational anticancer agent while on\n             study.\n\n          -  Be on immunosuppressive therapy or have known HIV infection or active hepatitis B or\n             C.\n\n          -  Receive radiotherapy within 28 days prior to receiving study drug.\n\n          -  Be a pregnant or breast-feeding woman. Female patients of childbearing potential must\n             agree to use effective contraception, must be surgically sterile, or must be\n             postmenopausal. Male patients must agree to use effective contraception or be\n             surgically sterile. Barrier methods are a recommended form of contraception.\n\n          -  Have clinically significant cardiac disease (New York Heart Association, Class III or\n             IV) including pre-existing arrhythmia, uncontrolled angina pectoris, myocardial\n             infarction 1 year prior to study entry, or grade 2 or higher compromised left\n             ventricular ejection fraction.\n\n          -  Have dementia or altered mental status that would prohibit informed consent.\n\n          -  Have any other severe, acute, or chronic medical or psychiatric condition or\n             laboratory abnormality that may increase the risk associated with study participation\n             or study drug administration or may interfere with the interpretation of study results\n             and, in the judgment of the Principal Investigator, would make the patient\n             inappropriate for this study.\n\n          -  Have HIGH BURDEN/SYMPTOMATIC brain metastases. LOW VOLUME / ASYMPTOMATIC and\n             pre-treated clinically stable brain metastases ARE allowed.Xx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 31 weeks after the last dose of nivolumabXx_NEWLINE_xXPregnancy or breast-feeding  female patients must be surgically sterile, be post-menopausal, or must agree to use effective contraception during the period of therapy and for 90 days following the last dose of RO7009789; all female patients with reproductive potential must have a negative pregnancy test prior to enrollment; women or men of reproductive potential may not participate unless they agree to use an effective contraceptive method; female patients should not become pregnant while participating in this research study or for 90 days following therapy; male patients should not father a child while in this research study or for 90 days following therapyXx_NEWLINE_xXPregnancy or breastfeeding; female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; all female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrollment; male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXWilling to use double-barrier contraception if sexually active and not surgically sterilized (female only)Xx_NEWLINE_xXFemales of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; they must also refrain from egg cell donation for 6 months after the final dose of investigational product\r\n* Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause)\r\n* A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctlyXx_NEWLINE_xXNon-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from days 1 through 90 post last dose; in addition, they must refrain from sperm donation for 90 days after the final dose of investigational productXx_NEWLINE_xXPatient must be willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least 35 days after the last dose of the study drug.Xx_NEWLINE_xXFertile male patients willing to use adequate contraceptive measuresXx_NEWLINE_xXMale and female patients of child-producing potential must agree to use effective contraception while enrolled on study and receiving the experimental drug, and for at least 3 months after the last treatment.Xx_NEWLINE_xXEffective contraception is required while receiving obinutuzumab; for women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab; for men, effective contraception is required to continue for 3 months after the last dose of obinutuzumab treatmentXx_NEWLINE_xXSubject must agree not to donate sperm or ova from first dose of study drug through 3 months after the last dose of study drug.Xx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 12 months after the last dose of MPDL3280A, and for male patients continued use of contraception must be for a minimum of 3 months post-treatmentXx_NEWLINE_xXPatients, even if surgically sterilized (i.e., status post vasectomy), who:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and for 4 months (120 days) after the last dose of study drug, or\r\n* Agree to completely abstain from intercourseXx_NEWLINE_xXWillingness to use a medically acceptable method of contraception throughout the study period and for 4 weeks after the final administration of AZD1775 or longer if needed as per chemotherapies product information (all subjects)Xx_NEWLINE_xXMale subjects must agree to practice contraception during the studyXx_NEWLINE_xXFemales of child-bearing potential must agree to use adequate contraception and for 3 months after the last dose of study drugXx_NEWLINE_xXMale patients should be documented to be sterile or agree to use barrier contraceptionXx_NEWLINE_xXIt is important patients understand the need to use birth control while on this study; female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening (< 3 days prior to first dose), male patients with partners of childbearing potential must agree to use effective contraception during the study period and a period of 3 months after the last dose of study drug; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last doseXx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective contraception method during the study and for 12 months following the last dose of the study drugs; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 31 weeks following the last dose of study drugsXx_NEWLINE_xXMen who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male subjects with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms from the date of the first dose of study drug through at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative.Xx_NEWLINE_xXFemales of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 3 months following the last dose of study drug.Xx_NEWLINE_xXPatients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception.Xx_NEWLINE_xXFemale patients of childbearing potential agree to and will have had effective contraception without interruption for 28 days before starting pomalidomideXx_NEWLINE_xXSexually active participants and their partners must agree to use medically accepted methods of contraceptionXx_NEWLINE_xXA male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy; if the partner is pregnant or breastfeeding, the subject must use a condomXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXWomen of child bearing potential and men must agree to use adequate contraception during the study and for 6 months after their last dose of study drug.Xx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 6 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMale subjects with female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the study and for a minimum of 4 weeks following the discontinuation of study treatmentXx_NEWLINE_xXMale patients whose sexual partner(s) are women of childbearing potential must agree to use adequate contraception during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMen who are not surgically sterile (vasectomy) must agree to use an acceptable method of contraception. Male subjects with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms from the first dose of study drug through at least 120 days after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative.Xx_NEWLINE_xXUse of adequate contraception (as described in protocol)Xx_NEWLINE_xXPatient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of PBI 05204, as follows:Xx_NEWLINE_xXPatients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; sexually active subjects must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug, even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug; pregnant women are excluded from this studyXx_NEWLINE_xXMale patients must use an effective barrier method of contraception during the study and for 30 days following the last dose of study treatment if sexually active with a female of childbearing potentialXx_NEWLINE_xXMen treated or enrolled on this protocol must agree to use 2 adequate methods of contraception starting with the screening visit, for the duration of study participation, and through 120 days after the last dose of MK-3475 administrationXx_NEWLINE_xXFemale and male patients who are fertile agree to use an effective form of contraception with their sexual partners from registration through 4 months after the end of treatmentXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception during the entire study treatment period and through 6 months after the last dose of lenalidomideXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG])\r\n* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 23 weeks post treatment completion\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion\r\n* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluidsXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of highly effective contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product; 10) Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through 90 days after receipt of the final dose of investigational productXx_NEWLINE_xXMale and female subjects who are not surgically sterile or post-menopausal must agree to use reliable methods of birth control for the duration of the study and for 90 days after the last dose of study drug administration; male partners of female subjects should use condoms for the duration of the study, and for 90 days after the last dose of study drug administrationXx_NEWLINE_xXAgreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.Xx_NEWLINE_xXMen must agree to use adequate contraception beginning at the signing of the informed consent (ICF) until at least 6 months after the last dose of study drug; men who are sexually active must agree to use condoms and their female partners of reproductive potential must agree to use a highly effective contraceptive method during and for 6 months after completing treatmentXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 3 months after the last dose of study drug, ORXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 3 months after the last dose of study drug, orXx_NEWLINE_xXSexually active patients of childbearing potential must agree to use effective contraceptionXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, ANDXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, ANDXx_NEWLINE_xXAgreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.Xx_NEWLINE_xXNegative serum pregnancy test done =< 7 days prior to registration/randomization, for women of childbearing potential only\r\n* Note:\r\n** Females: adequate contraception must be used by both patient and partner while receiving study drug and for 12 weeks after the last dose of study drug\r\n** Males: adequate contraception must be used by both patient and partner while receiving study drug; men who have a partner of childbearing age should also avoid fathering a child for 6 months after the last dose of study drugXx_NEWLINE_xXAgreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.Xx_NEWLINE_xXMale subjects must agree to use effective contraception or abstinence while on study and for 90 days after last dose of study drugXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 6 months after the end of treatment (male patients must use highly effective [double barrier] methods of contraception [e.g., spermicidal gel plus condom] for the entire duration of the study, and continuing using contraception and refrain from fathering a child for 6 months following the study drug; a condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the study treatment via seminal fluid)Xx_NEWLINE_xXWomen of childbearing potential and male participants with partners of childbearing potential must agree to use a \highly effective\ non-hormonal form of contraception or two \effective\ forms of non-hormonal contraception by the patient and/or partner. Contraception must continue for the duration of study treatment and for at least 7 months after the last dose of study treatmentXx_NEWLINE_xXMale patients should be willing to use barrier contraception, i.e. condoms.Xx_NEWLINE_xXFemale patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participationXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMale subjects of reproductive potential who are unwilling or unable to use an acceptable method of contraception with their female partners for their entire study period and for at least 3 months after cessation of study drugXx_NEWLINE_xXMales and females of childbearing potential must agree to use protocol-specified method(s) of contraceptionXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the consent form until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXFertile subjects must use effective contraception during the course of the study and for 30 days following withdrawal from the study;Xx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXPatients should not become pregnant or breastfeed while on this study; sexually active patients must agree to use contraception prior to study entry, for the duration of study participation, and for 30 days after the last doseXx_NEWLINE_xXFemale and male participants who are fertile must agree to use a highly effective form of contraception with their sexual partners throughout study participation.Xx_NEWLINE_xXFertility requirements:\r\n* Female patients with child bearing potential must have a negative pregnancy test within 7 days before starting treatment drugs\r\n* Male patients must agree to use an adequate method of contraception for the duration of the study and for 90 days after therapy discontinuation\r\n* Female patients must be either posy-menopausal, free from menses >= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening and continuing through 90 days after study therapy discontinuation\r\n* Female patients of child bearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist programXx_NEWLINE_xXConcurrent oral contraceptives/ Fertile patients must use effective barrier contraception;Xx_NEWLINE_xXSubjects with reproductive capability must agree to practice adequate contraception methods.Xx_NEWLINE_xXPatients must agree to use highly effective contraception (details outlined in the consent form) during treatment and for a period of 90 days after ending treatment with palbociclibXx_NEWLINE_xXSexually active patients must be willing to use an acceptable method of contraception such as double barrier contraception during treatment and for 3 months after the last dose of BMN 673Xx_NEWLINE_xXPatients, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse if female partner of childbearing ageXx_NEWLINE_xXPatients who are pregnant; patients with reproductive capability will need to use adequate contraception during the time of participation in the studyXx_NEWLINE_xXMale and female subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental drug, and for one month after the last immunization.Xx_NEWLINE_xXAgreement to use contraception during the study and for 90 days after the last dose of study drug if sexually active and able to bear children.Xx_NEWLINE_xXPatients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of <1% per year) during the study and for 12 weeks after the Follow-up visit.Xx_NEWLINE_xXMale or female patients of child-producing potential agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 dose.Xx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXUse of highly effective contraceptionXx_NEWLINE_xXIf a sexually active male or a sexually active female of child-bearing potential, agrees to use dual (two concurrent) forms of medically accepted contraception from the time of consent until 6 months after the last dose of either ONT-10 or T-DM1, whichever is longer.Xx_NEWLINE_xXPatient agrees to use an effective method of contraception (hormonal or two barrier methods) while on study and for at least 3 months following the plerixafor infusionXx_NEWLINE_xXOne of the following acceptable forms of contraception is required:Xx_NEWLINE_xXAgrees to protocol-defined use of effective contraceptionXx_NEWLINE_xXMen must agree not to donate sperm during and after the study for 6 months after the last dose of bendamustine, 12 months after the last dose of rituximab, or 3 months after the last dose of study medication, whichever is laterXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception. For male participants with partners of childbearing potential, one highly effective form of contraception or two effective forms of contraception must be used. Contraception must continue for the duration of study treatment and for 6 months after the last dose of study treatmentXx_NEWLINE_xXMale patients of childbearing potential must use a condom during sexual intercourse and shall not father a child during the study and for 6 months after the last dose of study medication.Xx_NEWLINE_xXFemale patients and male patients with female partners of reproductive potential must agree to use an effective method of contraception during therapy and for at least 6 months after the last dose of study therapy.Xx_NEWLINE_xXFemale Subjects of Childbearing Potential: Subjects must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agrees to use effective contraception, throughout the treatment period and for 4 months after the last dose of study treatment.Xx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 90 days after the last dose of atezolizumabXx_NEWLINE_xXIf of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapyXx_NEWLINE_xXWomen of childbearing potential must agree and commit to the use of a highly effective method of contraception as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product; men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after last dose of investigational productsXx_NEWLINE_xXMale participants must agree to use contraception during the treatment period and for ?180 days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condomXx_NEWLINE_xXAll men and women must agree to practice effective contraception during the entire study period and after discontinuing study drug, unless documentation of infertility existsXx_NEWLINE_xXIs a non-sterile male or female willing to use of one of the protocol-defined highly effective contraception methods:Xx_NEWLINE_xXFemale patients of childbearing potential (a female not free from menses > 2 years or not surgically sterilized) must be willing to use highly effective contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study; highly effective contraception, defined as male condom with spermicide, diaphragm with spermicide, intra-uterine device; highly effective contraception must be used by both sexes during the study and must be continued for 5 months after the last dose of denosumabXx_NEWLINE_xXPatient is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatmentXx_NEWLINE_xXAll subjects must agree to use effective means of contraception with their partner from entry into the trial through 6 months after the last dose of avelumabXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of MLN8237; male patients, even if surgically sterilized (ie, status postvasectomy) must agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of MLN8237; male patients, even if surgically sterilized (i.e., status postvasectomy) must agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXPatients who are having sex that could lead to pregnancy must agree to contraceptive use during the entire study periodXx_NEWLINE_xXFemale or male participant of reproductive potential must agree to use an effective contraceptive method throughout duration of study treatmentXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal or if of childbearing potential, must agree to use an adequate method of contraception during the study until 30 days after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediatelyXx_NEWLINE_xXPost-menarche female subjects and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study. Subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study. Females must not be pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study.Xx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 30 days after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMale subjects must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after last dose of study drug or practice true abstinenceXx_NEWLINE_xXPatients of both sexes must agree to the use of barrier contraceptives throughout the duration of treatment on this trial and for 3 months after discontinuing treatment; NOTE: hormonal contraceptives are not acceptable as a sole method of contraceptionXx_NEWLINE_xXPregnancy or breast feeding; patients must be surgically sterile, postmenopausal, or agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgement of the principal investigator or a designated associate; male patients must be surgically sterile or agree to effective contraception; female patients of child bearing potential (ages 11-55) must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 14 days prior to registrationXx_NEWLINE_xXMale subjects must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.Xx_NEWLINE_xXWomen of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of careXx_NEWLINE_xXFertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplantXx_NEWLINE_xXAgrees to protocol-defined use of effective contraception (for women, these restrictions apply for 12 months after the last dose of rituximab or 1 month after the last dose of study drug, whichever is later; for men, these restrictions apply for 12 months after the last dose of rituximab or 3 months after the last dose of study drug, whichever is later)Xx_NEWLINE_xXMen must agree to not donate sperm during and after the study for 12 months after the last dose of rituximab or 3 months after the last dose of study drug, whichever is laterXx_NEWLINE_xXMale patients who agree to practice effective barrier contraception or agree to practice true abstinence AND must adhere to the guidelines of the lenalidomide pregnancy prevention programXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXFemales of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception while on studyXx_NEWLINE_xXMale and female patients must use an effective contraceptive method during the study and for at least 6 months after study treatmentXx_NEWLINE_xXAll subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product, and for one month after the last immunization.Xx_NEWLINE_xXWillingness to use medically acceptable contraceptionXx_NEWLINE_xXSexually active fertile patients (male and female), and their partners, must agree to use medically accepted methods of contraception during the course of the study and for 3 months after the last dose of the study drugXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 30 days after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate.Xx_NEWLINE_xXMales are eligible to enter and participate in the study if they have either had a prior vasectomy or agree to avoid sexual activity or use adequate contraception from screening through two months post the last dose of decitabineXx_NEWLINE_xXBecause of the unknown potential risk to a gamete and/or developing embryo from these investigational therapies, patients must agree to use adequate contraception (barrier method for males) for the duration of study participation, and for three months after discontinuing therapy.Xx_NEWLINE_xXMale patients should be willing to use barrier contraception.Xx_NEWLINE_xXMale and female subjects of child producing potential must agree to use adequate forms of contraception or avoidance of pregnancy measures prior to study entry, while enrolled on study and for a minimum of one month after completion of the study.Xx_NEWLINE_xXA patient who is sexually active and their partner must agree and use two reliable barrier forms of contraception (for example, condoms and diaphragm), from first day of study drug administration until for 1 week after last dose of abiraterone acetate, unless partner is post-menopausalXx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI503 doseXx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 dose.Xx_NEWLINE_xXMale and female subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental drug and for one month after the last immunization.Xx_NEWLINE_xXFemale subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXMen or women of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoid intercourse during the study and for 90 days after the last dose of study drugXx_NEWLINE_xXWOCBP and male subjects as well as their female partners of childbearing potential must agree to use effective contraception throughout the study and for 6 months after the last dose of KW-0761Xx_NEWLINE_xXMale patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial and for a minimum of 6 months after study treatment.Xx_NEWLINE_xXFor men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenibXx_NEWLINE_xXIf a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential.Xx_NEWLINE_xXFemale subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects, even if surgically sterilized (ie, status post-vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXMust be willing to use contraception during the study, and for 30 days following the last dose of study drugXx_NEWLINE_xXFemale or male patients of reproductive capacity unwilling to use methods appropriate to prevent pregnancy are excluded; effective contraception is required for at least 6 months following the last administration of afliberceptXx_NEWLINE_xXWomen of child-bearing potential must use highly effective contraception during the study and for 84 days after the study drug infusion.Xx_NEWLINE_xXPatient (man or woman) must agree to practice effective contraception during the entire study period, unless documentation of infertility exists, and for at least 4 weeks after the last dose of the study drug(s)Xx_NEWLINE_xXSexually active females of child bearing potential and males must agree to use effective contraception for the duration of the transplant periodXx_NEWLINE_xXAgrees to protocol-defined use of effective contraceptionXx_NEWLINE_xXFemales: pregnant or breast feeding and if of child bearing potential (e.g. female of childbearing age that has not been amenorrheic for at least 12 consecutive month or surgically sterilized) not willing to use effective contraceptionXx_NEWLINE_xXPregnancy or breast-feeding; patients must be surgically sterile, postmenopausal, or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate; male patients must be surgically sterile or agree to use effective contraceptionXx_NEWLINE_xXInclusion criteria :\n\n        I 01. Males or females enrolled in Phase 1 or Phase 2 studies of SAR245408 or SAR245409 as\n        monotherapy or in combination with other regimens who have complete data collection for the\n        primary endpoint(s) of the parental study or who are being treated beyond the parental\n        study cut-off and meet all the criteria to continue to be treated per the parental\n        protocol.\n\n        I 02. All sexually active subjects (male and female) must agree to continue to use accepted\n        methods of barrier contraception (ie, condoms) during the course of the study and for 3\n        months after discontinuation of study treatment. For women of childbearing potential and\n        for men who can father a child, a second method of contraception in addition to a barrier\n        method is recommended. Hormonal contraception should be avoided in subjects taking\n        SAR245408 due to possible drug-drug interaction.\n\n        I 03. Female subjects of childbearing potential must have a negative pregnancy test at\n        baseline. Females of childbearing potential are defined as sexually mature women without\n        prior hysterectomy or who have had any evidence of menses in the past 12 months. However,\n        women who have been amenorrheic for 12 or more months are still considered to be of\n        childbearing potential if the amenorrhea is possibly due to other causes, including prior\n        chemotherapy, anti-estrogens, or ovarian suppression\n\n        Exclusion criteria:\n\n        E 01. The subject discontinued the parental study due to toxicity\n\n        E 02. Ongoing Grade 3 or higher Adverse Event (AE)\n\n        E 03. Ongoing Serious Adverse Event (SAE)\n\n        E 04. Subjects with ongoing dose interruption for any reason unless the subject fulfills\n        the criteria in the parental protocol for restarting IMP. In such case subject will start\n        the treatment-extension study on Day 1 of the initiation period\n\n        E 05. The subject has any of the following laboratory values ? Common Terminology of\n        Adverse Events (CTCAE) Grade 3\n\n          -  Absolute neutrophil count (ANC),\n\n          -  Platelet count,\n\n          -  Hemoglobin,\n\n          -  Bilirubin,\n\n          -  Serum creatinine or calculated creatinine clearance,\n\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST),\n\n          -  Fasting plasma glucose (FPG),\n\n          -  Prothrombin time/international normalized ratio (PT/INR) and activated partial\n             thromboplastin time (aPTT)\n\n        E 06. The subject has a baseline corrected QT interval (QTc) >481 msec or if a subject has\n        had a QTc interval increase of ? 60 msec from parental protocol baseline to an absolute\n        value of > 470 msec\n\n        E 07. The subject has a known allergy or hypersensitivity to components of the study\n        treatment formulation(s)\n\n        E 08. The subject is pregnant or breastfeeding\n\n        The above information is not intended to contain all considerations relevant to a patient's\n        potential participation in a clinical trial.Xx_NEWLINE_xXMen must agree to use effective contraception during treatment and for at least 1 week after the last administration of therapyXx_NEWLINE_xXAll patients of reproductive potential must agree to use adequate contraceptionXx_NEWLINE_xXAgreed to practice effective barrier contraception during the entire study treatment period and 90 days after the last dose of study treatment if their partner was of childbearing potential, even if they had a successful vasectomy, ANDXx_NEWLINE_xXMale subjects with a female partner of childbearing potential must be willing to continue practicing the same acceptable method of contraception as used in the parent study during the rollover study and for at least 16 weeks after the last dose of GSK2110183.Xx_NEWLINE_xXFemale subjects of childbearing potential, as defined in the parent study, must be willing to continue practicing the same acceptable method of contraception as used in the parent study during the rollover study and for at least 4 weeks after the last dose of GSK2110183.Xx_NEWLINE_xXPatients who are sexually active with a partner who could become pregnant are to use an effective form of barrier contraception, such as condoms or a partner using oral contraceptive pills; persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 8 weeks after ipilimumab is stoppedXx_NEWLINE_xXBoth females and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXMale and female patients of reproductive potential must use an effective contraceptive method during the study and for a minimum of 1 year after the after study treatmentXx_NEWLINE_xXPatients must agree to practice adequate contraception.Xx_NEWLINE_xXFor sexually active males, use of barrier form of contraception, even if they have had a vasectomy, during the study and for 6 months after stopping sonidegib is required; males should not donate sperm during treatment, and for up to six months after last doseXx_NEWLINE_xXWomen of child-bearing potential unless they are using highly effective methods of contraception during the dosing and for at least 36 hours after last dose. Highly effective contraception as defined in the protocol.Xx_NEWLINE_xXMale patients who, even if surgically sterilized, agree to practice effective barrier contraception through 3 months after the last dose of alisertib or agree to practice true abstinenceXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMales and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drugXx_NEWLINE_xXFemale subjects of childbearing potential, as defined in the parent study, must be willing to continue practicing the same acceptable method of contraception as used in the parent study during the rollover study and for at least 4 months after the last dose of GSK1120212.Xx_NEWLINE_xXFemale patients who: \r\n* Are postmenopausal for at least 1 year before the screening visit, OR \r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, (those who are post-menopausal for less than 1 year) must have negative serum or urine pregnancy test and agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale patients, even if surgically sterilized (i.e., status postvasectomy), who: \r\n* Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study drug, OR \r\n* Agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXFor female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participant and/or partner) to use highly effective forms of contraception and to continue its use for the duration of the study and for 4 months after last dose of study treatment (for females) and 6 months after last dose of study treatment (for males)Xx_NEWLINE_xXPatients who are sexually active must use a reliable form of contraception while on study and for 4 weeks after the last immunizationXx_NEWLINE_xXSexually active individuals capable of becoming pregnant who are unable or unwilling to use effective form(s) of contraception during time enrolled on study and for 1 year post-transplantXx_NEWLINE_xXPregnancy or breast feeding at the time of study enrollment. Eligible subjects of reproductive potential (both sexes) must agree to use adequate contraceptive methods during study therapy.Xx_NEWLINE_xXE 15. Participants with reproductive potential who did not agree to use accepted and effective method of contraception during the study treatment period.Xx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXWilling to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-302Xx_NEWLINE_xXFemale patients who: Are postmenopausal for at least 1 year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Male patients, even if surgically sterilized (ie, status postvasectomy), who: Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study drug, OR Agree to completely abstain from heterosexual intercourse.Xx_NEWLINE_xXWomen of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation and up to 6 months following completion of therapy; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of careXx_NEWLINE_xXMales and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drugXx_NEWLINE_xXFemale patients (including those < 1 year post-menopausal) and male patients who have not undergone previous surgical sterilization must agree to use contraceptionXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXAgree to use effective form of contraception (as applicable)Xx_NEWLINE_xXEXPANSION COHORT ONLY: Male patients whose sexual partner(s) are women of child-bearing potential (WOCBP) who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception for the duration of the study.Xx_NEWLINE_xXMale subjects who are partners of women of childbearing potential must use a condom and spermicide and their female partners if of childbearing potential must use a highly effective method of contraception beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 120 days after the last dose of study drug, unless the male subjects are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterileXx_NEWLINE_xXMale or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of ARQ 087Xx_NEWLINE_xXSexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.Xx_NEWLINE_xXMale patient who is surgically sterile, or male patient who is willing to agree to remain completely abstinent (refrain from heterosexual intercourse) or who use barrier contraceptive measures and agree to refrain from donating sperm during the entire study treatment periodXx_NEWLINE_xXFemale patient who is of childbearing potential willing to use adequate contraceptive measures while participating on study, OR willing to completely abstain from heterosexual intercourse during the entire study treatment periodXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 90 days after the last dose of atezolizumabXx_NEWLINE_xXEffective contraception for female subjects if risk of conception exists. Note: Effects of the study drug on the developing human fetus are unknown. Thus, women of childbearing potential and men must agree to use effective contraception, defined as 2 barrier methods, or 1 barrier method with a spermicide, an intrauterine device or use of oral female contraceptive. Effective contraception must be used 30 days before first study drug administration, for the duration of trial participation, and ?60 days after stopping trial participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately.Xx_NEWLINE_xXFemale of childbearing potential must be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation), abstinent (at the discretion of the investigator), or agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study drug administration. Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 2 years. - Males must agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study drug administration. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) at the discretion of the investigator.Xx_NEWLINE_xXA male subject who is sexually active with a woman of childbearing potential is eligible to enter the study if he agrees to use effective contraception throughout the study and for 6 months after the last dose of study agent.Xx_NEWLINE_xXFor both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatmentXx_NEWLINE_xXMale patients agree to use an adequate method of contraception for the duration of the studyXx_NEWLINE_xXMen or WOCBP, to include female partners of heterosexual or bisexual patients, must agree to use an effective method of contraception during the study and for up to three months following discontinuation of study drugXx_NEWLINE_xXMale patients agree to use an adequate method of contraception for the duration of the studyXx_NEWLINE_xXMale subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last study drug administrationXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXMale subject unwilling to use an acceptable method for contraception for the duration of the study and one year beyond treatment completionXx_NEWLINE_xXFemale subjects of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from screening and must agree to continue using such precautions for at least 180 days after the last dose of investigational product. Depending on the investigational product received, this period may be longer. Cessation of birth control after this point should be discussed with a responsible physicianXx_NEWLINE_xXNon-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception (Table 4.2.1-1) from at least Day 1 through 90 days after the last dose of investigational productXx_NEWLINE_xXPatients with child-bearing potential will agree to use contraception while on study and for 30 days from the date of the last therapy on protocolXx_NEWLINE_xXMale and female participants must use an effective contraceptive method during the study and for a minimum of 6 months after study treatmentXx_NEWLINE_xXFertile patients must use effective contraceptionXx_NEWLINE_xXPatients must be willing and able to comply with the FDA mandated iPLEDGE program for treatment with isotretinoin (cRA). Patients must sign specific informed consents for treatment with cRA, as mandated by iPLEDGE guidelines. Women of childbearing potential must not be pregnant, must not be breast-feeding and must practice adequate contraception during and one month after participation in the study. Male and Female patients on treatment with vorinostat must agree to use an adequate method of contraception for the duration of the study, and for 30 days after the last dose of study medication.Xx_NEWLINE_xXInclusion Criteria:\n\n          -  The subject must have already received CP-675,206 in another protocol\n\n          -  Females of childbearing potential must agree to practice a form of effective\n             contraception for 12 months following any dose of study drug. The definition of\n             effective contraception will be based on the judgement of the investigator.\n\n          -  Subject must be willing and able to provide written informed consent and to comply\n             with scheduled visits and other trial procedures\n\n        Exclusion Criteria:Xx_NEWLINE_xXMale subject even if surgically sterilized (i.e., status post vasectomy) must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXPregnancy, breast feeding, or unwillingness to use effective contraception during the study.Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test during Screening and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administrationXx_NEWLINE_xXMale subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administrationXx_NEWLINE_xXIf of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 90 days following last treatment dose.Xx_NEWLINE_xXMale and female patients of childbearing potential and at risk for pregnancy must agree to use two (2) highly effective methods of contraception throughout the study and for 60 days after the last dose of assigned study treatment.Xx_NEWLINE_xXFor women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of contraception during and for at least 6 months after completion of study treatment; OR, a fertile male partner willing and able to use effective non-hormonal of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilization) during and for at least 6 months after completion of study treatmentXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use adequate contraception throughout the study and for up to 180 days after study treatmentXx_NEWLINE_xXWomen of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 16 weeks after the last dose of ADCT-502. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception from the time of giving informed consent until at least 16 weeks after the patient receives his last dose of ADCT-502.Xx_NEWLINE_xXWillingness to use effective contraception.Xx_NEWLINE_xXMale and female patients of child-bearing potential unwilling to use effective means of contraceptionXx_NEWLINE_xXMale and female patients of child-bearing potential unwilling to use effective means of contraceptionXx_NEWLINE_xXMales (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with Female of Childbearing Potential as specified in Pregnancy Prevention Risk Minimization Plan.Xx_NEWLINE_xXMale subjects able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use two highly effective methods of contraception throughout the study and for 90 days after the last dose of assigned treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, as defined in protocol, during the study and for 7 days following the last dose of study treatment.Xx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in protocol from the administration of the first dose of study treatment until 3 months after the last dose of study treatment to allow for clearance of any altered sperm.Xx_NEWLINE_xXFemale subjects who:\r\n* Are postmenopausal for at least 1 year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects, even if surgically sterilized (i.e., status post vasectomy) who:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, OR\r\n* Agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMale and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.Xx_NEWLINE_xXSubject is of child bearing potential and is not willing to use, in combination with her partner, 2 highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatmentXx_NEWLINE_xXMale and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment.Xx_NEWLINE_xXAgrees to use a male condom starting at screening and continue throughout study treatment and for 90 days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile as defined below their female partner(s) is utilizing 1 form of highly effective birth control*starting at screening and continue throughout study treatment and for 90 days after the male subject receives their final study drug administration.Xx_NEWLINE_xXMale subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 90 days after the final study drug administrationXx_NEWLINE_xXVasectomy (A vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used).Xx_NEWLINE_xXFemales of childbearing potential with a fertile male sexual partner must agree to employ adequate contraception for the duration of the study.Xx_NEWLINE_xXMales must use adequate contraception and must not donate sperm for the duration of the study.Xx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [ 1 percent per year] when used consistently and correctly) and to continue its use for 6 months after the last dose of MPDL3280AXx_NEWLINE_xXUse of two forms of contraception with less than a 5% failure rate or abstinence by all transplanted participants for 18 months after the first dose of study therapy; for the first 60 days post-transplant, recipients should be encouraged to use nonhormonal contraceptives due to the potential adverse effect of hormones on bone\r\nmarrow engraftmentXx_NEWLINE_xXMale subject, even if surgically sterilized (i.e., status post-vasectomy), agrees to:\r\n* Use an acceptable method for contraception (effective barrier contraception or:\r\n* Completely abstain from heterosexual intercourse) during the entire study treatment period through 4 months after the last dose of alisertibXx_NEWLINE_xXSexually active participants must use medically acceptable methods of contraception during the course of this studyXx_NEWLINE_xXPatients who cannot or do not intend to practice effective contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test within 28 days prior to the first administration of study drug and agree to use highly effective physician-approved contraception from 30 days prior to the first study drug administration to 90 days following the last study drug administrationXx_NEWLINE_xXMale subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from 30 days prior to the first study drug administration to 90 days following the last study drug administrationXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXEffective contraception is required while receiving obinutuzumab; for women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab; for men, effective contraception is required to continue for 3 months after the last dose of obinutuzumab treatmentXx_NEWLINE_xXIf of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment.Xx_NEWLINE_xXAll subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product, and for one month after the last immunization.Xx_NEWLINE_xXFemale participants who are postmenopausal for at least 1 year before the screening visit or are surgically sterile, or are of childbearing potential, agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 30 days (or longer, as mandated by local labeling) after the last dose of study drug, or agree to practice true abstinence.Xx_NEWLINE_xXMale participants agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling, or agree to practice true abstinence.Xx_NEWLINE_xXIf of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment dose.Xx_NEWLINE_xXAgreement to use acceptable methods of contraception during the study and for ? 120 days after the last dose of PNT2258 if sexually active and able to bear or beget children.Xx_NEWLINE_xXSexually active female subjects of childbearing potential and male subjects and their sexual partners who are of childbearing potential must agree to use contraceptionXx_NEWLINE_xXSubjects of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 2 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXLactating or pregnant or will not agree to use contraception during the study and for 30 days after the last dose of study drug if sexually active and able to bear childrenXx_NEWLINE_xXEither commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting IP therapy (including dose interruptions), and while on study medication or for a longer period if required by local regulations following the last dose of IP; andXx_NEWLINE_xXUse of effective contraception by fertile males with a female partner of childbearing potential.Xx_NEWLINE_xXPatients of reproductive potential must agree to use an effective (> 90% reliability) form of contraception during the study and for 6 months following the last study drug administrationXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug; highly effective contraception must be used (e.g. male condom with spermicidal, diaphragm with spermicidal, intra-uterine device) by both sexesXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, orXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, orXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug; highly effective contraception must be used (e.g. male condom with spermicidal, diaphragm with spermicidal, intra-uterine device) must be used by both sexesXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of randomization until 16 weeks after the last dose of study treatmentXx_NEWLINE_xXAgreement to use effective contraception while on treatment and for at least 6 months after end of treatmentXx_NEWLINE_xXMale patients willing to use adequate contraceptive measures.Xx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior bilateral vasectomy with resultant azoospermia, bilateral orchiectomy, or must agree to use one of the contraception methods listed in protocol from the time of the first dose of study medication until at least 2 weeks (14 days) after the last dose of study treatment due to the long elimination phase of study drug.Xx_NEWLINE_xXMales & women of childbearing potential must agree to abstain from sex or use an adequate method of contraception for duration of study & for 6 months after last dose of study drugXx_NEWLINE_xXMales must agree to use a condom with spermicide every time they have sex during the study and for 3 months after the last dose of study drug; they also must agree to not donate sperm during the study and for 3 months after the last dose of study drugXx_NEWLINE_xXfemale subject must have a negative serum pregnancy result within 7 days before the start of the study; Both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatmentXx_NEWLINE_xXPatients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy and for two (2) months following the last dose of panitumumab; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate; male patients must be surgically sterile or agree to use effective contraceptionXx_NEWLINE_xXIf sexually active, the patient must agree to use contraception considered adequate and appropriate by the investigatorXx_NEWLINE_xXWOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 3 months after the last dose of study medication.Xx_NEWLINE_xXFemales of childbearing potential and males must agree to use effective contraception as defined by protocol during the treatment period and for at least 6 months after the last dose of study drugXx_NEWLINE_xXIf sexually active, the patient must agree to use contraception considered adequate and appropriate by the investigatorXx_NEWLINE_xXMale patients, even if surgically sterilized (ie, status post vasectomy) must agree to 1 of the following:\r\n* Practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourseXx_NEWLINE_xXWomen of childbearing potential must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment.Xx_NEWLINE_xXMales not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment.Xx_NEWLINE_xXIf childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapyXx_NEWLINE_xXEffective contraception during the study period and for 3 months after the last study treatment administration (male and female patient)Xx_NEWLINE_xXSexually active patients must agree to use adequate contraception (abstinence or barrier contraceptives must be used throughout the trial and one month after end of treatment) for the duration of the studyXx_NEWLINE_xXIf the subject is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 60 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method).Xx_NEWLINE_xXSubjects and their partners with reproductive potential must agree to use an effective form of contraception during the period of drug administration and for 4 weeks after completion of the last administration of the study drug; an effective form of contraception is defined as oral contraceptives plus 1 form of barrier or double-barrier method contraception (condom with spermicide or condom with diaphragm)Xx_NEWLINE_xXMale patients must agree to use an adequate method of contraception.Xx_NEWLINE_xXMales who have had a successful vasectomy (confirmed azoospermia) or they and their female partners meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period or for 120 days after study drug discontinuation). No sperm donation is allowed during the study period or for 120 days after study drug discontinuation.Xx_NEWLINE_xXEffective contraception is required while receiving obinutuzumab; for women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab; for men, effective contraception is required to continue for 3 months after the last dose of obinutuzumab treatmentXx_NEWLINE_xXInclusion Criteria- Group A:\n\n          -  Age ? 18 years.\n\n          -  Phase 1-Dose Escalation: Patients with histologically confirmed advanced solid tumors\n             who are refractory to, relapsed after, or intolerant to standard therapy or for whom\n             no standard therapy exists.\n\n          -  Phase 2a-RP2D Confirmation (Formulation 2) and Phase 2a-Dose Extension: Patients with\n             a history of histologically confirmed solid tumors with a BRAF mutation.\n\n               -  Phase 2a-Dose ExtensionCohort 1\n\n                    1. Patients with solid tumors driven by a BRAF-V600 mutation\n\n                    2. Patients with no prior exposure to BRAF-directed therapy and for whom no\n                       standard therapy exists.\n\n               -  Phase 2a-Dose ExtensionCohort 2\n\n                    1. Patients with solid tumors driven by BRAF non-V600 mutation.\n\n                    2. Patients with no prior exposure to BRAF-directed therapy and for whom no\n                       standard therapy exists.\n\n          -  Measurable disease by RECIST 1.1.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n\n          -  Adequate hematologic, hepatic, and renal function.\n\n          -  Women of child-bearing potential must have a negative pregnancy test and must agree to\n             use an effective form of contraception from the time of the negative pregnancy test up\n             to 3 months after the last dose of study drug. Women of non-child-bearing potential\n             may be included if they are either surgically sterile or have been postmenopausal for\n             ? 1 year.\n\n          -  Fertile men must agree to use an effective method of birth control during the study\n             and for up to 3 months after the last dose of study drug.\n\n          -  Completion of previous anti-cancer therapy at least 2 weeks before study drug\n             initiation.\n\n        Exclusion Criteria- Group A:\n\n          -  Phase 1 and Phase 2a RP2D confirmation-Dose Escalation: Investigational drug use\n             within 28 days (or 5 half-lives, whichever is shorter) of the first dose of PLX8394.\n\n          -  Major surgical procedure, open biopsy (excluding skin cancer resection), or\n             significant traumatic injury within 14 days of initiating study drug or anticipation\n             of the need for major surgery during the study.\n\n          -  Uncontrolled intercurrent illness.\n\n          -  Active secondary malignancy unless the malignancy is not expected to interfere with\n             the evaluation of safety and is approved by the Medical Monitor. Patients with a\n             completely treated prior malignancy and no evidence of disease for ? 2 years are\n             eligible.\n\n          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant\n             bowel resection that would preclude adequate absorption.\n\n          -  Clinically significant cardiac disease.\n\n          -  Known infection with HIV, HBV, or HCV or a known carrier of HBV or HCV.\n\n        Inclusion Criteria  Group B:\n\n          -  Age (all criteria are required):\n\n               -  ?3 and <18 years;\n\n               -  Ability to swallow and retain study drug;\n\n               -  A minimum BSA that allows for adequate dosing with PLX8394.\n\n               -  Patients with a history of activating BRAF mutation, such patients include those\n                  with the following:\n\n                    1. Diagnosis of pediatric brain tumor (e.g., pilocytic astrocytoma, pleomorphic\n                       xanthoastrocytoma, ganglioglioma, astrocytoma, papillary craniopharyngioma,\n                       glioblastoma) with an activating BRAF mutation.\n\n                    2. LCH (Langerhans cell histiocytosis) i.) Patients with either high-risk\n                       disease are eligible. ii) Patients with overlap histiocytic disorders (e.g.,\n                       LCH/juvenile xanthogranuloma, LCH/Erdheim-Chester disease, or\n                       LCH/Rosai-Dorfman disease) are eligible.\n\n                    3. Diagnosis of LCH-associated neurodegenerative disease (LCH-ND).\n\n                    4. Other advanced malignancy with an activating BRAF mutation.\n\n          -  ECOG performance status of 0-2.\n\n          -  Adequate hematologic, hepatic, and renal function.\n\n          -  Females of child-bearing potential must have a negative pregnancy test and must agree\n             to use an effective form of contraception from the time of the negative pregnancy test\n             and for 3 months after the last dose of study drug. Females of non-child-bearing\n             potential may be included if they are either surgically sterile, have been\n             postmenopausal for ?1 year, or are premenopausal.\n\n          -  Fertile male patients must agree to use an effective method of birth control during\n             the study and for 3 months after the last dose of study drug.\n\n          -  Completion of previous anti-cancer therapy at least 2 weeks before study drug\n             initiation.\n\n          -  All patients or their legal guardians (if the patient is <18 years old) must sign an\n             IRB-approved document of informed consent to demonstrate their understanding of the\n             investigational nature and the risks of this study before any protocol-related\n             procedures are performed. When appropriate, pediatric subjects will be included in all\n             discussions.\n\n        Exclusion Criteria  Group B:\n\n          -  Major surgical procedure, open biopsy (excluding skin cancer resection), or\n             significant traumatic injury within 14 days of initiating the study drug or\n             anticipation of the need for major surgery during the study.\n\n          -  Dose Escalation and Dose Extension  Investigational drug use within 28 days (or 5\n             half-lives, whichever is shorter) of the first dose of PLX8394.\n\n          -  Uncontrolled intercurrent illness.\n\n          -  Active secondary malignancy, unless the malignancy is not expected to interfere with\n             the evaluation of safety and is approved by the Medical Monitor.\n\n          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant\n             bowel resection that would preclude adequate absorption.\n\n          -  Clinically significant cardiac disease.\n\n          -  Known infection with HIV, HBV, or HCV or a known carrier of HBV or HCV.Xx_NEWLINE_xXSubjects and their partners with reproductive potential must agree to use an effective form of contraception during the period of drug administration and for 4 weeks after completion of the last administration of the study drug, an effective form of contraception is defined as oral contraceptives plus 1 form of barrier or double-barrier method contraception (condom with spermicide or condom with diaphragm)Xx_NEWLINE_xXUnless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods as specified in the PPRMP. *For Arm C, subjects must agree to use adequate contraceptive methods for 18 months (please refer to the obinutuzumab IB, PI, and SmPC).Xx_NEWLINE_xXWomen of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug; in addition, sexually active WCBP must agree to use adequate contraceptive methods (tubal ligation; intra-uterine device; or barrier contraceptive with spermicide) while on the study; oral, implantable, or injectable contraceptives are not considered effective for this study; WCBP must agree to have pregnancy tests every 4 weeks while on the study drug; male subject agrees to use an acceptable method of contraception for the duration of the study\r\n* Female patients who:\r\n** Are postmenopausal for at least 1 year before the screening visit, OR\r\n** Are surgically sterile, OR\r\n** If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse\r\n* Male patients, even if surgically sterilized (ie, status postvasectomy), who:\r\n** Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, OR\r\n** Agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMales and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraceptionXx_NEWLINE_xXMale patients with partners of childbearing potential must agree to use adequate contraception (barrier method or abstinence) during the study, including the follow-up time period.Xx_NEWLINE_xXUse of highly effective contraception (females) or male condom plus spermicide (males).Xx_NEWLINE_xXFor female participants of childbearing potential, agreement to use highly effective form(s) of contraception for the duration of the study and for at least 6 months after last dose of study treatmentXx_NEWLINE_xXMales and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for at least 3 months following the last dose of study drug. Females with childbearing potential must have had a negative serum pregnancy test 7 days before the first dose of study drug and must not be breast-feeding.Xx_NEWLINE_xXAgree to use adequate contraceptionXx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also usedXx_NEWLINE_xXMale patients with partners of childbearing potential who are unwilling to use condoms in combination with a second effective method of contraception during the trial and for 6 months after the last administration of BI 836858Xx_NEWLINE_xXMale patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of study drug through 105 days after last dose of study drug. Contraception should be considered for a nonpregnant female partner of childbearing potential.Xx_NEWLINE_xXAll female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 3 months after the last dose of study drug.Xx_NEWLINE_xXFemale and male patients of reproductive potential must agree to use effective contraception from screening until 90 days after discontinuing study treatment.Xx_NEWLINE_xXMale patients must agree not to donate sperm during the study and for 3 months after discontinuation of vismodegibXx_NEWLINE_xXFemales of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception; a woman is eligible to enter and participate in the study if she is of:\r\n* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who has had a hysterectomy or has had a bilateral oophorectomy (ovariectomy)\r\n* Childbearing potential, has a negative serum pregnancy test during the screening period and agrees to avoid sexual activity or use accepted methods of contraception from screening through follow-up\r\n* Men with a female partner of childbearing potential are eligible to enroll and participate in the study if they have had either a prior vasectomy or agree to avoid sexual activity or use appropriate barrier contraception from screening through post-treatment follow-upXx_NEWLINE_xXIf participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug. If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breastfeeding.Xx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, use of an effective form of contraception with continued use for study duration and up to 3 months or more following discontinuation of treatment drugXx_NEWLINE_xXMale or female of reproductive potential has agreed to use effective contraception for the duration of study participationXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception from 28 days prior to the first dose of the study drug, during the entire Treatment Period, and for at least 28 days after the last dose of the study drugXx_NEWLINE_xXWOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug FS102 plus 30 days (duration of ovulatory cycle) for a total of 30 days post-treatment completion.Xx_NEWLINE_xXMales who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug FS102 plus 90 days (duration of sperm turnover) for a total of 90 days post-treatment completion.Xx_NEWLINE_xXNot willing to use contraception (inclusive of abstinence)Xx_NEWLINE_xXAgree to use contraceptionXx_NEWLINE_xXPre-menopausal women must have a negative pregnancy test before study entry and agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuationXx_NEWLINE_xXMale and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.Xx_NEWLINE_xXWomen of child-bearing potential are required to use effective contraception throughout the study period. Effective contraception methods include:Xx_NEWLINE_xXMale patients with partners of childbearing potential must agree to use adequate contraception while on studyXx_NEWLINE_xXSubjects of childbearing potential not willing to use adequate contraception during study and 3 months after last dose of crenolanibXx_NEWLINE_xXMale subjects with female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the study and for 3 months after the last dose of the investigational productXx_NEWLINE_xXPregnant or breastfeeding females and male or female patients who refuse to use adequate contraception during the study and for 16 weeks after the last dose of study treatmentXx_NEWLINE_xXFor female individuals of childbearing potential, willingness to use a protocol- recommended method of contraceptionXx_NEWLINE_xXFor male individuals having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol- recommended method of contraceptionXx_NEWLINE_xXFemale or male of reproductive capacity unwilling to use methods of contraception to prevent pregnancy during this study. Participants unwilling to use methods of contraception to prevent pregnancy for 6 months after the last dose of RO7070179 due to the potential for prolonged half-life of RO7070179 in the liver.Xx_NEWLINE_xXPatients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.Xx_NEWLINE_xXPatients unwilling to use adequate contraceptionXx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after the last dose of trial therapy; highly effective contraception is one with a failure rate of < 0.1%; birth control pills on their own do not achieve that rateXx_NEWLINE_xXNonsterilized males who are sexually active with a female partner of child-bearing potential must, with their partner, use 2 acceptable methods of effective contraception from Day 1 through 60 days after receipt of the final dose of KTN3379.Xx_NEWLINE_xXPatients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose. The definition of \effective method of contraception\ will be based on the Investigator's judgment.Xx_NEWLINE_xXSubjects with child-bearing potential agree to use effective means of contraceptionXx_NEWLINE_xXWomen and men of reproductive potential must agree to use highly effective contraception when sexually active. This applies for the period between signing of the informed consent and 30 days after the last administration of study drug. Highly effective contraception includes a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, hysterectomy, or vasectomy of the partner. In addition, the use of condoms for subjects or their partners is required.Xx_NEWLINE_xXWomen of child bearing potential and their partners must use an acceptable method of contraception while enrolled on this study, and for a period of 3 months following study drug treatment. Patients unwilling or unable to follow this guideline will be excluded. Investigators should follow their Institutional standard regarding acceptable methods of contraception.Xx_NEWLINE_xXYou must commit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved contraception throughout the study without interruption; while receiving study medication or for a longer period if required by local regulations. Male subjects must:Xx_NEWLINE_xXFemale subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy. Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days (females and males) following the last dose of AG-221Xx_NEWLINE_xXMale or female participant of reproductive potential must agree to use appropriate methods of contraception for the duration of study treatment and for at least 30 days after last dose of protocol treatmentXx_NEWLINE_xXAgree to use contraceptionXx_NEWLINE_xXIf participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug.Xx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, orXx_NEWLINE_xXFor female participants of childbearing potential and male participants with female partners of childbearing potential, agreement to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception throughout the course of study treatment and for at least 30 days after the last dose of venetoclax and 12 months after the last dose of rituximab, whichever is longerXx_NEWLINE_xXFor male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 6 months after the final dose of Paclitaxel or for 30 days for female patients and for 90 days for male patients, of the final BBI608/Placebo dose if Paclitaxel was not administered.Xx_NEWLINE_xXMale subjects and WOCBP must agree to use double barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drugXx_NEWLINE_xXMale patients not willing to use a condomXx_NEWLINE_xXIf they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through four months after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, orXx_NEWLINE_xXMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXFemale patients of childbearing potential and sexually active male patients must agree to use an acceptable form of contraception for heterosexual activity (ie, oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for > 40 days before Screening, during the study, and for 60 days after the last dose of study drug. Men should not donate semen during the study and for 60 days after the last dose of study drug.Xx_NEWLINE_xXSubject (male and female) of childbearing/ reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug.Xx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in the protocol.Xx_NEWLINE_xXMales and their female partner(s) of child-bearing potential must use 2 forms of effective contraception (see Inclusion 11 plus condom or vasectomy for males) from the last menstrual period of the female partner during the study treatment and agree to continue use for 6 months after the final dose of study treatment.Xx_NEWLINE_xXInclusion Criteria\n\n        Each patient must meet all of the following inclusion criteria to be enrolled in the study:\n\n          1. Male or female patients 18 years or older.\n\n          2. Patients must have a histologically confirmed diagnosis of an advanced, metastatic\n             malignant solid tumor and must have failed or exhausted standard therapies or for\n             which no standard therapy is available.\n\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          4. Patients with adequate hematologic and organ function\n\n          5. All patients must have radiographically detectable tumors; however, measurable disease\n             as defined by RECIST (version 1.1) is not required for participation in the dose\n             escalation part of this study.\n\n          6. Patients undergoing a biopsy procedure must have accessible lesions which are safe to\n             biopsy.\n\n          7. Recovered (ie, ? Grade 1 toxicity) from the reversible effects of prior antineoplastic\n             therapy, except alopecia.\n\n          8. Female patients who are postmenopausal for at least 1 year before the screening visit,\n             surgically sterile, or agree to practice 2 effective methods of contraception, at the\n             same time, from the time of signing the informed consent form through 4 months after\n             the last dose of study drug, or agree to practice true abstinence.\n\n             Male patients who agree to practice effective barrier contraception during the entire\n             study treatment period through 4 months after the last dose of study drug or agree to\n             practice true abstinence.\n\n          9. Suitable venous access for the study-required blood sampling including PK sampling.\n\n        Exclusion Criteria\n\n        Patients meeting any of the following exclusion criteria are not to be enrolled in the\n        study:\n\n          1. Patients with clinically significant pre-existing cardiac impairment.\n\n          2. Patients with known active CNS lesions are excluded. Systemic antineoplastic therapy\n             or investigational agents within 21 days before the first dose of study drug.\n\n          3. Radiotherapy within 14 days before the first dose of study drug is not allowed except\n             for limited field radiotherapy for palliative bone pain.\n\n          4. For patients where tumor biopsies are required or requested:\n\n               -  Any known coagulation abnormalities that would contraindicate the tumor biopsy\n                  procedure.\n\n               -  Ongoing therapy with any anticoagulant or antiplatelet agents (eg, aspirin,\n                  clopidogrel [Plavix], heparin, or warfarin).\n\n          5. Major surgery within 28 days before the first dose of MLN7243.\n\n          6. Life-threatening illness unrelated to cancer.\n\n          7. Any evidence of active infection or antibiotic therapy within 14 days before the first\n             dose of MLN7243.\n\n          8. Known human immunodeficiency virus (HIV) positivity or AIDS-related illness, hepatitis\n             B virus, and hepatitis C virus.\n\n          9. Patients whose weight is <40 kg.\n\n         10. History of uncontrolled sleep apnea syndrome and other conditions that could result in\n             excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease.\n\n         11. Female patients who are lactating and breastfeeding or have a positive serum pregnancy\n             test during the Screening period or a positive urine pregnancy test on Day 1 before\n             first dose of study drug.\n\n        For the exhaustive list, please contact the study central contact.Xx_NEWLINE_xXUse of effective contraceptionXx_NEWLINE_xXFemales must be surgically sterile, one year post menopausal or negative results for a pregnancy test performed at Screening and agree to use two methods of contraception; Males who have not had a vasectomy must agree to two methods of contraceptionXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test. Sexually active patients must be willing to use non-hormonal contraception, including condom use by male partner, and barrier method by the female partner during the treatment period and for at least 3 months after the last dose of the study drug. Females considered not of childbearing potential include those who have been in menopause > 2 years, or are surgically sterile (status post tubal ligation or hysterectomy).Xx_NEWLINE_xXBe willing to abstain from heterosexual activity or practice physical barrier contraception from study entry to 6 months after the last day of treatmentXx_NEWLINE_xXMale and female patients of child bearing potential must use an effective contraceptive method during the course of the studyXx_NEWLINE_xXFemale participants of childbearing potential must use effective contraception as defined by study protocol and cannot be pregnant or breastfeeding. NSCLC-specific Inclusion Criteria:Xx_NEWLINE_xXIs the subject willing to use condoms for contraception for 6 months after receiving Toca 511 or until there is no evidence of the virus in his/her blood, whichever is longer. If the subject is a fertile female, is she willing to use contraception for at least 12 months?Xx_NEWLINE_xXUnwillingness, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods.Xx_NEWLINE_xXMale or female ? 18 years of age. Females of childbearing potential must agree to use an adequate and reliable method of contraception.Xx_NEWLINE_xXAgree to use adequate contraceptionXx_NEWLINE_xXPregnant and lactating women are not eligible; all participants of reproductive age must have a negative serum pregnancy test at baseline and agree to use an effective barrier method of contraception during the entire period of treatment on the studyXx_NEWLINE_xXParticipants of childbearing age must use effective contraceptionXx_NEWLINE_xXFemale patients of child bearing potential must have a negative pregnancy test (within 7 days from the time of randomization); patients must agree to use effective contraception (both males and females) for 2 weeks prior to the first dose of each study treatment and for 8 weeks after the last dose of each study treatmentXx_NEWLINE_xXAgreement for females of childbearing potential use 2 acceptable methods contraception; men with female partners of childbearing potential must agree to use of latex condom and advise female partner to use additional method contraception during the study and 6 months after discontinuation of vemurafenibXx_NEWLINE_xXPatients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug.Xx_NEWLINE_xXMale patients willing to use adequate contraceptive. (See Appendix B)Xx_NEWLINE_xXSubjects with reproductive capability must agree to practice adequate contraception methods.Xx_NEWLINE_xXMale patients, even if surgically sterilized (ie, status postvasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, or agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXFemale patients who are postmenopausal for at least 1 year before the Screening visit, or are surgically sterile, or if they are of childbearing potential, must have a negative pregnancy test within 72 hours of treatment start date and agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourseXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of randomization until 30 days after the last dose of investigational product.Xx_NEWLINE_xXMale patients must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a female of child-bearing potentialXx_NEWLINE_xXEffective contraception is required while receiving obinutuzumab. For women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab. For men, effective contraception is required to continue for 6 months after the last dose of chlorambucil treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, from 14 days prior to the first dose of study treatment, throughout the study, and for 6 months following the last dose of chemotherapy or 4 weeks after the last dose of GSK3052230, whichever is latest. .Xx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 2 weeks prior to administration of the first dose of study treatment and for at least 6 months after the last dose of chemotherapy to allow for clearance of any altered sperm.Xx_NEWLINE_xXUse of highly effective form of contraceptionXx_NEWLINE_xXMale subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completion if therapy.Xx_NEWLINE_xXPatients with reproductive potential must agree to use at least one form of barrier contraception prior to study entry and for up to 30 days beyond the last administration of study drug.Xx_NEWLINE_xXMale patients who agree to practice effective barrier contraception through 90 after the last dose of study drug or agree to practice true abstinenceXx_NEWLINE_xXPatient must consent to using effective contraception while on treatment and for 3 months thereafterXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement by the patient and/or partner to use a highly effective, non-hormonal form of contraception or two effective forms of non-hormonal contraception; female patients of childbearing potential must agree to use two effective forms of non-hormonal contraception; effective methods of contraception include: intrauterine device (IUD); female condom; male condom; diaphragm with spermicide; cervical cap; or a sterile sexual partner; male patients with partners of childbearing potential must use barrier contraception; in addition, male patients should also have their partners use another method of contraception from the time of informed consent through the duration of study activityXx_NEWLINE_xXMale participants with female partners of childbearing potential must agree to use contraception as defined by protocol during treatment and for 2 months after completion of study treatmentXx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of MLN8237Xx_NEWLINE_xXPatients capable of fathering children must agree to use an effective method of contraception for the duration of the trial and should continue use for 4 months after last dose of study drugXx_NEWLINE_xXFemales of childbearing potential must agree to ongoing pregnancy testing and to practice contraception or abstain from heterosexual intercourseXx_NEWLINE_xXMale patients must agree to practice contraception or to abstain from heterosexual intercourseXx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 2 weeks prior to the first dose of study treatment until 16 weeks after the last dose of study treatment to allow for clearance of any altered spermXx_NEWLINE_xXFor males, participants must agree to use adequate contraceptive measures including at least 1 barrier method, and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of investigational product.Xx_NEWLINE_xXPatients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug.Xx_NEWLINE_xXWilling to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-141Xx_NEWLINE_xXA male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy; if the partner is pregnant or breastfeeding, the subject must use a condomXx_NEWLINE_xXMale subjects, even if surgically sterilized (i.e., post-vasectomy) must agree to one of the following: complete abstention from heterosexual intercourse or practice of effective barrier contraception starting at signing of informed consent and continuing through the entire study treatment period and a minimum of 28 days after the last dose of study drugXx_NEWLINE_xXMales and females with reproductive potential must agree to use medically approved contraceptive precautions starting 4 weeks prior to initiation of the therapy and during the trial and for 18 months following the last dose of study drugXx_NEWLINE_xXIf female and has begun menstruating, must have a negative pregnancy test prior to study participation and agree to remain abstinent or use a barrier form of contraceptionXx_NEWLINE_xXPatient who does not use highly effective contraception methods to avoid becoming pregnant or conceiving offspring.Xx_NEWLINE_xXFertile males not willing to use contraception, as stated aboveXx_NEWLINE_xXMales must agree to use condoms during sex to prevent spillage of semen for the duration of the study and for 3 months after the patient leaves the studyXx_NEWLINE_xXFor women who are not postmenopausal or surgically sterile; agreement to use an adequate method of contraception (hormonal implant) during the treatment period and for at least 90 days after the last dose of onartuzumab/placebo and 6 months after the last dose of oxaliplatinXx_NEWLINE_xXFor men: agreement to use a barrier method of contraception during the treatment period and for 90 days after the last dose of onartuzumab/placebo and 6 months after the last dose of oxaliplatinXx_NEWLINE_xXPatients must agree to practice contraceptionXx_NEWLINE_xXMale subjects must agree to use medically accepted form of contraception during the study period. Abstinence is an acceptable method of contraception.Xx_NEWLINE_xX5. Fertile males and females must agree to the use of an adequate form of contraception, e.g., condoms for males.Xx_NEWLINE_xXUnwillingness, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods.Xx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 or BBI503 doseXx_NEWLINE_xXMale subject with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of Screening until 3 months after the last dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire treatment period and after receipt of brachytherapy; male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapyXx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at registration until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigatorXx_NEWLINE_xXWomen of child-bearing potential and men must agree to use adequate contraception; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s); sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also usedXx_NEWLINE_xXFemale patients who are post-menarchal must have a negative pregnancy test; patients of reproductive potential must agree to use an effective contraceptive methodXx_NEWLINE_xXPatients must be postmenopausal, free from menses for > 1 year, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through180 days after the last dose of study treatment.Xx_NEWLINE_xXFemales of childbearing potential must be surgically sterile, have a sterile male partner, be premenarchal or at least 2 years postmenopausal, practice abstinence or otherwise must use 2 effective methods of contraception from the time of initiation of investigational product.Xx_NEWLINE_xXMales, unless surgically sterile, must use 2 effective methods of contraception with a female partner and must agree to continue using such contraception for 90 days after the last dose of MEDI0639Xx_NEWLINE_xXMale patients must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a FCBP.Xx_NEWLINE_xXWomen of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-151 (an effective form of contraception is an oral contraceptive or a double barrier method)Xx_NEWLINE_xXMale and female patients reproductive potential must agree to use measures to avoid pregnancy throughout the study and for 3 months following discontinuing study drug.Xx_NEWLINE_xXUse of two effective forms of contraceptionXx_NEWLINE_xXFertile Participants must use 2 effective methods of contraception prior to and through 6 months after the last dose of the study drugXx_NEWLINE_xXAgree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drugXx_NEWLINE_xXMale subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration;Xx_NEWLINE_xXMale subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXMale subject agrees to use an acceptable method of contraception for the duration of the studyXx_NEWLINE_xXFemale patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse; must also adhere to the guidelines of the lenalidomide pregnancy prevention programXx_NEWLINE_xXMale patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse AND must adhere to the guidelines of the lenalidomide pregnancy prevention programXx_NEWLINE_xXSexually active male and pre-menopausal female subjects (and their partners) unless they agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug. All fertile male and female subjects (and their partners) must agree to use a highly effective method of contraception. Highly effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)Xx_NEWLINE_xXFemale participants must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (at the discretion of the investigator), or if sexually active, be practicing an effective method of birth control. Male participants must agree to use an adequate contraception method as deemed appropriate by the investigator (e.g., vasectomy, double-barrier, partner using effective contraception) and to not donate sperm for a minimum of 5 months after treatment discontinuation Optional Extension Phase (OEP) Phase:Xx_NEWLINE_xXAll female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation greater than or equal to 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy). Female subjects of child-bearing potential must agree to use two forms of highly effective contraception from the last menstrual period prior to randomization (or use a double barrier method as described below until they are on two forms of highly effective contraception for at least one menstrual cycle), during the study treatment, and for 3 months after the final dose of study treatment. Female subjects exempt from this requirement are subjects who practice total abstinence. If currently abstinent, the subject must agree to use a double barrier method of contraception, i.e., condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide or until they are on two forms of highly effective contraception for at least one menstrual cycle if they become sexually active during the study treatment and for 3 months after the final dose of study treatment. Highly effective contraception includes:Xx_NEWLINE_xXMale subjects and their female partner who are of child-bearing potential (as defined in Inclusion 10), and are not practicing total abstinence, must agree to use two forms of highly effective contraception from the last menstrual period of their female partner prior to randomization (or use a double barrier method as described above until they are on two forms of highly effective contraception for at least one menstrual cycle), during study treatment, and for 3 months (or 6 months if they received dacarbazine) after the final dose of study treatment. If currently abstinent, must agree to use a double barrier method of contraception if they become sexually active, or until they are on two forms of highly effective contraception as described above.Xx_NEWLINE_xXPersons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 8 weeks after ipilimumab is stoppedXx_NEWLINE_xXMales must agree to use a latex condom during any sexual during the study and for 28 days following discontinuation from this studyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception during the study and for one year following the last dose of study drug.Xx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from 2 weeks prior to administration of the first dose of study treatment until one year after the last dose of study treatment.Xx_NEWLINE_xXMales and females (reproductive potential): Use medically approved contraceptive precautions during the study and for 4 months following the last dose of study drug.Xx_NEWLINE_xXDocumented willingness to use an effective means of contraceptionXx_NEWLINE_xXPregnant female or nursing mother. All females with an intact uterus (unless amenorrheic for the 24 months before enrollment) must have a negative serum pregnancy test at screening. All non-sterile or non-postmenopausal females must practice a medically accepted method of contraception over the course of the study and for 60 days after the last dose of study agent.Xx_NEWLINE_xXMales who do not agree to use effective contraception during the study and for a period of 60 days following the final dose of study agent.Xx_NEWLINE_xXFemales of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for 3 months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence during that time frameXx_NEWLINE_xXMen engaging in sexual intercourse with a FCBP must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc), barrier method contraception (i.e. condoms), or abstinence while on study drug and for 3 months after discontinuation from study drugXx_NEWLINE_xXAgrees to use adequate contraception during the study period and for 12 weeks after the last dose of study medicationXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method or abstain from sexual activity during the study and for 3 months after last study drug administration; sexually active males and their female partners must agree to use two methods of accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the studyXx_NEWLINE_xXMales and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of any study drug.Xx_NEWLINE_xXMale subjects who are sexually active must agree to use a condom from the beginning of treatment and for 1 month after the last doseXx_NEWLINE_xXIf sexually active, must be post-menopausal, surgically sterile, or using effective contraception; and agrees to use adequate contraception during the study period and for up to 6 months after the last dose of study medicationXx_NEWLINE_xXPatients who are pregnant or nursing; subjects of child-bearing age have to use effective means of contraceptionXx_NEWLINE_xXA male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception or abstinence during the studyXx_NEWLINE_xXMale patients, and female patients of childbearing potential, must agree to use method(s) of contraception specified in the protocolXx_NEWLINE_xXFemales of childbearing potential must agree to ongoing pregnancy testing and to practice contraceptionXx_NEWLINE_xXMale subjects must agree to practice contraceptionXx_NEWLINE_xXAgree to contraception requirements.Xx_NEWLINE_xXSexually active subject (male and female) must use medically acceptable methods of contraception during the course of the studyXx_NEWLINE_xXAgreement to use an effective form of contraception for the duration of the studyXx_NEWLINE_xXMale patient whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXChild-bearing potential, has a negative serum pregnancy test at baseline, and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception from two weeks prior to the administration of study drug and throughout the entire active study treatment period until four weeks after the last dose of study medication.Xx_NEWLINE_xXFemale subject of child bearing potential is not willing to use two methods of highly effective contraception during treatment and for 5 months after the end of treatmentXx_NEWLINE_xXFemales of childbearing potential not using adequate contraception precautions for the duration of the study treatment and for 2 months after the last administration of investigational product.Xx_NEWLINE_xXFertile patients must use effective contraceptionXx_NEWLINE_xXMales with partners of childbearing potential, must agree for the duration of the treatment with talimogene laherparepvec and continuing for 3 months after the last tumor injection of talimogene laherparepvec to either:\r\n* Abstain from sexual activity\r\n* Use highly effective barrier protection (latex condom)Xx_NEWLINE_xXFemale subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvecXx_NEWLINE_xXWomen of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception for 4 months after study treatment is completed; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 4 months after study treatment is completed; if a female patient or a female partner of a patient becomes pregnant while the patient receives talazoparib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXIf female, must be:\r\n* Postmenopausal for at least 1 year before the screening visit; OR\r\n* Surgically sterile; OR\r\n* Agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatmentXx_NEWLINE_xXIf a sexually active heterosexual male, must be agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatmentXx_NEWLINE_xXPregnant and lactating females, and unwillingness to use contraception; or male subject not willing to use contraception during and for 21 days after the last dose of pazopanib therapyXx_NEWLINE_xXFertile males not willing to use contraception; fertile males must use condom with spermicide; highly effective contraception, as defined above, must be used by both sexes (male patients and their female partners) during study treatment and for 90 days after the last dose of study medication and should not father a child in this period; a condom is required to be used also by vasectomized menXx_NEWLINE_xXMale and female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last investigational drug dose receivedXx_NEWLINE_xXFemale patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two effective methods of contraceptionXx_NEWLINE_xXWillingness to use adequate methods of contraception beginning at the signing of the ICF until at least 30 days after the last dose of study drugXx_NEWLINE_xXPremenopausal women must have a negative pregnancy test and must agree to use barrier contraception throughout the study periodXx_NEWLINE_xX202 Females of childbearing potential on denosumab and not willing to continue to use 1 highly effective method of contraception during treatment and for 5 months after the end of treatmentXx_NEWLINE_xXFemale patients of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from 7 days post-screening, and must agree to continue using such precautions for 90 days after the last dose of investigational product.Xx_NEWLINE_xXNonsterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from 7 days post-screening and for 90 days after receipt of the last dose of investigational product.Xx_NEWLINE_xXFemale and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapyXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 5 half-lives of study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks posttreatment completionXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test at screening and must agree to use a highly effective form of contraception from the time of the first dose of study drug through 45 days after the last dose of study drug.Xx_NEWLINE_xXMale patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.Xx_NEWLINE_xXMale patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.Xx_NEWLINE_xXFemale subjects of childbearing potential (FCBP) must have a negative urine or serum pregnancy test AND must agree to use effective contraception throughout the study, starting at the first dose of chemotherapy for at least 12 months thereafter and 4 months after the gene modified cells are no longer detected in the blood, whichever is longer. OrXx_NEWLINE_xXMale subjects must be surgically sterile or agree to use effective contraception starting at the first dose of chemotherapy and for 4 months thereafter (if indicated in the country specific monograph/label for cyclophosphamide).Xx_NEWLINE_xXIf they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, orXx_NEWLINE_xXMale patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of talazoparib through 105 days after the last dose. Contraception should be considered for a nonpregnant female partner of childbearing potential.Xx_NEWLINE_xXAre currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from being sexually active during the study period or for 28 days after study drug discontinuationXx_NEWLINE_xXMales who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period or for 28 days after study drug discontinuation). No sperm donation is allowed during the study period and for 28 days after study drug discontinuation.Xx_NEWLINE_xXFor female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective forms of contraception and to continue its use 6 months after the last dose of atezolizumab or bevacizumabXx_NEWLINE_xXMale subjects with female partners of child bearing potential must agree to use one of the methods of contraception specified in protocol from time of first dose of study treatment until 120 days after the last dose of study treatment.Xx_NEWLINE_xXFertile patients must use adequate contraceptionXx_NEWLINE_xXRefusing to use contraception up to 90 days post-HCTXx_NEWLINE_xXPregnancy or failure to use effective contraception in fertile males or females, and breast-feeding femalesXx_NEWLINE_xXPatients who enter this study and their sexual partners who are of childbearing potential must agree to use an effective form of contraception throughout participation in this studyXx_NEWLINE_xXMales and females must agree to use effective contraception starting prior to the first day of treatment and continuing for 30 days after the last dose of GC4419Xx_NEWLINE_xXSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 2 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXNote: investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception; highly effective methods of contraception have a failure rate of < 1% when used consistently and correctlyXx_NEWLINE_xXFemales who are sexually active without use of effective contraceptionXx_NEWLINE_xXMen of reproductive potential and those who are surgically sterilized (i.e., post vasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < 1% during and for 30 days after discontinuation of study treatment\r\n* If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occurXx_NEWLINE_xXWoman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug; men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last doseXx_NEWLINE_xXPregnancy or potential pregnancy and nursing; female subjects of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception; contraception must continue for the duration of study treatmentXx_NEWLINE_xXAny woman of childbearing potential or male partner of a woman of childbearing potential unwilling to employ acceptable contraception throughout the study and for at least 30 days after the last dose of the study drugXx_NEWLINE_xXFemale research participant of childbearing age and male research participant of child fathering potential must agree to use safe contraceptive methodsXx_NEWLINE_xXFemale subject of child bearing potential must be willing to use, in combination with her partner, 2 forms highly effective contraception during treatment and for 1 month after the end of treatmentXx_NEWLINE_xXFemale subject of child bearing potential is not willing to use highly effective contraception during treatment and for 5 months after the end of treatment (see section 6.3)Xx_NEWLINE_xXUse of an effective contraceptive method during the course of the study and for 2 months following the last administration of Investigational ProductXx_NEWLINE_xXFertile patients must use effective contraceptionXx_NEWLINE_xXFor males and females of child-producing potential, use of effective contraceptive methods during the study and for at least 6 months after the last dose of romidepsinXx_NEWLINE_xXAll subjects, except post-menopausal women, must be willing to utilize a highly effective method of contraception throughout the studyXx_NEWLINE_xXFemale patient who is postmenarcheal has agreed to use an effective contraceptive method (including abstinence) for the duration of study participationXx_NEWLINE_xXFemale patients (and female partners of male patients) of childbearing potential who are sexually active must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 14 weeks after the last dose of defibrotide.Xx_NEWLINE_xXThey are using an effective method of contraception from screening to the end of the study, unless their sexual partner is surgically sterileXx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\r\n** Note: women of child bearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 33 days after finishing the last dose\r\n** Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 93 days after finishing the last dose\r\n** Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements; however they must still undergo pregnancy testing as described in this section; note: investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy; investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception; at a minimum, subjects must agree to the use of one method of highly effective contraception as listed below:\r\n*** Male condoms with spermicide\r\n*** Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena by WOCBP subject or male subjects WOCBP partner \r\n*** Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception\r\n*** IUDs, such as ParaGard\r\n*** Tubal ligation\r\n*** Vasectomy\r\n*** Complete abstinence\r\n**** Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs; acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinenceXx_NEWLINE_xXWilling to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agentXx_NEWLINE_xXWillingness to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agentXx_NEWLINE_xXFemale subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing of the informed consent through 12 months post-transplantXx_NEWLINE_xXMale subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception, or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplantXx_NEWLINE_xXSubject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for at least 4 weeks after the last dose of study drug to minimize the risk of pregnancyXx_NEWLINE_xXMale patients are to agree to use a barrier method of contraception from study treatment initiation until at least 90 days after the last administration of FolotynXx_NEWLINE_xXMust agree to use medically acceptable barrier and/or chemical method of contraception while on study and for at least one month following the last vaccine injection; should a participant's partner become pregnant or suspect she is pregnant while the participant is participating in this study, the study physician should be informed immediately; in the event a participants partner becomes pregnant, the study sponsor may request additional information regarding the course of the pregnancy and if the pregnancy is carried to term, the birth of the child (i.e., the outcome of the pregnancy)Xx_NEWLINE_xXWilling to continue on the same or similar type of contraception during the 12 month course of study; if using non-hormonal contraception, continue that and if hormonal contraception continue that; if heterosexually active, must be agreeable to use some form of contraception during the trial unless husband or partner has had a vasectomy or subject has had uterus removed; safety of SDG during pregnancy has not been documentedXx_NEWLINE_xXUse of adequate contraception during the studyXx_NEWLINE_xXMale subjects must agree to use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 2 months after the last doseXx_NEWLINE_xXMale patients must agree not to donate sperm during the study and for 2 months after discontinuation of vismodegibXx_NEWLINE_xXAgree to practice true abstinence2 (which must be reviewed on a monthly basis and source documented) or agree to the use of highly effective methods of contraception from 28 days prior to starting azacitidine, and must agree to continue using such precautions while taking azacitidine (including dose interruptions) and for up to 90 days after the last dose of azacitidine. Cessation of contraception after this point should be discussed with a responsible physicianXx_NEWLINE_xXEither practice true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of child bearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of azacitidine.Xx_NEWLINE_xXMale patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXMen with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of first dose of study until 60 days after the last dose of study treatment to allow for clearance of any altered spermXx_NEWLINE_xXMale or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 doseXx_NEWLINE_xXMale patients must use an effective, non-hormonal form of contraception from Screening throughout the Treatment Phase and until 130 days after last dose of Study treatment  Acceptable methods include male/female condoms with spermicide, or vasectomy with medical confirmation of surgical success.Xx_NEWLINE_xXParticipants must agree to use effective contraceptionXx_NEWLINE_xXUse of the following:Xx_NEWLINE_xXMale participants must agree to use an acceptable method for contraception during the entire study treatment period and through 6 months after the last dose of treatmentXx_NEWLINE_xXFemale subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two effective methods of contraception or agree to complete abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplantXx_NEWLINE_xXMale subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplantXx_NEWLINE_xXFemale subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post transplant (see Section 2.6.4 for definition of postmenopausal).Xx_NEWLINE_xXMale subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post transplant.Xx_NEWLINE_xXFemale patients of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completionXx_NEWLINE_xXWillingness to use adequate contraception throughout study and for a period of 90 days last dose of study drugXx_NEWLINE_xXFemale patients with reproductive capability must be willing to use effective contraceptionXx_NEWLINE_xXMale subjects of childbearing potential must be willing to use a condom during sexual intercourse and shall not father a child during the course of the study or will practice complete abstinence while on studyXx_NEWLINE_xXFemale subjects of childbearing potential must agree to the use of two physician-approved contraceptive methods simultaneously or practice complete abstinence while on studyXx_NEWLINE_xXWillingness to use adequate contraception for 12 months after completion of all therapyXx_NEWLINE_xXWillingness to use adequate contraception for 12 months after completion of all therapyXx_NEWLINE_xXThe patient, if of childbearing potential, is willing to use effective, non-hormonal contraception while on treatment and for at least 6 months following the last dose of therapyXx_NEWLINE_xXSexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least 6 months after the completion of bevacizumab therapyXx_NEWLINE_xXIf of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 6 months following last treatment.Xx_NEWLINE_xXAgree to use highly effective contraception (that is, methods with a failure rate of less than 1 percent per year) if the subject is male or a female of childbearing potential (female partners of childbearing potential of male subjects must also agree to use highly effective contraception)Xx_NEWLINE_xXWOCBP and male subjects who are sexually active with WOCBP must agree to use 2 highly effective methods of contraception (including a physical barrier) before the first dose of study drugs, during the study, and for 5 months for women and 7 months for men following the last dose of study drug.Xx_NEWLINE_xXWomen of child-bearing potential must agree to use adequate contraception for the duration of study participation and for 2 months after completion of SL-401 and azacitidine administration; men treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation and 2 months after completion of SL-401 and azacitidine administrationXx_NEWLINE_xXAgrees to use an adequate method of contraception during the study and until 3 months after the last treatment.Xx_NEWLINE_xXWilling to use non-hormonal birth control: Male subjects who are surgically sterile (eg, after vasectomy) or who must agree to use an adequate method of contraception during participation in the trial and for at least 1 complete month after the final dose of trial medication. Female subjects who are surgically sterile (eg, 2-sided tubal ligation, resection or ovariectomy, hysterectomy) or post-menopausal (defined as at least 50 years of age and who have a history of no menses for at least 24 months) or female subjects of childbearing potential with no male partner, or use an adequate method of contraception during participation in the trial and for at least 1 complete month after the final dose of trial medication. An adequate method of contraception is defined as one of the following acceptable birth control methods:Xx_NEWLINE_xXMale or female patients who are sexually active and of reproductive potential must agree to use an effective contraceptive method throughout the study and for at least 60 days after last avelumab treatment administration; abstinence is an acceptable form of contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use adequate contraception for the course of the studyXx_NEWLINE_xXAgree not to try to become pregnant during the study and for 6 months after the final study drug administrationXx_NEWLINE_xXAnd, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and throughout the study period and for 6 months after the final study drug administration.Xx_NEWLINE_xXFemale subject must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration.Xx_NEWLINE_xXMale subject and subject's female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and continue throughout the study period and for 4 months and 1 week after the final study drug administration.Xx_NEWLINE_xXMale subject must not donate sperm starting at screening and throughout the study period and for 4 months and 1 week after the final study drug administration.Xx_NEWLINE_xXWilling to use contraception during and for 1 month after completion of the studyXx_NEWLINE_xXFemale patient must have effective contraception throughout the study and must have a negative urine pregnancy test at inclusion, or be surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea)Xx_NEWLINE_xXInclusion Criteria\n\n        Each patient must meet all of the following inclusion criteria to be enrolled in the study:\n\n          -  Male or female patients 18 years or older.\n\n          -  Must be diagnosed with colorectal cancer (CRC) with liver metastasis and eligible and\n             scheduled for resection of liver metastases as part of their standard of care\n             treatment plan. The planned surgery must occur greater than 14 days after the day of\n             imaging.\n\n          -  Patients must consent to provide the sponsor with tumor tissue samples from their\n             resected liver metastases.\n\n          -  Easter Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n          -  Female patients who are post menopausal, surgically sterile, or agree to practice\n             effective methods of contraception from the time of signing the informed consent form\n             through 60 days after the dose of [68Ga]MLN6907 or agree to practice true abstinence.\n\n          -  Male patients who agree to practice effective barrier contraception during the entire\n             study treatment period and through 4 months after the dose of [68Ga]MLN6907 or agree\n             to practice true abstinence.\n\n          -  Voluntary written consent must be given before performance of any study-related\n             procedure not part of standard medical care, with the understanding that consent may\n             be withdrawn by the patient at any time without prejudice to future medical care.\n\n          -  Suitable venous access for the study-required, blood sampling (ie, including PK\n             sampling)\n\n          -  Adequate hepatic function as defined in the protocol.\n\n          -  Adequate renal function as defined in the protocol.\n\n          -  Hemoglobin ? 9 g/dL.\n\n          -  Recovery from all adverse effects from prior antitumor therapy to at least Common\n             Terminology Criteria for Adverse Events (CTCAE) (V4.03) Grade 1.\n\n        Exclusion Criteria\n\n        Patients meeting any of the following exclusion criteria are not to be enrolled in the\n        study.\n\n          -  Female patients who are lactating and breastfeeding or have a positive serum pregnancy\n             test during the screening period or a positive urine pregnancy test on Day 1 before\n             the first dose of [68Ga]MLN6907.\n\n          -  Any serious medical or psychiatric illness, condition, or personal circumstance,\n             including severe claustrophobia, severe dyspnea, severe back pain, etc., that, in the\n             judgment of the investigator or project clinician, might potentially interfere with\n             the procedures required in this study.\n\n          -  Involvement in an investigative radioactive or other research procedure within 4 weeks\n             prior to administration of [68Ga]MLN6907.\n\n          -  Major surgery within 14 days prior to administration of [68Ga]MLN6907 5. Serious\n             infection (viral, bacterial, or fungal) within 14 days before administration of\n             [68Ga]MLN6907 or evidence of active infection during screening.\n\n          -  Life-threatening illness unrelated to cancer.\n\n          -  Clinically significant central nervous system (CNS) metastases.\n\n          -  Known inflammatory bowel disease.\n\n          -  Known hepatitis B surface antigen-positive or known or suspected active hepatitis C\n             infection (testing not required).\n\n          -  History of any hypersensitivity to any component of [68Ga]MLN6907.\n\n          -  Symptomatic cardiac disease, including ventricular dysfunction, coronary artery\n             disease, or arrhythmias, if this would, in the opinion of the investigator or project\n             clinician, interfere with assessment of efficacy or safety of [68Ga]MLN6907.\n\n          -  Admission or evidence of addictive disorders (eg, illicit drug use, drug abuse, or\n             alcohol abuse) that would limit compliance with study requirements.\n\n          -  Inability to lie flat for the duration of image acquisition.Xx_NEWLINE_xXFemales of childbearing potential should avoid becoming pregnant and use highly effective contraception while on treatment and for at least 1 month after finishing treatment.Xx_NEWLINE_xXFemales participants must complete the Female Enrollment Form. Childbearing potential participants must agree to use one of the medically accepted forms of contraception for a period of one month after study participation. Female participants who meet the criteria for non-childbearing will still complete the Female Enrollment Form, but are not restricted to the use of contraception following study participation.Xx_NEWLINE_xXFemale subjects of childbearing potential and all male subjects are required to consent to use a medically acceptable method of contraception throughout the study period and for 30 days after amatuximab administration; a barrier method of contraception is requiredXx_NEWLINE_xXHighly effective contraception for both male and female subjects if the risk of conception exists; (Note: women of childbearing potential and men able to father a child must agree to use 2 methods of highly effective contraception, defined as methods with a failure rate of less than 1 % per year; highly effective contraception is required at least 28 days prior, throughout and for at least and 5 months following the last dose of trabectedin)Xx_NEWLINE_xXWilling to abstain from procreative sex or partake in appropriate form of contraception; for the purpose of this study, condom use or abstinence will be requiredXx_NEWLINE_xXFor study Arm 1, female subjects of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completion unless total hysterectomy performed at the time of original operationXx_NEWLINE_xXAgree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study (women for 23 weeks and men for 31 weeks after the last dose of study drug)Xx_NEWLINE_xXMale and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.Xx_NEWLINE_xXPregnant females; breastfeeding females; males and females of childbearing potential; males and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 28 days after last dose of investigational product; males and females of childbearing potential not using two (2) methods of highly effective contraception or not agreeing to continue two (2) methods of highly effective contraception for at least 28 days after last dose of investigational product.Xx_NEWLINE_xXWilling to use adequate contraception if applicable, and to continue use for 16 weeks post last dose of GSK1120212Xx_NEWLINE_xXIf of childbearing potential, is willing to abstain for sexual intercourse or to use an effective form of contraception (double-barrier method) during the study and for 90 days following the last dose of ganetespibXx_NEWLINE_xXFemale subject of childbearing potential or male subject of reproductive potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvec/placebo or 4 months after the last dose of pembrolizumab, whichever is later.Xx_NEWLINE_xXSexually active patients and their partners agree to use an accepted method of contraception during the course of the studyXx_NEWLINE_xXSubjects who are sexually active and not willing/able to use medically acceptable forms of contraception upon entering the study.Xx_NEWLINE_xXIf of child-bearing potential, agree to continued use of two reliable methods of contraceptive from study entry (time of informed consent) through 30 days after BLZ-100 administration. Male subjects with vasectomy do not need to use a second form of contraceptive.Xx_NEWLINE_xXFemale patients of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completionXx_NEWLINE_xXSubjects who are sexually active and not willing/able to use medically acceptable forms of contraception upon entering the study.Xx_NEWLINE_xXFertile patients must agree to use effective contraception during and for 4 weeks after completion of studyXx_NEWLINE_xXIf childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, orXx_NEWLINE_xXAgree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, orXx_NEWLINE_xXUse of effective contraception method during and for 1 year following study drug dosing if female of childbearing potential or sexually active maleXx_NEWLINE_xXPatient must be a candidate for systemic therapy with erlotinib based on clinical assessment; patients must meet the following criteria before beginning therapy (Note: these are not required for initial study enrollment and plasma genotyping):\r\n* ECOG performance status of 0-2\r\n* Platelets > 75\r\n* Aspartate aminotransferase (AST) & alanine aminotransferase (ALT) < 3 x the upper limit of normal\r\n* Creatinine clearance > 30 mL/min by Cockroft-Gault\r\n* No other contraindication to erlotinib\r\n* Female participants of child-bearing age must agree to use adequate contraception (hormonal, barrier or abstinence) for the duration of the study while receiving erlotinib and undergo a pregnancy test; any evidence or suspicion of pregnancy should be reported to the treating physician immediately\r\n* Male participants must agree to use adequate contraception for the duration of the study while receiving erlotinibXx_NEWLINE_xXFemale subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvec. Note: Acceptable methods of effective contraception are defined in the informed consent/assent form. Where required by local laws and regulations, additional country-specific contraception requirements may be outlined in a country-specific protocol supplement at the end of the Appendix Section of protocol.Xx_NEWLINE_xXSexually active women and men of reproductive potential must agree to use highly effective contraception. This applies for the period between signing of the informed consent and 3 months after the last administration of study drug. These procedures should be documented in source documents. The investigator or a designated associate is requested to advise the patient on how to achieve highly effective birth control. Highly effective contraception includes:Xx_NEWLINE_xXSexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.Xx_NEWLINE_xXFertile patients must agree to use effective contraception during and for 4 weeks after completion of studyXx_NEWLINE_xXAll female subjects of child bearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least 8 weeks after the last dose of study drug.Xx_NEWLINE_xXWomen of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; sexually active men and women of child-bearing potential must use highly effective contraceptives (e.g., condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 30 days after the last dose of study drug for females and 90 days for males; if a female subject or the partner of a male subject becomes pregnant, the sponsor must be notified; male subjects should refrain from sperm donation for 90 days after the last dose of study drugXx_NEWLINE_xX